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Glossary
Alternative splicing
The process whereby identical pre-mRNA molecules are spliced in different ways 
leading to additional RNA and protein expression diversity.
DNA pools
A pool of DNA from individual samples in which an equal amount of DNA of each 
individual sample is represented.
Epigenetic events
Heritable changes in gene expression that are not accompanied by nucleotide 
changes in DNA sequences but e.g. by gene methylation.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Tumour derived from epithelial cells lining the upper aerodigestive tract. Different 
tumour locations can be distinguished: oral cavity, larynx and pharynx (oropharynx, 
hypopharynx and nasopharynx).
Human Leukocyte Antigen (HLA)
The HLA system is the human equivalent of the Major Histocompatibility Complex 
(MHC) and includes three regions: class I, II and III. The polymorphic HLA 
genes are located in the class I and II regions, able to bind peptides derived 
from endogenous and exogenous proteins respectively. Presentation of these 
peptides to CD4+ and CD8+ T-cells may result in a humoral or cytotoxic immune 
response.
HLA allele
An HLA allele is a nucleotide variant of a particular HLA locus. The HLA-A*010101 
allele is a variant of the HLA-A locus.
HLA antigen
The expressed form of an HLA allele. The HLA-A1 antigen represents the expressed 
form of the HLA-A*01 alleles.
Low expressed allele
The allele is associated with unusual expression levels.
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MICA
MHC class I chain-related gene A. The MICA gene is related to the HLA genes in 
structure, but it does not bind and present peptides nor interacts with beta-2-
microglobulin. Nucleotide polymorphism is present throughout the entire gene 
whereas repeat polymorphism, located in the transmembrane region, inﬂ uences 
the length of the transmembrane region. MICA interacts with T- and NK-cells via 
the NKG2D receptor and in this way activates immune reactivity.
Microsatellite or Short Tandem Repeat (STR) markers
Repeated sequences of 2-6 bp in length, displaying a high degree of polymorphism 
between individuals. They are located throughout the genome, primarily in non-
coding regions. They can be applied as follow-up for monitoring mixed chimerism 
status after stem cell transplantation, for mapping predisposing genes in disease 
association studies, in population genetics and evolutionary aspects of population 
genetics, in forensic analysis and for the determination of microsatellite instability 
in tumours.
Null allele
A sequence variation in an HLA allele or gene that prevents normal expression of 
the molecule at the cell surface.
Sequencing Based Typing (SBT)
A direct sequencing approach to determine the nucleotides present in the DNA 
and subsequent allele assignment based on identiﬁ ed polymorphism.
Soluble allele
An allele specifying a protein that is expressed as a soluble “secreted” molecule 
but not present on the cell surface.
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The Human Leukocyte System
The Human Leukocyte Antigen (HLA) system, the human equivalent of 
the Major Histocompatibility Complex (MHC), possesses the highest degree of 
polymorphism present in the human genome. The HLA complex is located on the 
short arm of chromosome six, 6p21.3, and is divided into three main regions: the 
class I, II and III regions and in addition the extended class I and class II regions. 
This entire complex encompasses 7.6 Mb, with 421 identiﬁ ed genes to date: 252 
are expressed genes, 139 pseudogenes and 30 transcripts without a characterized 
open reading frame [1]. 
In the class I region, the classical genes HLA-A, HLA-B and HLA-C, the 
non-classical genes HLA-E, HLA-F and HLA-G and the pseudogenes HLA-H, HLA-J, 
HLA-K and HLA-L are located. Within the class II region the classical class II genes 
HLA-DR, HLA-DQ and HLA-DP, their pseudogenes and the class II-like genes HLA-
DO and HLA-DM are present. Genes involved in the class I antigen processing 
and presentation pathway, the proteasome subunit β (PSMB) and the transporter 
associated with antigen processing (TAP) genes are also located in this region 
[2]. The class III region, interspersed between the classes I and II, is the most 
dense gene region in the human genome, with an average of 8.5 genes per 100 
kb. Although many class III genes have unknown function, several of the genes 
are involved in the innate immune system (i.e. the complement genes C2, C4 and 
factor B), the immune/inﬂ ammatory response (i.e. the cytokines TNF, LTA, LTB 
and the lymphocyte antigen 6 (Ly6) genes and stress-induced signalling genes 
(heat shock proteins) [3].
During evolution the HLA region has diversiﬁ ed from ancestral genes. It is 
presumed that the HLA region has emerged in two rounds of large-scale genomic 
duplication from a common ancestral region resulting in four paralogous regions 
[4]. The regions paralogous to the HLA region on the short arm of chromosome 
6 are located on chromosomes 1, 9 and 19. Each of these regions has undergone 
positive and negative genetic selection, explaining why not all genes present in 
the HLA region are present in one of the other paralogous regions. The region on 
chromosome 1 is the region most closely related to the HLA region on chromosome 
6, with numerous genes similar as in the HLA region. This region contains for 
example a cluster of genes, the CD1 genes that resemble the HLA genes in structure 
and function. The CD1 molecules are cell surface glycoproteins and are able to 
bind antigens from (glyco)lipids and to present them to γδ T-cells, NKT-cells and 
natural killer (NK) cells [5]. Associations of genes with particular diseases have 
been described for chromosome 6, but also for genes in the paralogous region on 
chromosome 1 [5].
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Chapter 1
Classical HLA genes
The classical class I molecules, HLA-A, HLA-B and HLA-C, are cell-surface 
glycoproteins consisting of a polymorphic heavy or α chain (~45 kDa) and 
a monomorphic light or α chain (~12 kDa). Constitutive expression for these 
classical HLA molecules is observed on most nucleated cells, although the level 
of expression can differ between tissues and cell types. Higher expression levels 
are in general detected for HLA-A and HLA-B compared to HLA-C. An increased 
turnover of HLA-C mRNA and restricted peptide binding has been suggested to 
reduce HLA-C cell surface expression. The function of the classical HLA class I 
molecules is binding and presentation of endogenously derived peptides to CD8+ 
cytotoxic T-cells, eliciting a cellular immune response if a non-self peptide is 
presented. Stable expression of the class I molecules requires a complex of the 
heavy and light chain and in addition a bound peptide [6-10].
Genes encoding for the polymorphic heavy chain are located in the HLA 
class I region and the gene for the monomorphic light chain, beta2-microglobulin 
(β2m), on chromosome 15. Extracellular and intracellular domains in the HLA 
class I α chain are deﬁ ned by different exons. The signal sequence encoded by 
exon 1, is necessary for the correct transport of the HLA class I heavy chain into 
the endoplasmatic reticulum (ER) after which the signal sequence is cleaved off. 
The extracellular domains, α1, α2 and α3, are encoded by respectively exons 2, 3 
and 4. The α1 and α2 domains form the peptide binding groove of the HLA class I 
molecule and deﬁ ne the polymorphism in the peptide-binding groove. The peptide-
binding groove presents peptides to CD8+ T-cells and binds the T-cell receptor. 
The α2 domain and the α3 domain, an immunoglobulin-like domain, interact with 
the CD8 co-receptor on CD8+ T-cells. The hydrophobic transmembrane domain 
is encoded by exon 5, the hydrophilic cytoplasmic tail is encoded by exons 6 and 
7 and the termination codon is present in exon 8 for HLA-A and HLA-C. In HLA-B, 
exons 6 and 7 encode the cytoplasmic tail and the termination codon [7, 11-13]. 
The classical class II molecules HLA-DR, HLA-DQ and HLA-DP are cell-surface 
molecules composed of a polymorphic α chain (~33-35 kDa) and a polymorphic 
β chain (~26-28 kDa). A restricted expression pattern is observed for the class 
II molecules. Constitutive expression is observed on B cells, whereas expression 
can be induced by IFN-γ on antigen presenting cells, dendritic cells, macrophages, 
monocytes, Langerhans cells and vascular endothelial cells. Upon activation T-
cells are also able to express class II molecules. Stable class II complexes bind 
exogenously derived peptides and present those to CD4+ T-cells. If non-self 
peptides are bound, presentation may elicit a humoral immune response [7, 14].
The α and β chain are respectively encoded by an A and a B gene in the 
class II region. HLA-DR can have more than one polymorphic β chain and more 
than one B gene, depending on the haplotype. The α chain is encoded by 4 exons 
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and the β chain by 5 exons. In both chains exon 1 encodes for the signal sequence 
and exons 2 and 3 for the extracellular domains α1, α2 and β1, β2. In the α 
chain the hydrophobic transmembrane domain and the hydrophilic intracellular 
domain are encoded by exon 4, while in the β chain the transmembrane domain 
is encoded by exon 4 and the intracellular domain by exon 5. The peptide-binding 
groove of the class II molecule, formed by the α1 and β1 domain of both chains, 
is able to present peptides to CD4+ T-cells and interacts with the T-cell receptor. 
The α2, β1 and β2 domains are able to interact with the CD4 co-receptor on CD4+ 
T-cells [7, 11, 12, 15-17]. 
The organization of the peptide-binding groove is overall the same for HLA 
class I and class II molecules. The groove is composed of 6 pockets in the class 
I molecule and 5 pockets in the class II molecule. The impact of each pocket on 
peptide binding can differ, depending on the polymorphism present. Amino acids 
in respectively the α1/α2 domains and the α1/β1 domains are involved in the 
formation of these pockets [7]. The peptides to be presented differ in length as 
class I peptides are shorter (8-10 amino acids) and are attached with their ends 
in the peptide-binding groove compared to class II peptides that are longer (12-
24 amino acids) and attached with amino acids in the middle of the peptide to the 
peptide-binding groove, so that the ends of a class II peptide are located outside 
the peptide-binding groove [18].
HLA polymorphism
HLA polymorphism has been established during million of years evolution 
in which exposure to the (pathogenic) environment has shaped the HLA region as 
it is nowadays, with the capacity to distinguish between self and non-self and to 
improve the survival of species. The extent to which HLA class I and II genes have 
diversiﬁ ed differs extremely between species. For example, the Syrian hamster 
is monomorphic for his HLA class I genes, but polymorphic for his class II genes 
whereas the cheetah is monomorphic for all HLA genes. In human and mice, on 
the contrary, the class I and II polymorphisms is considerable [19].
The majority of the HLA polymorphism is located within the peptide-
binding groove, giving rise to the ability to present a divers amount of peptides. 
However, polymorphism can also be observed in other exons (not involved in the 
peptide-binding groove), introns and untranslated regions (UTRs) and can result 
in non-coding polymorphism, synonymous or non-synonymous substitutions, 
stop codons, alternative splicing and aberrant expression [20-33]. Several 
mechanisms account for the origin of HLA polymorphism: point mutations, gene-
conversion and recombination [18]. For example, the HLA-A69 allele evolved from 
a recombination between HLA-A68 and one of the HLA-A2 alleles [34], and the 
HLA-B42 allele evolved from HLA-B7 and HLA-B8 alleles [35]. An unique interlocus 
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recombination is observed for the HLA-B*4601 allele, that for the majority exists 
of the HLA-B*1501 allele, while the amino acids at positions 66 though 76 are 
derived from the HLA-Cw*0102 allele [36]. These mechanisms led to a numerous 
number of HLA class I and class II alleles for which names have been assigned by 
the World Health Organization (WHO) HLA Nomenclature Committee. The IMGT/
HLA database (version 2.11) (http://www.ebi.ac.uk/imgt/hla/) harbours 1403 
class I alleles, 781 class II alleles and 96 alleles of HLA related and non-HLA 
related genes. The major contributors for the class I alleles is HLA-B and HLA-
DRB1 for class II [12].
The different loci with their extensive polymorphism result in high numbers 
of HLA haplotypes, deﬁ ned as “the combination of HLA alleles from different 
HLA loci on a single chromosome in an individual” [1]. As a result of linkage 
disequilibrium, deﬁ ned as “the non-random association of HLA alleles at adjacent 
HLA loci”, linkage between alleles of different loci exists. The frequencies of these 
HLA haplotypes are higher or lower than was expected based upon the frequencies 
of the individual alleles of the loci. Linkage disequilibrium exists among HLA class 
I alleles, among class II alleles and between class I and II alleles. Based upon 
segregation analysis in family studies and independent non-family studies, linkage 
disequilibria have been determined [37-45].
HLA nomenclature
The HLA Nomenclature Committee, under the auspices of the WHO, was 
founded to formulate guidelines for the ofﬁ cial assignment of HLA antigens and 
alleles [46]. Serological methods initially detected a few HLA speciﬁ cities for class 
I, the broad speciﬁ cities and public epitopes, and these speciﬁ cities received 
names based upon the gene locus and followed by a number, e.g. HLA-A2 or 
HLA-A9. Later on, splits or private epitopes for several broad speciﬁ cities could 
be identiﬁ ed, e.g. the HLA-A23 and HLA-A24 splits belong to the broad speciﬁ city 
HLA-A9. The introduction of cellular methods added additional information in the 
identiﬁ cation of HLA antigens. This technique not only detected more subtypes 
within a single class I antigen, that generally could not be detected by serology, 
but revealed also the existence of another group of HLA antigens, the class II 
antigens. This resulted in complexities in the correct deﬁ nition of HLA antigens. 
Monoclonal antibodies, biochemical and molecular approaches were subsequently 
developed in order to discriminate HLA antigens intra- and interlocus [11, 18]. 
Guidelines for the assignment of HLA antigens and alleles, as formulated 
by the WHO, resulted in the following nomenclature: the name of the locus is 
followed by an asterisk, indicating that the HLA allele was determined at molecular 
level. The 1st and 2nd digits identify the allele family, in general corresponding 
with the serological group to which the allele belongs (HLA-A*02 alleles belong to 
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the serological antigen HLA-A2). The 3rd and 4th digits indicate non-synonymous 
substitutions in exons, changing thus the amino acid composition of the antigen. 
The 5th and 6th digits give a synonymous substitution in an exon and sequence 
polymorphism within introns, the 5´-untranslated (UTR) or 3´-UTR is given by the 
7th and 8th digits [12]. In addition, 5 extra sufﬁ xes can be added for HLA alleles 
designating their expression status: “N”, “L”, “S”, “C” and “A” [47-49]. An “N”-sufﬁ x 
indicates an HLA null allele that according to the HLA Nomenclature Committee 
is deﬁ ned as “a sequence defect in an HLA allele or gene which prevents normal 
expression of the product at the cell surface (it does not necessarily imply that no 
internal partial product is made which might be a T-cell target)” [48]. The sufﬁ x 
“L” indicates that the allele “is associated with unusual expression levels” [47]. 
The sufﬁ x “S” denotes “an allele specifying a protein that is expressed as a soluble 
“secreted” molecule but is not present on the cell surface”. No alleles have been 
described to date for the sufﬁ xes “C”, “an allele product present in the cytoplasm 
but not at the cell surface” and “A”, “aberrant expression if there is some doubt 
whether the protein is expressed” [49].
HLA typing
Since the discovery of the HLA system HLA typing methods have been 
developed to discriminate alleles intra- en interlocus and these methods can be used 
in a variety of disciplines, i.e. in solid organ and haematological transplantations, 
disease-association studies, anthropology, epidemiology and forensics. Several 
factors should be taken into consideration when performing HLA typing regarding 
the material, the required resolution and the choice of typing system. In family 
transplantation low-resolution typing by serology may provide sufﬁ cient information 
to select an appropriate family donor, while in unrelated donor settings, the donor 
should be typed by high-resolution. Three levels of resolution can be discriminated: 
low-resolution, obtained with serological methods or sequence-speciﬁ c priming 
(SSP) mimicking serological equivalents, and intermediate and high-resolution 
methods with molecular-based approaches.
The complement-dependent cytotoxicity test (CDC) is used for obtaining a 
low-resolution class I HLA typing. Polyclonal antisera, with known HLA speciﬁ cities, 
are mixed with viable cells from the sample with unknown HLA typing. Recognition 
by the polyclonal sera, reﬂ ected by the lysis of the cells to be tested, indicates that 
the same HLA typing is present in the cells to be tested. For class II the mixed 
lymphocyte reaction (MLR) was available in which stimulator cells with known HLA 
typing were mixed with responder cells with unknown HLA typing. Proliferation 
of the responder cells indicates that the HLA typing of the responder cells is not 
the same as the stimulator cells. Although serological typing is able to provide 
information regarding the presence of particular HLA antigens, shortcomings are 
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the need for viable cells and the limited ability to provide a detailed HLA typing. 
Polymorphism present deep within the peptide-binding groove is in general not 
accessible for the polyclonal antisera [11].
The introduction of molecular-based approaches paved the way for a 
straightforward identiﬁ cation of the class I and II allelic variants, deﬁ ning the 
alleles that belong to the same serological deﬁ ned group. Three techniques will 
be discussed: sequence-speciﬁ c oligonucleotide probing (SSOP), sequence-
speciﬁ c priming (SSP) and sequencing based typing (SBT). All three methods 
use a polymerase chain reaction (PCR) as the initial basis to selectively amplify 
the entire or partial HLA locus of interest. Subsequently, additional probing or 
sequencing can be performed to identify the allele or alleles individually.
The PCR template generated with the SSOP method is ﬁ xed to a membrane 
and labelled oligonucleotide probes, speciﬁ c for different polymorphic sequences, 
are hybridized to the membrane. The opposite is also possible, called the reverse 
dot blot approach and this approach is more widely used than the conventional dot 
blot approach since one hybridization step is required for typing of one sample. 
The oligonucleotide probes are ﬁ xed to the membrane and a labelled PCR product 
is subsequently hybridized to the membrane. The obtained hybridization pattern 
will result in an HLA typing [11]. Similar to the concept of SSOP, an oligonucleotide 
micro-array has recently been introduced for HLA-DRB1 genotyping [50].
The SSP method is based on speciﬁ c PCRs only. One or more sequence 
speciﬁ c PCRs are developed for each allele or allele-group that generates a pattern 
of positive and negative PCR product fragments with deﬁ ned sizes. Depending 
on the HLA locus investigated, the number of PCRs to be performed varies. The 
combination of the results of the speciﬁ cally ampliﬁ ed fragments results in an HLA 
typing. Probes and primers used in the SSOP and SSP approach are in general 
located at polymorphic positions to discriminate between the different HLA alleles 
or allele groups within a locus [11].
The SSP and SSOP method are useful for the identiﬁ cation of serological 
equivalents. For the identiﬁ cation of allelic variants belonging to the serological 
equivalents, the number of primers/probes required for the identiﬁ cation is much 
higher compared to the number required for identiﬁ cation of the serological 
equivalents. For new alleles, primers or probes may have to be added, changed 
or relocated and in addition implemented into the SSP and SSOP method. New 
polymorphisms present within existing PCR products will likely not be determined 
with the SSP and SSOP method. The resolution obtained with these methods is in 
most cases an intermediate resolution (two-digit level). To obtain a higher typing 
resolution a higher number of hybridization or SSP reactions are required. 
In 1977, Sanger et al. initiated a sequencing method based upon dideoxy 
chain termination to determine nucleotide sequences of bacteriophage DNA [51]. 
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Throughout the years reﬁ nements have been realized, e.g. automated sequencing, 
resulting in the SBT method that is now considered to be the golden standard for 
allele identiﬁ cation. In the context of HLA typing, the SBT method was initially 
developed to conﬁ rm HLA typings obtained with SSP/SSOP and solve the difﬁ cult 
samples. Direct sequencing approaches were developed subsequently to directly 
identify the alleles. The International Histocompatibility Working Group (IHWG; 
http://www.ihwg.org/) has initiated protocol development for SBT of the HLA 
class I and II loci during International Workshops, resulting in a Technical Manual 
with standardized strategies for HLA typing. These protocols enable to investigate 
coding and non-coding sequences to obtain insight into the polymorphic character 
of HLA. Software for sequence data analysis and allele assignment were developed 
(SBTengine®; Genome Diagnostics, Utrecht, The Netherlands) [52].
As for SSOP and SSP, the SBT method starts with the ampliﬁ cation of HLA 
alleles of interest. The PCR ampliﬁ cation primers are located in introns where 
possible. In the next step, sequencing reactions determine the exact sequence 
in the alleles and computerized-based analysis assigns the correct HLA alleles 
in a sample. Knowledge of polymorphism of different exons may be required to 
identify the alleles. In heterozygous sequencing separation of alleles is sometimes 
required if ambiguous allele combinations are obtained. New polymorphic positions, 
if present in the ampliﬁ ed product, are easily recognised with the SBT method.
Inﬂ uence of HLA polymorphism
HLA polymorphism is present in all coding and non-coding regions of an 
HLA gene and is determined by different techniques. The density of polymorphic 
positions varies between the different regions, with the peptide-binding groove by 
far the most polymorphic region in the HLA molecule. Polymorphism in the HLA 
molecule inﬂ uences the peptide binding, the interaction of HLA molecules with 
T-cells/NK-cells, the expression level of HLA molecules and the transport of the 
HLA molecules to the cell surface. Polymorphism in the peptide-binding groove, 
composed of 5 or 6 pockets, enables the HLA molecules to present a wide range of 
different peptides to T-cells and B-cells. The chemical composition of the pockets 
of an HLA molecule has a direct impact on the structural composition and charge 
of the peptide binding-groove. Thus, polymorphism affects peptide-binding, T-cell 
binding and T-cell reactivity.
Depending on the amino acids present in the peptide-binding groove, 
different outcomes are observed: i) differences in amino acid with minimal effect 
on peptide binding, indicating that the same peptides can be bound [53], ii) 
binding of different peptides [53-57], that results in a distinct T-cell recognition 
and reactivity pattern [54, 56], iii) inﬂ uencing the strength of the peptide-binding 
[58], iv) although differences in amino acids in HLA are present, the peptide 
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binding is the same, but interacts in a different way with the HLA molecules and 
induces in this way different T-cell repertoires [59, 60] or v) based upon the amino 
acid present in the peptide, the peptide is loaded onto the HLA molecule in a TAP-
dependent or TAP-independent pathway [61, 62]. 
NK-cells interact with HLA molecules via killer-cell immunoglobulin-like 
receptors (KIR) present on the NK-cells. These KIRs either inhibit or activate 
lysis of cells, depending whether the KIR ligand is present on HLA molecules that 
are expressed on the cell surface. HLA-C molecules, one of the major ligands, 
can be divided into two groups based upon polymorphism present at positions 
77-83 in the α2 domain for interaction with particular KIRs, while the Bw4 
epitope (positions 77-83) is required for the interaction between KIRs and HLA-B 
molecules. In addition to these positions, other positions outside the Bw4 epitope 
also contribute to the HLA-B/NK cell interaction [63-65].
HLA cell surface expression can be affected by polymorphisms in the 
genomic sequence of an HLA allele. At present 68 null alleles, 1 soluble allele 
and 4 low expressed alleles are identiﬁ ed (IMGT/HLA database, version 2.11) 
[12]. Loss of expression is caused by nucleotide substitutions leading to an 
immediate premature stop codon [66-68], insertions or deletions causing a frame 
shift with consecutive stop codon [69-73] and substitutions or deletions affecting 
the splicing machinery [74-76]. The low expressed alleles “HLA-A*0101null” [77] 
and HLA-A*02010102L [78] are both caused by polymorphism in the enhancer B 
element in the promoter region, and in the HLA-A*24020102L allele, an intronic 
substitution in the splice acceptor site caused low expression levels [70, 79]. A 
non-synonymous substitution in codon 164 resulted in improper folding and loss of 
expression for the HLA-A*3014L (GenBank AY323229) and the HLA-B*39010102L 
has a two-nucleotide deletion in the 5’-UTR causing the low expression level 
(GenBank AB091216). The transmembrane region, encoded by exon 5, is not 
included in the HLA-B*44020102S due to a single nucleotide difference in intron 4 
at the acceptor splice site leading to a soluble molecule [80]. 
Functionality of HLA polymorphism
Immune surveillance of HLA molecules by T- and NK-cells ensures the 
elimination of invading pathogens during a viral infection. In autoimmune diseases 
on the other hand, the immune system attacks healthy cells of a person, thereby 
initiating an immune response with subsequent damage. Tumour cells developed 
mechanisms to escape immune surveillance by T- and NK-cells, e.g. through 
down-regulation of HLA expression. From a tumour’s point of view, it would be 
advantageous to downregulate expression of those HLA molecules that could 
present tumour-associated antigens (TAA). In leukaemic blasts a downregulated 
expression was observed for HLA-A molecules and HLA-B alleles with a Bw6 epitope 
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while expression of HLA-B alleles with a Bw4 epitope was not downregulated, 
indicating that in this way leukaemic blasts could both escape from T and NK-cell 
immune surveillance [81] and in this way promote tumour growth. In solid organ 
and haematological transplantations, matching for HLA polymorphisms between 
donor and recipient has shown essential. Mismatching may inﬂ uence peptide 
presentation, initiating an immune response, leading to graft rejection and graft-
versus-host disease (GvHD), and resulting in lower survival rates and increased 
mortality, thus inﬂ uencing the outcome of transplantation.
HLA and transplantation
Initially only serological methods were available for identiﬁ cation of HLA 
antigens in patient and donor. Typing for HLA at high-resolution level with 
molecular-based approaches provides more insight in HLA polymorphism compared 
to typing at low-resolution level with serological methods. Studies have shown 
that mismatching at antigen level has worse transplant outcomes when compared 
to mismatching at allelic level [82-84]. Finding a matched donor is complicated by 
extensive HLA polymorphism, linkage disequilibrium and constraints on time limits 
[82]. Identiﬁ cation of permissible and immunogenic mismatches was performed 
in kidney transplantations. The presence of permissible mismatches resulted 
in kidney graft survival rates equally or better than in matched donor-recipient 
couples. Signiﬁ cant higher graft survival rates were observed compared to the 
immunogenic mismatches, for which graft survival was poor [85]. 
Investigation of the inﬂ uence of HLA class I and II allele matching on graft 
rejection, GvHD, relapse, survival and mortality rates in stem cell transplantation 
have not resulted in clear conclusions regarding the exact role of the different 
HLA loci [86-91]. Some single class I or single class II mismatches in stem cell 
transplantation give clinical outcomes almost as good as HLA matched recipient/
donor couples [92]. Mismatches at position 116 in the class I molecules however, 
involved in peptide binding, result in an increased risk for developing severe acute 
GvHD and transplant related mortality compared to other polymorphisms involved 
in peptide binding [93]. 
In HLA-DPB1 matched kidney cadaver retransplants, survival is improved 
compared to mismatched retransplants [94]. Epitope matching for HLA-DPB1 in 
cadaver kidney transplantation, based upon hypervariable regions A through F in the 
β1 domain of the DP molecule, indicated that speciﬁ c DPB1 hypervariable regions 
were associated with improved graft survival. Matching for speciﬁ c hypervariable 
regions seemed to be functionally more relevant than allelic matching [95].
The role of HLA-DP in stem cell transplantation is not yet understood and 
provide contradictory results [86, 89, 91, 96, 97]. Evaluation of matching for HLA-
DPB1 in stem cell transplantations showed that HLA-DPB1 matching had either no 
chapter 1.indd   Sec1:20 1/5/2006   12:42:17
21
Chapter 1
effect on the outcome [86, 89], or improved survival [91], or increased relapse 
rates [96], or was associated with GvHD [91, 96, 97]. If speciﬁ c amino acids of 
HLA-DPB1 are considered, mismatching of amino acid position 69, involved in 
peptide binding, was associated with increased helper T lymphocytes precursor 
frequencies in stem cell transplantations [98]. In patients with a single HLA 
mismatch at the DP locus, T-cells restricted for the mismatched DPB1 allele were 
observed in the patients [99-101]. Functional studies with DPB1 restricted T-
cells predicted three groups of HLA-DPB1 alleles with different immunogenicity 
for the HLA-DP restricted T-cells. From these functional studies an algorithm was 
developed to predict permissive and non-permissive HLA-DPB1 allele combinations 
[102]. Non-permissive HLA-DPB1 mismatches increased acute grade II to III GvHD 
frequency and transplantation related mortality in patients matched for HLA-A, -B, 
-Cw, -DRB1 and -DQB1 at allele level.
HLA and autoimmune disease
Several hypotheses have been postulated that may explain HLA associations 
in autoimmune diseases. Presentation of pathogenic peptides or biochemically 
modiﬁ ed self-peptides, selection of T-cells in the thymus that are speciﬁ c for HLA 
molecules presenting self-peptides, modiﬁ cation of the peptide binding groove, 
altering the peptide-binding speciﬁ city and linkage of an HLA gene/allele to a 
predisposing non-HLA disease gene are some examples [103]. Associations with 
HLA are either identiﬁ ed as susceptible or protective. The majority of autoimmune 
diseases is associated with HLA class II genes, and only a few associations have 
been reported with HLA class I genes.
The ﬁ rst recognized association between HLA and an autoimmune disease, 
and one of the strongest associations, was the observation that almost all patients 
with ankylosing spondylitis have HLA-B27 while the B27 only in a few percent of 
healthy individuals was detected. Other associations with class I genes are HLA-
B51 in Behçet’s syndrome, HLA-Cw6 with psoriasis vulgaris and HLA-A*2902 with 
birdshot retinitis, which shows an association as strong as observed for B27 and 
ankylosing spondylitis [104-108]. 
For associations with class II loci, it is often difﬁ cult to determine whether 
the DR or the DQ locus is primarily involved due to the extensive linkage 
disequilibrium between both loci. This is the case in insulin-dependent diabetes 
mellitus (IDDM, type 1 diabetes) and rheumatoid arthritis (RA). Depending on 
the individual DR or DQ alleles or the combination of DR/DQ alleles in a patient 
present, either susceptible or protective DR-DQ associations can be deﬁ ned. It 
is thought that the DR/DQ association in RA and IDDM depends on respectively 
shared epitopes in RA-associated DRB1 alleles and on individual amino acids in 
IDDM-associated DR and DQ alleles [103, 109-112]. In sarcoidosis a DRB1-DQB1 
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haplotype association is observed but it was not clear whether the DRB1*150101 
allele or the DQB1*0602 allele is primarily involved in the disease [113].
Celiac disease is one of the few autoimmune diseases for which the cause 
has been explained. Patients diagnosed with this disease are intolerant to gluten 
and related products. The disease is associated with two DQ molecules that 
contribute both directly in the pathogenesis of celiac disease: the DQ2 molecule 
(DQA1*0501,DQB1*0201) and the DQ8 molecule (DQA1*0301,DQB1*0302) 
[114]. CD4+ restricted T-cells for the DQ2 and DQ8 molecules have been isolated 
from the intestine from celiac patients, recognizing gluten peptides [115, 116]. 
Elucidation of the peptide-binding characteristics of the DQ2 molecule indicated 
that the structural requirements of the DQ2 molecule did not ﬁ t entirely possible 
candidate gluten-derived peptides [117]. However, the breakthrough came with 
the ﬁ nding that peptides derived from gluten were in general ﬁ rst deamidated 
by an enzyme called tissue transglutaminase, before they were presented by the 
DQ2 and DQ8 molecules and subsequently eliciting an immune response [118].
With the availability of the entire sequences of the human genome as 
performed by the Human Genome Project, information has become available 
on genes other than the HLA genes in the HLA region. Reﬁ nement of the HLA 
associations observed in (autoimmune) diseases may result in the identiﬁ cation 
of other genes in the HLA region that are primarily involved in the disease 
pathogenesis. 
HLA related and non-HLA related diversity
The entire HLA region, including the extended regions, has been sequenced 
by the Human Genome Project, and has revealed an enormous amount of gene 
information. Six gene clusters and six gene superclusters can be discriminated in 
the HLA and its extended regions [1]. A cluster is deﬁ ned as “a cluster of genes 
with three or more paralogous genes or pseudogenes present within 1 Mb”. The six 
clusters are: solute carrier cluster, vomeronasal-receptor cluster, tumour necrosis 
factor cluster, lymphocyte antigen cluster, heath shock cluster and HLA class II 
cluster. A supercluster is deﬁ ned as “clusters with additional related gene(s) outside 
the core cluster, but within the HLA and its extended region”. The six superclusters 
are: histone supercluster, HLA class I supercluster, tRNA supercluster, butyrophilin 
supercluster, olfactory-receptor supercluster and the zinc-ﬁ nger supercluster [1]. 
The genes in the HLA and extended regions have several biological functions, 
with an emphasis on immunological functions. Those genes with immunological 
functions can be categorized into groups: i) antigen processing and presentation; 
ii) immunoglobulin superfamily; iii) inﬂ ammation; iv) leukocyte maturation; v) 
complement cascade; vi) non-classical MHC molecules; vii) immune regulation 
and viii) stress response [1].
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An example of HLA related genes are the MIC genes, located in the class 
I region, structurally related to the class I molecules, but not able to present 
peptides or interact with β2m [119, 120]. Two functional genes, MICA and MICB, 
and ﬁ ve pseudogenes, MICC, MICD, MICE and MICF, have been identiﬁ ed [121]. 
Particularly MICA displays a high degree of polymorphism, with currently 60 
identiﬁ ed MICA alleles [12]. MICA and MICB are stress-inducible molecules are can 
be recognized by NK-cells and T-cells, expressing the NKG2D receptor [122-124]. 
Different cell types constitutively express MICA and expression can be induced 
in cells upon stress, for example after viral infection or tumour transformation 
[123, 125-128]. The precise function of MICA in the immune response cascade is 
unknown.
In addition to the HLA, HLA related and non-HLA related genes, repeated 
sequences are located throughout the HLA region, named microsatellites or short 
tandem repeats (STR) that can be used as markers. These microsatellite markers 
are located primarily in non-coding regions, consisting of repeated lengths of 2 to 
6 basepairs and are in linkage disequilibrium with the classical HLA loci [129, 130]. 
Since the majority of microsatellite markers are located in non-coding regions, 
they do not have a direct correlation with gene expression. Microsatellite markers 
are used in the context of different purposes: as follow-up for monitoring mixed 
chimerism status after stem cell transplantation, for the mapping of predisposing 
genes in disease association studies, in population genetics and for evolutionary 
aspects of population genetics, in forensics and for determination of microsatellite 
instability in tumours. Several research groups have established a microsatellite 
marker map for the HLA region with information regarding the microsatellite 
markers within the HLA region [131-137]. These reports harbour information 
concerning the length of the repeat, the number of different alleles observed for 
the marker, the localization of the marker within the HLA region and the primer 
sequences used to amplify the microsatellite marker.
Disease-associations were initially based on HLA locus/allele associations. 
Since it is difﬁ cult to determine if the HLA gene itself or a gene in linkage 
disequilibrium with the associated HLA allele or haplotype is involved, further 
reﬁ nement is required. The identiﬁ cation of the gene responsible for the disease 
can be reﬁ ned and deﬁ ned with microsatellite analysis. For example, Behçet 
disease is associated with HLA-B*5101 [107], but analysis of microsatellite 
markers located in the vicinity of the HLA-B locus identiﬁ ed an associated region 
of 46 kb between the MICA gene and HLA-B, indicating that within this region the 
candidate gene for Behçet disease might be located [138]. MICA analysis revealed 
associations between Behçet disease and the MICA-A6 repeat and the MICA*009 
allele [139-141]. HLA-B*51 and MICA-A6/MICA*009 are in linkage disequilibrium; 
it is therefore difﬁ cult to indicate which is the primary disease factor. The same 
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holds for psoriasis vulgaris, initially associated with HLA-Cw6, but microsatellite 
association analysis indicated a region spanning 111 kb telomeric from HLA-C 
to be a susceptibility locus with candidate genes for psoriasis [142]. In other 
diseases microsatellite analysis has been applied either as a ﬁ rst screening or as 
a reﬁ nement for existing HLA associations to identify susceptibility regions: non-
melanoma skin cancer [143], insulin-dependent diabetes mellitus [144, 145], 
rheumatoid arthritis [146] and idiopathic arthritis [147]. In contrast, very few 
information is available regarding HLA associations in cancer. 
Head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) originates from epithelial 
cells that line the upper aerodigestive tract. In HNSCC different tumour locations 
can be distinguished: the oral cavity includes lips, buccal mucosa, alveolar 
ridges, retromolar trigone, ﬂ oor of the mouth, anterior two thirds of the tongue, 
hard palate and gingivae. Laryngeal tumours originate from supraglottis, glottis 
and subglottis and nasopharyngeal tumours from the nasopharyngeal tonsils. 
The oropharynx includes soft palate, tonsillar pillars, palatine tonsils, posterior 
tonsillar pillars, uvula, base of the tongue and vallecula whereas hypopharynx 
includes the pyriform sinus, cricoid cartilage, thyroid cartilage, hyoid bone and 
posterior part of the pharynx wall, major (parotid, submandibular, submaxillary 
and sublingual glands) and minor salivary glands and the ear (external, middle 
and internal) [148]. The oropharynx, hypopharynx and nasopharynx are grouped 
together under the name pharynx. Tumours occur most frequently in the larynx, 
oral cavity and oropharynx (http://www.iKCnet.nl). Nasopharyngeal tumours on 
the other hand are very rare in the Netherlands whereas in the Mediterranean 
region and Asia higher incidences are observed for this type of tumour [149, 
150]. In general more males are affected than females with HNSCC, although the 
number of females increases due to changes in their life style in the second half 
of the previous century. Classiﬁ cation of the tumours occurs via a standardized 
system, the TNM system that includes 4 stages (I, II, III and IV). This staging is 
based upon the size of the tumour, presence or absence of lymph node metastases 
and presence or absence of distant metastases [148].
Although the numbers of all new HNSCC cases diagnosed per year have 
increased between 1989 and 2003 (1950 new cases in 1989 to 2408 new cases in 
2003), the overall incidence of HNSCC per 100,000 inhabitants has not changed 
dramatically during these years according to the Dutch Comprehensive Cancer 
Centres (Vereniging van Integrale Kankercentra, VIKC; http://www.iKCnet.nl). In 
1989 an overall incidence of 14.1 per 100,000 inhabitants was observed to 13.7 
per 100,000 in 2003. If the different HNSCC tumour locations are considered 
separately in the context of their incidence, differences are observed. The overall 
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incidence of tumours in the oral cavity, and in the pharynx has increased with 
respectively 44% and 15% in the period 1989-2003, whereas the overall incidence 
for larynx, lip, nasopharynx/ear has decreased (28%, 33% and 25% respectively). 
The overall incidence for tumours of the salivary glands did not change. A distinction 
based upon sex shows that the ratio males/females diagnosed with HNSCC was 
3.1 in 1989 and 2.2 in 2003, indicating that the number of females diagnosed 
has increased during this period. When HNSCC tumour locations are considered 
in relation to sex during the period 1989-2003, incidences for tumours of the 
oral cavity, the lip, the larynx and the salivary glands have increased in females 
while they have decreased in males. The largest increase in females is observed 
for tumours of the lip: in 1989 12.4% of the lip tumours were present in females 
while in 2003 this percentage was increased to 25.8% (http://www.iKCnet.nl).
The 10-year survival of HNSCC differs also between tumour locations, their 
sub-locations and the sex of the patient. Patients with a lip tumour have a good 
prognosis, 90% of patients are still alive after 10 years; although patients with 
small tumours and TNM stage I or II have higher survival rates than patients 
with TNM stage III or IV. For tumours of the oral cavity approximately 50% of 
the patients are still alive after 10 years, but this depends on the sub-location 
of the oral cavity tumour, the TNM stage and the age of the patient. A worse 
prognosis is seen in patients with a tumour in the pharynx; approximately 30% 
is still alive after 10 years. Increasing age, sub-locations and higher TNM stage 
are not advantageous for survival of the patients. Sixty percent of patients with 
a laryngeal tumour are still alive after 10 years; for this type of tumour being a 
female, older than 75 years, sub-location and higher TNM stage contribute to a 
poor survival (http://www.iKCnet.nl).
Two major risk factors are correlated with the development of HNSCC. 
The ﬁ rst is excessive alcohol consumption and the second is smoking tobacco, 
particularly cigarettes. These two factors confer each an individual risk, but in 
combination they provide a highly increased risk for HNSCC development [148, 
151-154]. Depending on the location of the HNSCC tumour and the sex of the 
patient, differences in risk contribution can be observed for alcohol and tobacco 
consumption. Patients who present with advanced stage of disease are heavy 
drinkers and smokers [151-153]. The rising incidence of females diagnosed with 
HNSCC is attributable to the fact that their smoking and/or drinking habits have 
increased in the second half of the 20th century. Several other factors are also 
potential risk factors for the development of HNSCC: long exposure to sunlight 
(lip tumours), occupational exposure to nickel, asbestos, and wood, familiar and 
genetic factors and several viruses [148, 155-157].
Current therapies for treatment of HNSCC are surgery, radiotherapy and 
chemotherapy, either alone or in combination. Several factors should be taken 
chapter 1.indd   Sec1:25 1/5/2006   12:42:17
26
into account for the choice of treatment: tumour location, TNM stage and absence 
or presence of (lymph node) metastases and the preservation of the organ [158]. 
Tumours that are detected in an early phase can be treated well with surgery 
or radiotherapy but over time it has become clear that an increasing number of 
patients present with advanced stage of HNSCC when diagnosed at the hospital 
[159]. Advanced stage tumours are then treated with surgery or radiotherapy 
in combination with chemotherapy, which is either given before, during or after 
surgery or radiotherapy [158, 160]. For these patients, cure is not always feasible; 
therefore this combination therapy is also given as palliative treatment.
In spite of many years of research, HNSCC remains a very heterogeneous 
disease for which the precise biological and molecular mechanisms involved 
are not entirely elucidated. Characterization of these mechanisms involved 
might eventually lead to a better treatment for the patients. The occurrence 
of chromosomal aberrations, (epi)genetic changes in tumour suppressor genes 
and oncogenes, with subsequent altered expression levels, have been observed 
in HNSCC. The tumour suppressor gene p53 has a high mutation frequency 
in HNSCC’s, resulting in aberrant expression [161, 162]. In addition, loss of 
heterozygosity (LOH) of the short arm of chromosome 17, on which the p53 is 
located, is also observed [163]. Loss of the chromosomal region 9p, related with 
the altered functioning of the p16/p14ARF gene, loss of chromosomal region 3p, 
with the candidate tumour suppressor genes FHIT and RASSF1A, and ampliﬁ cation 
of the 13q region, with oncogenes as bcl-1, int-2, hst-1 and proto-oncogene cyclin 
D1, are observed in HNSCC. Protein and mRNA EGFR overexpression is observed 
in many HNSCCs and thought to correlate with poor prognoses [163]. Recently, 
a gene expression predictor proﬁ le was identiﬁ ed that allows detection of those 
HNSCC tumours at risk for development of metastases [164]. A total of 102 
predictor genes were identiﬁ ed with this approach, a number of them already 
known for their involvement in metastases but the majority still unknown and 
functionally involved as extracellular matrix components, in cell adhesion, cell 
death and cell growth.
Head and neck squamous cell carcinoma and HLA
Genes located on several chromosomes are involved in the carcinogenic 
process occurring in HNSCC. HLA and other genes within the HLA region on the 
short arm of chromosome 6 are also important for clearance of the HNSCC tumour 
cells. Associations with HLA genes have mainly been investigated in patients 
diagnosed with nasopharyngeal carcinoma (NPC). These studies show that only 
certain HLA-A and HLA-B alleles are associated with NPC [165-168]. In Asian 
patients for example, the HLA-A*02-B*46 haplotype confers an increased risk for 
development of NPC [165, 166]. In addition to HLA-A*02 and HLA-B*46, HLA-
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A*11 was identiﬁ ed as a protective allele for the development of NPC [166, 167]. 
In Caucasian HNSCC patients, the relation between HLA genes and prognosis was 
investigated and it has been shown that the presence of either HLA-A11 or HLA-
DR6 was associated with decreased survival rates among these patients [169]. 
Whether these associations are directly involved in the carcinogenic process of 
HNSCC is not yet known, but due to the phenomenon of linkage disequilibrium in 
this region, it cannot be excluded that other genes, linked to these HLA genes/
haplotypes, are the true genetic factors involved.
Aberrant expression of HLA molecules on tumour cells is a well-known 
phenomenon in tumours. Aberrant HLA class I expression can be classiﬁ ed 
into groups [170-172]. Monomorphic, locus speciﬁ c, allele speciﬁ c and anti-
β2m antibodies were used in primary HNSCC tumours and their lymph node 
metastases to determine HLA expression [173-175]. Besides the presence of 
diverse HLA expression patterns in HNSCC, these studies as well demonstrated 
the important advantage of allele speciﬁ c antibodies over monomorphic and locus 
speciﬁ c antibodies. A striking observation was the difference in HLA expression 
patterns between primary tumours and lymph node metastases in several 
patients [174], indicating that knowledge about the expression status is crucial 
for immunotherapeutical intervention. Several molecular mechanisms have been 
identiﬁ ed for the aberrant expression patterns [171]. Sequencing based mutation 
analysis of the β2m gene indicated that β2m mutations are rare in HNSCC [176, 
177] while in melanomas and colorectal tumours “hotspot” mutations in β2m have 
been described [177, 178]. In laryngeal tumours, among other tumour types, loss 
of HLA-B44 antigen expression was observed more frequently than expression 
loss of HLA antigens. This was not correlated with a decreased HLA-B*44 allele 
frequency in the patients [179]. The loss of HLA-B44 antigen expression in colon 
carcinomas was due to a defective tapasin transcription [180]. Other mechanisms 
that can contribute to the loss of expression are LOH of chromosomes 6 and 15. It 
should however be kept in mind that with determination of LOH no discrimination 
can be made between ampliﬁ cation and loss of chromosomal regions or genes. 
Additional techniques as ﬂ uorescent in-situ hybridisation (FISH) analysis and 
immunohistochemistry should be used to validate the LOH results [175, 181-
183]. HLA expression loss at both the mRNA and protein level can be caused by 
hypermethylation of the HLA genes themselves. HLA-A, -B and -C have numerous 
locations where DNA methylation can occur [184]. Aberrant expression of genes 
involved in the antigen processing and presentation pathway for class I molecules 
has also been investigated as cause of HLA class I expression loss [174, 178, 185, 
186]. 
Determination of HLA diversity provides information on the functional role 
of HLA diversity in health and disease, explaining e.g. whether aberrant HLA 
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expression arises as a consequence of HLA diversity or as a consequence of the 
involvement of other genes in the HLA region. The availability of this information 
is useful to acquire knowledge about HLA diversity and functionality in several 
biological processes. This thesis has been performed to understand if, and how, 
HLA diversity is functionally involved in the pathogenesis of HNSCC. 
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Outline of the thesis
The human leukocyte antigen (HLA) system on the short arm of chromosome 
6, the human equivalent of the major histocompatibility complex (MHC), is the 
most polymorphic region of the human genome and includes three regions: HLA 
class I, II and III. Within these regions many HLA, HLA-related and non-HLA related 
genes are located, which have an important function in immune responses. Disease 
associations with HLA alleles have been described and aberrant HLA expression 
patterns are observed in tumours. The rationale of this thesis is therefore to 
determine if and how HLA genes, HLA-related and non-HLA related genes in the 
HLA region are involved in the pathogenesis of HNSCC.
The role of genes, within the HLA region, in the pathogenesis of head and 
neck squamous cell carcinoma (HNSCC) can be inﬂ uenced by the diversity within 
a gene, or by expression differences. Diversity can be determined with DNA-based 
techniques, whereas the expression of genes can be determined by using speciﬁ c 
monoclonal and/or polyclonal antibodies. The scarcity of available allele speciﬁ c 
antibodies limits a broad applicability for the identiﬁ cation of HLA molecules 
by immunohistochemical methods. RNA-based approaches provide information 
regarding the diversity, expression and functional status of genes in tumours at 
transcriptional level and partially compensate for the lack of the limited availability 
of antibodies. Aberrant HLA expression patters are present in HNSCC. Exploring 
the HLA diversity and the functionality of HLA diversity in HNSCC provides insight 
in the pathogenesis of HNSCC.
HLA gene diversity is determined both at the allele and antigen level for 
which molecular and serological approaches are widely used. For detection of 
transcripts, RNA sequencing based typing (SBT) protocols for the class I genes 
HLA-A, -B and -C and the class II gene HLA-DPB1 were developed. The diversity of 
HLA, HLA-related and non-HLA related genes within the HLA region was correlated 
with the pathogenesis of HNSCC. 
An RNA SBT approach was developed to evaluate the inﬂ uence of 
polymorphisms on RNA transcription. Speciﬁ c ampliﬁ cation for each of the class 
I RNA transcripts, subsequently followed by sequencing the entire coding region, 
was performed for HLA expressed and non-expressed alleles present in reference 
cell lines. RNA expression of these alleles was evaluated considering the amount 
of RNA present in the reference cell lines (chapter 2). 
The inﬂ uence of nucleotide polymorphism on RNA expression was examined 
with the developed class I RNA SBT protocol for HLA-A in a leukaemia patient. 
A new nucleotide polymorphism affected RNA transcription and cell surface 
expression of one of the HLA-A alleles (chapter 3). 
Few antibodies are available for diversity and expression analysis of HLA-
DPB1 antigens. Analysis with RNA approaches provides information regarding 
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the expression status of DPB1 and in addition DPB1 diversity is obtained. More 
than 100 HLA-DPB1 alleles have been identiﬁ ed so far, only for a few alleles 
sequence information is available for the DPB1 regions extending exon 2. An RNA 
SBT approach was developed to investigate the extended polymorphism and the 
functional relevance of the extended polymorphism (chapter 4).
HLA-A, -B, -C, -DRB1 and -DQB1 polymorphism was investigated in HNSCC 
patients and in controls to determine whether particular HLA alleles or haplotypes 
were associated with HNSCC. The results observed point towards associations with 
HLA-B*40 and B*35 alleles and the HLA-B*40-DRB1*13 haplotype (chapter 5). 
The frequency of the associated HLA-B-DRB1 haplotype was low in the patients, 
hence this could not be the only risk factor involved in HSNCC.
A potential candidate gene, the MICA gene, was further investigated for its 
role in the pathogenesis of HNSCC. MICA is in linkage disequilibrium with HLA-B 
and is involved in the immune response. Nucleotide and repeat polymorphism 
is present throughout the gene. The repeat polymorphism, present in the 
transmembrane region of MICA, and expression levels of MICA were determined 
with a monoclonal antibody against MICA. The majority of tumours expressed 
MICA protein, no correlation was found between the repeat and MICA expression 
(chapter 6).
A subsequent efﬁ cient screening of the MHC region with microsatellites 
in the class I, II and III regions, using DNA pools from patients with different 
tumour locations, identiﬁ ed associated regions with candidate genes, particularly 
in the oral cavity. mRNA expression of 18 selected genes from these regions 
was evaluated in oral cavity tumour tissue compared to the surrounding healthy 
tissue. MICA mRNA expression was increased signiﬁ cantly in tumour tissue. In 
addition, hydroxysteroid (17-beta) dehydrogenase 8 (HSD17B8) mRNA expression 
was signiﬁ cantly decreased in tumour tissue, especially in those tumours without 
lymph node metastases, while the receptors retinoid X receptor β (RXRβ) and 
NOTCH4 showed a not signiﬁ cant but decreased RNA expression in tumour tissue 
(chapter 7). 
The general discussion reﬂ ects on the potential functional implication of the 
results of this thesis (chapter 8).
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Abstract
An RNA sequencing based typing (SBT) approach for the class I genes HLA-
A, -B and -C was developed to evaluate HLA RNA transcripts and enable full-length 
allele typing. HLA alleles covering the major allelic groups and HLA null alleles 
were evaluated. Full-length RNA sequences were obtained and conﬁ rmed the DNA 
typing. RNA transcripts for most HLA null alleles were present except for the 
HLA-A*0104N and HLA-A*6818N alleles. In addition to the normal spliced alleles, 
alternative spliced transcripts for the HLA-*240201, HLA-A*2409N, HLA-A*2308N 
and HLA-Cw*040101 alleles were identiﬁ ed. For the HLA-A*240201 and the HLA-
A*2409N alleles two different alternative spliced products were identiﬁ ed, one 
product lacking exons 3 and 4, the other exons 3, 4 and 5. For HLA-A*2308N 
one alternatively spliced product was observed, lacking exons 3, 4 and 5. Exon 5 
was deleted in the HLA-Cw*040101 allele. Indicative was the high expression at 
the transcriptional level for the HLA-A*02 alleles compared to the other alleles. 
The RNA SBT protocol allows an easy identiﬁ cation of RNA transcripts and splice 
variants and includes all exon polymorphism.
Introduction
The human leukocyte antigen (HLA) system, the human equivalent of 
the major histocompatibility complex (MHC), is located on the short arm of 
chromosome 6. Three regions, the class I, II and III with the extended class I and 
II regions, comprise together approximately 7.6 Mb of sequence information [1]. 
The classical HLA class I and II molecules are encoded by genes in the class I and 
II region for which 2184 alleles have been identiﬁ ed to date (IMGT/HLA database 
version 2.11) (http://www.ebi.ac.uk/imgt/hla/) [2].
Polymorphism located in the peptide-binding groove of the HLA molecule 
deﬁ nes the peptides that can be bound by the HLA molecule and be presented 
to T-cells. For that reason approaches to determine polymorphism mainly cover 
exons 2 and 3 in class I genes and exon 2 in class II genes, participating in 
the formation of the peptide-binding groove. However, additional polymorphism 
located outside the peptide-binding groove has been described [3-7]. This 
additional polymorphism inﬂ uences binding with the co-receptors CD4 and CD8, 
interaction with β2m, conformational changes of the molecule and cell surface 
expression. 
The ﬁ rst approach for HLA sequencing based typing (SBT) using RNA as 
template was performed in the early nineties with HLA class I locus speciﬁ c 
PCRs and radio-labelled sequencing of exons 2 and 3 [8]. This approach has 
been further developed [9-11]. In the present study an RNA SBT approach 
was developed to identify polymorphism in the entire coding and untranslated 
regions. Additional information regarding the presence of HLA splice variants and 
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consequently aberrant expression of HLA molecules is provided with this approach. 
The combined exons in RNA facilitate the consideration of all exons, which is a 
major advantage of the RNA approach compared to DNA approaches. For a small 
number of null alleles information regarding the presence of a RNA transcript is 
available [12]. The SBT RNA protocol developed in the present study enables 
and provides information regarding the presence or absence of RNA transcripts 
for HLA null alleles. However, full characterization of HLA null alleles can only be 
accomplished with DNA-, RNA and protein-based approaches as shown for HLA-
A*0111N [13].
The aim of this study was to develop a general applicable SBT protocol 
with RNA as template for the identiﬁ cation of RNA transcripts and full-length 
polymorphism. HLA-A, -B and -C alleles from the major allelic groups were included 
in the SBT reference panel and HLA-A and -B null alleles were evaluated for their 
RNA expression.
Material and methods
EBV transformed human B-cell lymphoblastoid cell lines
Epstein Barr virus (EBV) transformed human B-cell lymphoblastoid cell lines 
from the International Histocompatibility Working Group (IHWG; http://www.
ihwg.org/) were selected to evaluate the HLA-A, HLA-B and HLA-C RNA based SBT 
approach. The cell lines include alleles from all major allele groups and ﬁ ve HLA-
A and one HLA-B null alleles. Table 1A summarizes the reference cell lines and 
their HLA class I alleles according to the IHWG and table 1B the cell lines with the 
HLA-A and HLA-B null alleles used in this study. Human B-cell lymphoblastoid cell 
lines were grown and cultured as previously described [14]. 
RNA isolation and cDNA synthesis
Approximately 5 million EBV transformed human B-cells were used to isolate 
total RNA with Trizol reagent according to the manufacturer’s protocol (Invitrogen 
Ltd., Paisley, United Kingdom). The total amount of isolated RNA from the B-cells 
was measured with a spectophotometer at 260/280 nm (Perkin Elmer, Wiesbaden, 
Germany). cDNA synthesis was performed with the Superscript III First-Strand 
Synthesis System for RT-PCR according to the manufacturer’s protocol (Invitrogen 
Ltd., Paisley, United Kingdom) and described previously [13]. For veriﬁ cation of the 
quality of the cDNA a PCR for the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was performed [14, 15].
RNA sequencing based typing of HLA-A, HLA-B and HLA-C
A locus speciﬁ c class I RNA SBT approach was developed to amplify the 
entire coding region of the HLA-A, -B and -C genes, using the protocol earlier 
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described [13]. Table 2A shows the locus speciﬁ c ampliﬁ cation primers for HLA-
A, HLA-B and HLA-C. Ampliﬁ cation of the HLA-A RNA transcript was performed 
with one forward and one reversed locus speciﬁ c primer (primers 1 and 2, table 
2A). A mixture of two forward and two reversed ampliﬁ cation primers were used 
to amplify the HLA-B RNA transcript (primers 3-6, table 2A) and for HLA-C two 
forward and one reversed ampliﬁ cation primer were used (primers 7-9, table 
2A). After ampliﬁ cation, sequencing of the PCR product was performed for all 
three loci with the Big Dye Terminator Ready Reaction Mix v1.1 according to the 
manufacturer’s protocol with class I (locus) speciﬁ c sequencing primers (primers 
10-18, table 2B) and group speciﬁ c sequencing primers (GSSP) (primers 19-33, 
table 2C). Subsequently, sequence products were electrophoresed on an ABI 377 
DNA sequencer (Applied Biosystems). The software package SBTengine® (Genome 
Diagnostics, Utrecht, The Netherlands) was used for allele identiﬁ cation and 
assignment of HLA class I alleles. 
Results
Evaluation of HLA class I transcripts by RNA sequencing based typing
An HLA class I RNA SBT protocol was developed to evaluate HLA class I 
transcripts of expressed and non-expressed HLA molecules. The entire coding 
region was included in the ampliﬁ cation product. Validation of the RNA SBT protocol 
was performed by including HLA class I alleles from most allele groups present 
from a reference panel. For HLA-A, HLA-B and HLA-C, locus speciﬁ c ampliﬁ cations 
were performed and subsequently sequenced with primers speciﬁ c for the class I 
loci as described in table 2B.
Fifteen cell lines with 21 different HLA-A alleles (table 1A), twenty HLA-B 
cell lines with 27 different HLA-B alleles (table 1B) and seventeen different HLA-C 
alleles, present in ﬁ fteen cell lines (table 1C), were evaluated with the RNA SBT 
protocol. The HLA-A, HLA-B and HLA-C typing results obtained with the RNA SBT 
protocol were consistent with the DNA-typing results.
Complex electropherogram proﬁ les were obtained with primers AHRNA-
seqBC-E4F and AHRNA-seqABC-E7R (primers 16 and 17, table 2B) in cell lines 
IHW09024 (HLA-Cw*030301,040101) and IHW09215 (HLA-Cw*040101,-). 
Preliminary results indicate the presence of an alternative spliced transcript for the 
Cw*040101 allele in these cell lines. In addition to the normal spliced Cw*040101 
allele, an alternative spliced transcript with a deletion of exon 5 is identiﬁ ed. In 
the HLA-B*44020102S exon 5 is also deleted giving rise to a soluble HLA antigen 
[16].
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RNA transcripts of HLA class I alleles
The amount of RNA transcript present for one HLA allele, compared to the 
other allele within one locus, was measured based upon the signal heights of 
the polymorphic positions of the individual alleles (Table 3A-C). The amount of 
RNA transcript for each individual allele, compared to the other allele, represents 
the mean amount of RNA transcript deduced from 4 sequence proﬁ les. These 4 
sequence proﬁ les are obtained with exon 1 forward sequencing (primers 10, 11 
or 12 depending on the locus, table 2B), exon 2 reversed sequencing (primer 
13, table 2B), exon 3 forward sequencing (primer 14, table 2B) and exon 4 
reversed sequencing (primer 15, table 2B). For cell lines that are heterozygous 
and for which the sequence proﬁ les from the 4 sequencing primers were available, 
the ratio was calculated with the software package ALRATIO (E.H. Rozemuller, 
personal communication) (table 3). E.g., for cell line IHW09076, the ratio for the 
HLA-A*020601 and HLA-A*0207 is almost equal (ratio is 1.08) indicating that the 
amount of RNA transcript present for both the HLA-A alleles is almost equal. For 
cell line IHW09045, the ratio indicates that the amount of RNA transcript present 
for the HLA-A*02 allele is more than 7 times higher than the amount of RNA 
transcript present for the HLA-A*03 allele. 
Depending on the combination of HLA alleles present in the cell lines, 
the amount of RNA for the individual alleles differed. If HLA-A*02 is present 
in a heterozygous sample, a higher amount of RNA for this allele is observed 
(IHW09045, IHW09273 and IHW09368). Cell lines IHW09103 and IHW09368 
both have the same HLA-A*24 allele but different HLA-A*26 alleles. In cell line 
IHW09103 the amount of RNA for both alleles is almost the same whereas in cell 
line IHW09368 more RNA is present for the HLA-A*24 allele (Table 3A). In six cell 
lines (IHW09273, IHW09367, IHW09370, IHW09374, IHW09380 and IHW09381) 
the amount of RNA transcript for one HLA-B allele was approximately 35% and for 
the other 65%, whereas in the other cell lines the RNA transcript present for both 
HLA-B alleles was approximately 50%-50% (Table 3B). For the majority of HLA-C 
allele combinations, the amount of RNA transcript deviated from the 50%-50%. 
Only in cell lines IHW09263 and IHW09382, and to a lesser extent in IHW09381, 
both HLA-C alleles were equally present (Table 3C). 
HLA null alleles
Five HLA-A null alleles and 1 HLA-B null allele were evaluated for their 
RNA transcripts. HLA-A*2308N (IHW09426), HLA-A*2409N (IHW09422) and 
HLA-B*1526N (IHW09369) all have an one-nucleotide substitution either in exon 
3 (HLA-A*2308N and HLA-B*1526N) or in exon 4 (HLA-A*2409N), resulting in 
premature stop codons [12, 17]. The HLA-A*0104N (IHW09417), HLA-A*6811N 
(IHW09419) and HLA-A*6818N (IHW09420) alleles are characterized by frame-
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shifts with subsequent premature stop codons due to a nucleotide insertion (HLA-
A*0104N), a nucleotide deletion and a substitution (HLA-A*6811N) and a 20-
nucleotide insertion (HLA-A*6818N) [12, 18].
The RNA SBT approach applied for the HLA-A alleles present in cell lines 
IHW09417 (HLA-A*0104N,020101) and IHW09420 (HLA-A*6818N,2902) did not 
identify the null alleles in both cell lines. Subsequent allele speciﬁ c sequencing 
in both cell lines with GSSP’s (primer 19 for the HLA-A*0104N allele and primer 
33 for the HLA-A*6818N allele; table 2C) indicated the presence of a very low 
amount of RNA for both the HLA-A*0104N and HLA-A*6818N alleles in these cell 
lines. Sequencing of the HLA-A*020101 and HLA-A*2902 alleles with their speciﬁ c 
GSSP’s showed normal RNA expression. Sequencing of the HLA-B*1526N allele in 
cell line IHW09369 showed the presence of RNA for this null allele. Heterozygous 
Table 3A HLA-A Ratio
IHW number HLA-A allele 1 HLA-A allele 2 allele 1 / allele 2
IHW09021 *3001 *6802 0.88
IHW09045 *0216 *030101 7.51
IHW09076 *020601 *0207 1.08
IHW09103 *240201 *2602 1.14
IHW09253 *240301 *330301 1.11
IHW09263 *010101 *290101 0.42
IHW09267 *3201 *6601 1.92
IHW09273 *0201 *8001 2.13
IHW09367 *020301 *1102 2.64
IHW09368 *240201 *2604 1.70
Table 3B HLA-B Ratio
IHW number HLA-B allele 1 HLA-B allele 2 allele 1 / allele 2
IHW09024 *150101 *350101 0.79
IHW09215 *5301 *350101 1.08
IHW09253 *1512 *4601 0.98
IHW09273 *0702 *5703 0.61
IHW09364 *4004 *3505 1.19
IHW09367 *380201 *4601 1.86
IHW09370 *070201 *5103 0.54
IHW09374 *400102 *440201 0.61
IHW09376 *270502 *2703 0.74
IHW09380 *0705 *2702 0.51
IHW09381 *180101 *3908 1.90
IHW09382 *270502 *8201 0.88
IHW09422 *270502 *440301 0.83
Table 3C HLA-C Ratio
IHW number HLA-C allele 1 HLA-C allele 2 allele 1 / allele 2
IHW9024 *030301 *040101 0.29
IHW9045 *070401 *150201 0.33
IHW9103 *080101 *140201 0.31
IHW9263 *120202 *150201 0.85
IHW9370 *070201 *140201 0.35
IHW9381 *050101 *070201 0.65
IHW9382 *010201 *030202 1.22
IHW9390 *010201 *070101 2.70
Table 3: Ratio for HLA-A, HLA-B and HLA-C RNA transcripts in the 
reference cell lines. The ratio of RNA transcript present is given for 
allele 1 compared to allele 2
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sequencing of the HLA-A*6811N,240201 alleles in cell line IHW09419 revealed 
that the amount of RNA present for the HLA-A*6811N allele is comparable to 
the amount of RNA present for the HLA-A*240201 allele, as signal heights at the 
polymorphic positions were equal. For the latter allele alternative splicing was 
observed. 
In three cell lines, IHW09419 (HLA-A*6811N,240201), IHW09422 (HLA-
A*2409N,2902) and IHW09426 (HLA-A*2308N,0301), alternative splicing was 
observed for the HLA-A*23 and HLA-A*24 alleles. Analysis of the ampliﬁ cation 
product for each cell line showed the expected PCR product size, but additional 
PCR products of smaller size were also detected. Sequencing using primer 10 
(AHRNA-seqA-E1F, table 2B) revealed subsequently in each cell line a similar 
pattern: a complex sequence proﬁ le starting at position 344, codon 91, in exon 3. 
Separation of the alleles, with GSSP’s speciﬁ c for both the alleles present in each 
cell line, indicated the presence of additional splice products.
For the HLA-A*2308N allele (IHW09426) an alternatively spliced product 
was present that lacks exons 3, 4 and 5 at the RNA level. This was demonstrated 
with a GSSP speciﬁ c for the HLA-A*2308N allele (primer 26, table 2C).
The GSSP used for the HLA-A*2409N (primer 27, table 2C) still revealed 
a complex sequence proﬁ le starting at position 344, indicating that for the 
HLA-A*2409N allele more than one alternative spliced product was present at RNA 
level. GSSP’s were subsequently developed for the boundaries between exon 2 and 
5 (primer 29, AH-A2409-E2-E5F, table 2C) and between exon 2 and 6 (primer 30, 
AH-A2409-E2-E6F, table 2C) and showed that two alternatively spliced products 
were present for the HLA-A*2409N allele. One product lacked exons 3 and 4 and 
the other product lacked exons 3, 4 and 5.
The alternatively spliced allele, HLA-A*240201, revealed after allele 
separation (with primer 26, table 2C), still a complex sequence proﬁ le starting 
at position 344. Sequencing of the ampliﬁ ed product with primers 29 and 30 
(AH-A2409-E2-E5F and AH-A2409-E2-E6F, table 2C) for the alternatively spliced 
products indicated that, in addition to the RNA present for the normal allele     HLA-
A*240201, RNA was present for two alternatively spliced products for this allele. 
One product lacked exons 3 and 4 and the other product lacked exons 3, 4 and 
5. 
In summary, two different alternatively spliced products were detected 
for the HLA-A*240201 and the HLA-A*2409N allele and one alternatively spliced 
product was observed for the HLA-A*2308N allele. For the other alleles, present 
in these cell lines with the alternative spliced transcripts, normally spliced RNA 
transcripts were present as was demonstrated with GSSP’s speciﬁ c for these 
alleles. 
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Discussion
Evaluation of RNA transcripts for the class I HLA-A, -B and -C genes was 
performed with an RNA SBT protocol. This protocol enabled us to correctly type 
RNA transcripts, to identify truncated RNA transcripts, e.g. null alleles produced 
by alternative splicing or alternative spliced products of normal expressed alleles, 
and to evaluate the relative amount of RNA transcript present for all alleles, 
including the null alleles. 
An optimal characterization of null alleles requires the combination of DNA-, 
RNA- and protein-based approaches, as was accomplished for the HLA-A*0111N 
allele [13]. Detection of an RNA transcript or protein expression has not been 
investigated or determined for each null allele described [12]. For HLA-A*6811N and 
HLA-A*6818N no RNA transcripts were reported [12]. The present study showed 
the presence of RNA transcripts for both the HLA-A*68 null alleles. However, the 
amount of transcript present for the HLA-A*6818N allele and also for the HLA-
A*0104N allele was very low and only detectable after allele speciﬁ c sequencing. 
The low amount of RNA transcript present for HLA-A*0104N was earlier described 
for a colorectal cell line [18]. In that study the reversed ampliﬁ cation primer was 
located at different positions (exon 3, exon 4, exon 7/8 and the 3’UTR); only the 
exon 3 primer detected, in combination with the forward primer, an RNA transcript, 
suggesting that an aberrant RNA transcript was present for this HLA-A*0104N 
allele [18]. A study performed by Watanabe et al. [19] showed that mRNA levels 
were signiﬁ cantly reduced if the premature stop codon was located upstream 
of the 5’ part of exon 5 [19]. This could explain the low amount of transcripts 
present for HLA-A*0104N and HLA-A*6818N, since they both have a premature 
stop codon located upstream of the 5’ part of exon 5. In contrast, the amount of 
HLA-A*6811N RNA transcript is comparable to the amount for the second allele, 
the HLA-A*240201 as observed in this study, although the premature stop codon 
in the HLA-A*6811N is located in exon 1. 
Transcriptional expression analysis of HLA class I loci has been described with 
RT-PCR and competitive PCR and detected variable amounts of RNA transcripts for 
the three class I loci in several cell types. In the present study, the ratios obtained 
for the HLA-A, HLA-B and HLA-C allele transcripts indicate different expression 
levels for the different HLA class I alleles. This approach cannot be considered 
quantitative, because for HLA-B and HLA-C different primer combinations were 
used, but results are indicative regarding the RNA expression. Thus, in addition to 
different expression levels for each of the HLA class I loci [20], different expression 
levels are also present for individual HLA alleles.
Alternative splicing for HLA-A*23 and HLA-A*24 alleles was detected in 
several cell lines in which exons 3 and 4 or exons 3, 4 and 5 were deleted from the 
RNA transcript. The presence of alternative spliced HLA transcripts seems common 
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in HLA allele transcripts. In peripheral blood and tumour samples from patients 
with colorectal and melanoma cancer and in a colon tumour cell line, deletion 
of exon 3 and of exons 2 and 3 were detected in HLA-A*02, HLA-A*23, HLA-
A*24, HLA-A*26 and HLA-A*31 alleles [21, 22]. In addition to these alternative 
spliced transcripts, normal full-length spliced transcripts were also present for 
these alleles. Alternative splicing of exon 5 results in the generation of soluble HLA 
molecules as was shown for HLA-A24 [23], HLA-A2 [24], and HLA-B*44020102S 
[16]. Variation at the 5′ and 3′ splice sites result in alternative spliced products 
generating HLA null or soluble alleles: HLA-A*0104N [18], HLA-A*0111N [13], 
HLA-A*24020102L [17, 25], HLA-A*29010102N [26], HLA-B*15010102N [27], 
HLA-DRB4*01030102N [28] and HLA-B*44020102S [16]. In patient AHPEN, the 
polymorphism causing the HLA-A*0111N null allele was identiﬁ ed as a synonymous 
substitution at DNA level whereas RNA analysis showed alternative splicing leading 
to a null allele [13]. This RNA SBT protocol provides additional information for the 
elucidation of the mechanism responsible for expression loss.
Aberrant HLA expression, downregulation or loss of HLA class I cell surface 
expression, has been described for solid and haematological tumours [29-36]. 
Application of the RNA SBT protocol, as developed in this study, will reveal 
whether genetic variation within the HLA genes themselves characterizes the 
aberrant HLA expression. Preliminary results indicate that no genetic alterations 
occur in the HLA-A and HLA-B RNA transcripts present in tumour tissue from 
patients diagnosed with head and neck squamous cell carcinomas and in blasts 
from patients diagnosed with leukaemia. 
The RNA SBT protocol developed provides a valuable additional tool for RNA 
transcript analysis to obtain insight in the expression and polymorphism of alleles. 
In addition HLA null alleles and alternative splice products are identiﬁ ed.
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Abstract
A new variant of the HLA-A*010101 allele designated as HLA-A*0111N, 
previously known as HLA-A*010101var, was identiﬁ ed in a patient requiring a stem 
cell transplantation (SCT). The patient was typed by serological methods as HLA-
A2 homozygous and by sequencing based typing (SBT) as HLA-A*010101,020601. 
Flow-cytometric (FCM) analysis with 11 human monoclonal antibodies (mAbs) for 
the A1 molecule conﬁ rmed lack of any cell membrane expression of the HLA-
A*0111N allele. One-dimensional isoelectric focusing (1D-IEF) of total cell lysate 
from the patient’s cells showed no cell surface and cytoplasmic HLA-A1 protein 
expression, whereas the HLA-A2 molecule was identiﬁ ed by both FCM analysis and 
1D-IEF. DNA sequence analysis showed the presence of a synonymous substitution 
from “G” to “T” at position 597 in codon 175. RNA SBT revealed a deletion of 24 
bp in exon 3, position 596 through 619, encoding codons 175 through 182 of the 
HLA-A*0111N allele. The synonymous substitution introduced a new splice site, 
resulting in an efﬁ cient splicing, since no classical A1 protein could be detected in 
the patient. This alternative splicing prevented the translation into a correct and 
stable class I molecule expression on the cell surface.
Introduction
The human equivalent of the major histocompatibility complex (MHC), the 
human leukocyte antigen (HLA) system, is located on the short arm of chromosome 
6. Genes encoding the classical transplantation antigens are located in the HLA 
class I and class II region. The classical class I molecules are composed of a 
polymorphic heavy or α-chain, encoded by the HLA-A, HLA-B or HLA-C genes 
on chromosome 6, and a monomorphic light chain, β2m, encoded by a gene on 
chromosome 15. The class II molecules HLA-DR, HLA-DQ and HLA-DP are composed 
of a polymorphic α-chain and a polymorphic β-chain, both chains encoded by the 
“A” and “B” genes on chromosome 6. The α-chain, encoded in the class I genes, 
solely contributes to the diversity of the peptide-binding groove, while in the 
class II genes both chains are involved. Class I molecules predominantly present 
endogenously derived peptides to CD8+ T-cells and are able to elicit a cellular 
response while class II molecules present exogenously derived peptides to CD4+ 
T-cells and T-helper cells, able to elicit a humoral immune response [1, 2].
Matching for HLA molecules is a crucial component in SCT. Mismatches 
between patient and donor may lead to transplantation-related complications 
resulting in morbidity or mortality in which graft failure or graft-versus-host 
disease (GvHD) play a major role [3-8]. To minimize the risk for developing 
transplantation-related complications, HLA allele identiﬁ cation in patient and 
donor is performed at high-resolution (HR) level to identify HLA alleles at the four-
digit level. Different methods can be applied for HR allele identiﬁ cation, with SBT 
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providing the most detailed information regarding the HLA alleles in patient and 
donor. The minimal requirement for HLA allele identiﬁ cation is determination of 
polymorphism of exons 2 and 3 for class I and exon 2 for class II, as these exons 
are involved in the formation of the peptide-binding groove [1, 9]. Serological 
methods can be used to conﬁ rm HLA cell membrane expression, albeit only at low 
resolution. Absence of HLA cell surface expression can be caused by insertions, 
deletions or substitutions of one or more nucleotides in the gene leading to a frame-
shift introducing a stop codon, transformation into a stop codon or disruption of 
splice sites [10]. The presence of these aberrantly expressed HLA alleles in patient 
or donor in SCT requires an other selection of an appropriate donor, matching 
membrane expression [9, 11].
In this study we describe the identiﬁ cation of the null allele HLA-A*0111N in 
a patient: a splice variant of the HLA-A*010101 allele, which is not expressed as 
a protein. The lack of expression of the HLA-A1 molecule identiﬁ ed by serological 
methods was studied by ﬂ ow-cytometric (FCM), one-dimensional isoelectric 
focusing (1D-IEF), DNA and RNA analyses.
Material and methods
Patient AHPEN
AHPEN, a 48 years old male, was diagnosed in 2001 with myelodysplastic 
syndrome (type RAEB), without cytogenetic abnormalities. Initially, no treatment 
was given but progression of the disease to AML M6 necessitated chemotherapeutical 
treatment in 2001. After the ﬁ rst course, consisting of Idarubicin and Cytarabine, 
partial remission was obtained. The second course (Amsacrine and Cytarabine) led 
to complete remission. An allogeneic SCT was performed in 2002, with a matched 
unrelated donor (MUD). The conditioning regimen consisted of anti-thymocyte 
globulin, cyclophosphamide and total body irradiation. The only complication of 
this procedure was a self limiting mild chronic GvHD of the skin grade I.
DNA, isolated from peripheral blood with the salting out method [12], was 
used for routine HLA typing by SBT for AHPEN, his MUD, and a non-related control 
sample AHRIN and for the cloning of the full-length HLA-A gene of AHPEN. EBV 
transformed B-cell lines from AHPEN and control sample AHRIN, established at 
the UMC-Utrecht, were cultured. These cell lines were used for FCM analysis, RNA 
isolation and one-dimensional isoelectric focusing. Patient AHPEN and individual 
AHRIN gave their informed consent for participation in this study.
HLA typing with serology and FCM analysis
Peripheral blood mononuclear cells from patient AHPEN, the MUD for patient 
AHPEN and control sample AHRIN were typed at serological level for HLA-A and 
HLA-B with the conventional complement dependent cytotoxicity assay covering 
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all HLA class I allospeciﬁ cities. FCM analysis was performed on cultured EBV 
transformed cells from AHPEN and AHRIN to identify HLA-A cell surface expression. 
EBV transformed cells (2.5 x 104) were incubated with an optimal concentration of 
human mAb [13] as primary antibody for 15 min at room temperature, followed by 
a washing step with PBS. Subsequently, cells were prepared for FCM by incubation 
with rabbit F(ab’)2 anti IgM-FITC or anti IgG-FITC (DAKO Cytomation Denmark 
A/S, Glostrup, Denmark), for 15 min at room temperature followed by washing. 
A total of 10.000 cells were analysed using a FACSCalibur (BD Biosciences, San 
Jose, CA, USA). Non-viable cells were gated out and viable cells were analysed for 
their HLA-A expression.
Isoelectricfocusing
Total cell lysates from patient sample AHPEN and control sample AHRIN 
were used in1D-IEF gel electrophoresis as described [14] using mAb W6/32 for 
immunoprecipitation.
HLA typing at DNA level by SBT
HLA alleles have been identiﬁ ed by high-resolution SBT for HLA-A, HLA-
B, HLA-DRB1, HLA-DRB3, HLA-DRB4 and HLA-DRB5 (Applied Biosystems, Foster 
City, CA, USA). High-resolution SBT for HLA-C, HLA-DQB1 and HLA-DPB1 were 
performed according to protocols previously described [15-19]. All six loci were 
determined at high-resolution SBT for patient AHPEN and the MUD for AHPEN. 
HLA-A and HLA-B were determined at high-resolution SBT for control sample 
AHRIN.
Cloning HLA-A alleles sample AHPEN
Cloning of sample AHPEN for HLA-A was performed with the TA Cloning®
Kit according to the manufacturer's protocol (Invitrogen Ltd., Paisley, United 
Kingdom). The High Fidelity Expand® PCR system (Roche Diagnostics GmbH, 
Mannheim, Germany) was used to amplify HLA-A at DNA level from the 5'UTR 
through the 3'UTR with the ampliﬁ cation primers HLA5AUT and HLA3AUT, located 
respectively in the 5'UTR and 3'UTR [16]. A HLA-A PCR product of approximately 
3.4 kb was generated including a major part of the HLA-A promoter region, all 
exons and all introns. After puriﬁ cation of the PCR product with 1 unit of shrimp 
alkaline phosphatase (SAP) and 10 units of Exonuclease I (both from USB 
Corporation, Cleveland, USA), the cloning procedure was performed. Clones with 
either of the HLA-A alleles were sequenced in forward and reversed direction with 
a total of 14 sequencing primers located throughout the HLA-A gene [15] with Big 
Dye Terminator chemistry on an ABI 3100 DNA sequencer (Applied Biosystems). 
For both the HLA-A*0111N allele and the HLA-A*020601 allele three clones were 
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sequenced from 5'UTR through 3'UTR. The software program SBTengine® (Genome 
Diagnostics, Utrecht, The Netherlands) was used for allele identiﬁ cation.
RNA isolation and cDNA synthesis
Total RNA was isolated from approximately 5 million cultured cells from 
the EBV transformed cell line from patient AHPEN with Trizol reagent according 
to the manufacturer’s protocol (Invitrogen). Measurement of the RNA yield was 
performed with a spectrophotometer at 260/280 nm (Perkin Elmer, Wiesbaden, 
Germany).
cDNA synthesis was performed with the Superscript III First-Strand Synthesis 
System for RT-PCR according to the manufacturer’s protocol (Invitrogen). In brief, 
about 5 µg RNA was mixed with 1 µl oligo dT20 (50 µM) or 1 µl hexamers (50 
ng/µl), 1 µl dNTPs (10 mM) and diethyl pyrocarbonate (DEPC) treated water was 
added to a total volume of 10 µl and incubated for 5 min at 65°C. The mixture 
was subsequently cooled down on ice for at least 1 min. The cDNA synthesis 
mixture, containing 2 µl 10x RT buffer, 4 µl MgCl2 (25mM), 2 µl DTT (0.1 mM), 1 
µl RNaseOUT (40 U/µl) and 1 µl Superscript III RT (200 U/µl), was incubated for 
50 min at 50°C and the reaction was terminated at 85°C for 5 min. The cDNA was 
immediately placed on ice hereafter and 1 µl of RNase H (2 U/µl) (Invitrogen) was 
added and incubated for 20 min at 37°C. For veriﬁ cation of the quality of the cDNA 
a PCR with the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was performed [20].
HLA typing at RNA level by SBT
A locus speciﬁ c reverse transcriptase (RT) PCR was set up to amplify HLA-
A from exon 1 through exon 8 with the ampliﬁ cation primers, AHRNA-5’Ex1-A-6 
and AHRNA-3’A-Ex8-1, located in respectively the 5’UTR and 3’UTR [21]. The PCR 
mixture, which contains 1 µl cDNA, 4 µl 10x PCR buffer (Applied Biosystems), 2.4 
µl MgCl2 (25 mM) (Applied Biosystems), 0.2 µl of each dNTP (10 mM) (Invitrogen), 
0.2 µl AmpliTaq Gold (5 U/µl) (Applied Biosystems), 10 pmol of forward primer, 10 
pmol of reversed primer is adjusted to  a ﬁ nal volume of 40 µl with MilliQ. The PCR 
program started with a hot-start at 95°C for 10 min, followed by 5 cycles of 30s 
95°C, 30s 62°C, 1 min 72°C and 25 cycles of 30s 95°C, 30s 57°C, 1 min 72°C and 
ending at 72°C for 10 min and maintained at 4°C. Puriﬁ cation of the approximately 
1100 bp ampliﬁ ed HLA-A product was performed with 1 unit of shrimp alkaline 
phosphatase (SAP) and 10 units of Exonuclease I (both from USB Corporation, 
Cleveland, USA) by incubation at 37°C for 15 min and enzymes were deactivated at 
80°C for 15 min and followed by hold at 4°C. Subsequently, sequencing reactions 
were performed in forward and reversed direction with sequencing primers [21, 22] 
with the Big Dye Terminator Ready Reaction Mix version 1.1 (Applied Biosystems) 
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according to the manufacturer's protocol. Sequence products were run on an ABI 
3100 DNA sequencer (Applied Biosystems) and the software package SBTengine®
(Genome Diagnostics) was used for allele identiﬁ cation.
Results
HLA expression
Serological analysis was performed for HLA-A and HLA-B for patient AHPEN, 
his MUD and control sample AHRIN. Human allospeciﬁ c anti-sera were used 
recognizing either HLA-A1 or HLA-A2. AHPEN and his MUD showed expression 
of only HLA-A2, whereas both HLA-A1 and HLA-A2 could be detected in AHRIN. 
HLA-B serology indicated the presence of HLA-B8,44 cell surface molecules in 
samples AHPEN, his MUD and control sample AHRIN (data not shown). Sensitivity 
and speciﬁ city of the 4 human sera recognizing HLA-A1 are between 81-100% 
indicating that technical failure of HLA-A1 detection on patient AHPEN by all 4 sera 
is unlikely (Table 1).
(a) Tested cellsa
Reactivity anti-HLA-A1 serab
serum 1 + - serum 2 + -
+ 116 13 + 42 3
- 3 256 - 2 243
serum 3 + - serum 4 + -
+ 98 23 + 113 1
- 0 160 - 6 286
(b) Serum
1 2 3 4
Sensitivityc 97% 95% 100% 95%
Speciﬁ cityd 90% 93% 81% 99%
Table 1: Speciﬁ city and sensitivity of the four allosera speciﬁ c for HLA-A1
aTested cell have HLA-A1 (+) or not (-) on their cell membrane (column direction). 
bTested cells are either recognized (+) or not recognized (-) for HLA-A1 by the anti-HLA-A1 sera (row 
direction); for each alloserum (sera 1 - 4) is indicated the number of cells recognized or not. For example: 
116 different cells, bearing HLA-A1 on their cell surface are recognized by serum 1, while 256 different 
cells, not bearing HLA-A1 on their cell surface are not recognized by serum 1. Three different cells bearing 
HLA-A1 are not recognized or false negative with serum 1 and 13 different cells not bearing HLA-A1 are 
recognized or false positive with serum 1. The calculation for the sensitivity has been performed for each 
of the allosera. 
c,dThe sensitivity and speciﬁ city of the four allospeciﬁ c anti-sera for HLA-A1 were calculated from the 
values depicted in table 1a.
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FCM analysis was performed on cells from patient AHPEN and control sample 
AHRIN with 11 HLA-A1 reactive human mAbs, all recognizing distinct epitopes on 
the HLA-A1 molecule, and 3 HLA-A2 reactive human mAbs (table 2). Epitopes 
recognized by several of these human mAbs have been described by Duquesnoy 
et al. [23]. HLA-A1 cell membrane expression was not detected in patient AHPEN 
with any of the HLA-A1 speciﬁ c mAbs. In contrast, HLA-A2 expression was detected 
with the HLA-A2 mAbs. Both HLA-A1 and HLA-A2 were identiﬁ ed with the HLA-
A1 and HLA-A2 reactive mAbs in control sample AHRIN by FCM analysis (table 
2 and ﬁ g. 1). To examine whether AHPEN produces soluble HLA-A1 molecules, 
supernatants from cultured EBV transformed cells from both AHPEN and AHRIN 
were incubated with the 11 human mAbs. Subsequent use of these pre-treated 
mAbs in FCM analysis gave no inhibition of HLA-A1 staining, indicating that soluble 
HLA-A1 is not expressed in both samples (data not shown).
1D-IEF was performed on total cell lysates of patient AHPEN (HLA-
A*010101var,020601) and control sample AHRIN (A*010101,020101). HLA-B 
antigens were identiﬁ ed as cell surface proteins in AHRIN and AHPEN as well as 
β2m (ﬁ g. 2). In AHRIN and AHPEN, antigens encoded by the alleles HLA-A*0201 
and HLA-A*020601 respectively, were detected as cell surface proteins; the HLA-
A1 antigen in sample AHRIN was present but no product was detected in AHPEN 
(ﬁ g. 2).
mAb Isotype Speciﬁ city AHPEN AHRIN
OK2H12 IgM,κ A1/A3/A11/A32/A36 − +
OK5A3 IgM,λ A1/A3/A24/A11/A36 − +
OK4F9 IgM,κ A1/A3/A26/A34/A66/A11/A29/A30/A31/A33/A36 − +
GV5D1 IgG1,λ A1/A9 − +
VDK 1D12 IgM,κ A1/A36 − +
MUL7C7 IgM,λ A1/A3/A26/A30/A33 − +
MUL1E11 IgM,λ A1/A3/A24/A11 − +
OK4F10 IgM,κ A1/A3/A26/A11/A29/A30/A31/A33 − +
SIL2A2 IgM,κ A1/A9 − +
VIN1B10 IgG1,κ A1A11 − +
GV2D5 IgG1,κ A1 − +
SN230G6 IgG1,λ A2/B17 + +
SN66E3 IgM,κ A2/A28 + +
SN607D8 IgG1,κ A2/A28 + +
Table 2: FCM results of patient AHPEN (HLA-A*0111N,020601) and control sample AHRIN 
(HLA-A*010101,0201) with speciﬁ c HLA-A1 and HLA-A2 human mAbsa
a No cell membrane expression (-) or cell membrane expression (+)
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Figure 1: FCM analysis of patient AHPEN and control sample AHRIN for HLA-A1 and HLA-A2 expression. 
mAbs against HLA-A1 were tested in AHPEN (A, C) and AHRIN (B, D). (A, B) The following mAbs against 
the A1 molecule were used: isotype control (red), OK2H12 (black), OK4F9 (green), MUL7C7 (blue), 
and MUL1E11 (purple). (C, D) The following mAbs against the A1 molecule were used: isotype control 
(red), VIN1B10 (black) and GV2D5 (green). mAbs against HLA-A2 were tested in AHPEN (E, G) and 
AHRIN (F, H). (E, F) The following mAbs against the A2 molecule were used: isotype control (red) and 
SN66E3 (black). (G, H) The following mAbs against the A2 molecule were used: isotype control (red) and 
SN230G6 (black). Data obtained with mAbs OK5A3, GV5D1, OK4F10 and SIL2A2 (HLA-A1) and SN607D8 
(HLA-A2) are not shown. No HLA-A1 expression was detected in patient AHPEN (A, C). HLA-A1 expression 
was detected in control sample AHRIN (B, D). HLA-A2 expression was detected in both AHPEN and AHRIN 
(E-H).
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Figure 2: 1D-IEF results for control sample AHRIN and patient AHPEN. The 
monoclonal antibody W6/32 was used for detection of the HLA molecules. 
AHPEN was typed as HLA-A*0111N,020601 and HLA-B*0801,4402 and 
sample AHRIN was typed as HLA-A*010101,020101 and HLA-B*0801,4402. 
No molecule is present for the HLA-A*0111N allele in patient AHPEN.
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HLA typing
Molecular analysis revealed heterozygosity at the HLA-A locus for patient 
AHPEN at DNA level at high-resolution SBT (HLA-A*010101var,020601). Sequence 
analysis of the HLA-A alleles revealed a new polymorphic position in exon 3 of 
HLA-A, at position 597, codon 175. At this position a “G” was the consensus 
and considered conserved for both the HLA-A*010101 and A*020601 alleles 
according to the IMGT database [24]. In patient AHPEN a heterozygous “GT” was 
observed at this position, indicating that in one of the HLA-A alleles the “G” was 
substituted by a “T”. Cloning results showed that this new polymorphism was 
present in the HLA-A*010101var allele (HLA-A*0111N) (table 3). No additional 
polymorphisms were found, either in the promoter or in the exons or introns. 
This substitution changed codon 175 from GGG to GGT, which is a synonymous 
substitution (Gly175Gly). HLA typing results for all HLA loci for patient AHPEN, 
his MUD and control sample AHRIN are given in table 4. HLA high-resolution SBT 
results conﬁ rmed intermediate sequence speciﬁ c priming (SSP) typing.
RNA sequence analysis indicated an insertion or deletion (indel) polymorphism 
compared to the HLA-A*010101 allele starting at position 596 in exon 3, one 
nucleotide 5’ upstream of the silent mutation at position 597 (table 3). Allele 
separation with group speciﬁ c sequencing primers (GSSP) speciﬁ c for the HLA-
A*01 and HLA-A*02 alleles, designed in exons 3 and 4, was applied subsequently 
to identify the indel polymorphism. Sequence analysis revealed that 24 bp of exon 
3 were deleted in the HLA-A*0111N allele, corresponding with the loss of 8 amino 
acids, codons 175 through 182, continued in frame by the exon 4 sequence as 
shown in table 3, and starting with codon 183.
Discussion
Simultaneous serological analysis and DNA typing revealed a discrepancy in 
the HLA-A typing of patient AHPEN. At the DNA level a new variation was observed 
in exon 3 of the HLA-A*0111N allele, but this synonymous substitution could not 
explain the loss on the patient’s cells. Extensive FCM analysis with 11 human 
mAbs and 1D-IEF with W6/32 indicated the lack of protein expression of HLA-A1 
encoded by the HLA-A*0111N allele (table 2 and ﬁ g. 1) and conﬁ rmed serological 
typing. An RNA-based SBT protocol was developed to investigate the inﬂ uence 
of this silent mutation on RNA expression. Twenty-four nucleotides (codons 175 
through 182) in exon 3 were deleted in the HLA-A*0111N allele at RNA level 
compared with the control A*010101 allele (table 3). Comparable amounts of RNA 
are present for both the HLA-A*010101 and HLA-A*0111N relative to the HLA-
A*02 alleles. SBT at RNA level indicated that equal signal heights were present in 
both AHPEN and control AHRIN at heterozygous positions for both HLA-A alleles.
The α2 domain encoded by exon 3 of the HLA-A gene, forms an anti-parallel 
chapter 3.indd   66 1/5/2006   10:12:16
67
Chapter 3
sa
m
pl
e
te
ch
ni
qu
e
H
LA
-A
H
LA
-B
H
LA
-C
w
H
LA
-D
R
B
1
H
LA
-D
R
B
34
5
H
LA
-D
Q
B
1
H
LA
-D
PB
1
A
H
PE
N
se
ro
lo
gy
2
44
(1
2)
,8
N
D
a
N
D
a
N
D
a
N
D
a
N
D
a
S
B
T
*0
11
1N
b,
c  
,*
02
06
0
1b
,c
*0
80
1,
*4
40
2
*0
50
10
1,
*0
70
10
1
*0
30
10
1,
*1
30
1
D
R
B
3*
01
01
*
0
2
0
1
0
1
,*
0
6
0
3
*
0
1
0
1
0
1
,*
1
0
0
1
M
U
D
se
ro
lo
gy
2
44
(1
2)
,8
N
D
a
N
D
a
N
D
a
N
D
a
N
D
a
S
B
T
*0
20
10
1,
-
*0
80
1,
*4
40
2
*0
50
10
1,
*0
70
10
1
*0
30
10
1,
*1
30
1
D
R
B
3*
01
01
*
0
2
0
1
0
1
,*
0
6
0
3
*
0
1
0
1
0
1
,*
0
5
0
1
A
H
R
IN
se
ro
lo
gy
1,
2
44
(1
2)
,8
N
D
a
N
D
a
N
D
a
N
D
a
N
D
a
S
B
T
*0
10
10
1,
*0
20
20
1
*0
80
1,
*4
40
2
N
D
a
N
D
a
N
D
a
N
D
a
N
D
a
C
od
on
S
am
pl
ea
17
4
17
5
17
6
17
7
17
8
17
9
18
0
18
1
18
2
1
8
3
A
H
R
IN
 (
H
LA
-A
*0
10
10
1)
  
  
D
N
A
 &
 R
N
A
 le
ve
l
A
A
C
G
G
G
A
A
G
G
A
G
A
C
G
C
TG
C
A
G
C
G
C
A
C
G
G
A
C
  
  
Pr
ot
ei
n 
le
ve
l
A
sn
G
ly
Ly
s
G
lu
Th
r
Le
u
G
ln
A
rg
Th
r
A
sp
A
H
PE
N
 (
H
LA
-A
*0
11
1N
)
  
  
D
N
A
 le
ve
l
A
A
C
G
G
T
A
A
G
G
A
G
A
C
G
C
TG
C
A
G
C
G
C
A
C
G
G
A
C
  
  
R
N
A
 le
ve
l
A
A
C
G
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
A
C
  
  
Pr
ot
ei
n 
le
ve
l
A
sn
*
*
*
*
*
*
*
*
A
sp
Ta
bl
e 
3:
 H
LA
 m
ol
ec
ul
ar
 t
yp
in
g 
re
su
lt
s 
fo
r 
th
e 
H
LA
-A
*0
10
10
1 
al
le
le
 in
 c
on
tr
ol
 s
am
pl
e 
A
H
R
IN
 
an
d 
th
e 
H
LA
-A
*0
11
1N
 a
lle
le
 in
 p
at
ie
nt
 s
am
pl
e 
A
H
PE
N
.
a F
or
 e
ac
h 
sa
m
pl
e 
ar
e 
in
di
ca
te
d 
th
e 
D
N
A
 a
nd
 R
N
A
 s
eq
ue
nc
e 
an
d 
th
e 
pr
ot
ei
n 
se
qu
en
ce
 d
ed
uc
ed
 f
ro
m
 t
he
 
R
N
A
 s
eq
ue
nc
e 
of
 c
od
on
s 
17
4 
th
ro
ug
h 
18
3.
 T
he
 s
yn
on
ym
ou
s 
su
bs
ti
tu
ti
on
 (
fr
om
 5
97
 G
 t
o 
T 
an
d 
in
di
ca
te
d 
in
 b
ol
d)
 i
s 
pr
es
en
t 
in
 c
od
on
 1
75
. 
−
−
−
 i
nd
ic
at
es
 t
he
 d
el
et
io
n 
of
 n
uc
le
ot
id
es
; 
* 
in
di
ca
te
s 
th
e 
de
le
ti
on
 o
f 
am
in
o 
ac
id
s.
Ta
bl
e 
4:
 H
LA
 t
yp
in
g 
re
su
lt
s 
fo
r 
pa
ti
en
t 
A
H
PE
N
, 
hi
s 
M
U
D
 a
nd
 t
he
 c
on
tr
ol
 s
am
pl
e 
A
H
R
IN
.
a  
N
D
 =
 n
ot
 d
et
er
m
in
ed
.
b  
Th
e 
na
m
e 
lis
te
d 
H
LA
-A
*0
11
N
 h
as
 b
ee
n 
of
ﬁ c
ia
lly
 a
ss
ig
ne
d 
by
 t
he
 W
H
O
 N
om
en
cl
at
ur
e 
C
om
m
it
te
e 
in
 J
an
ua
ry
 2
00
5.
 T
he
 n
am
e 
lis
te
d 
H
LA
-A
*
0
2
0
6
0
1
 h
as
 
be
en
 o
fﬁ
 c
ia
lly
 a
ss
ig
ne
d 
by
 t
he
 W
H
O
 N
om
en
cl
at
ur
e 
C
om
m
it
te
e 
in
 A
ug
us
t 
19
89
.T
hi
s 
fo
llo
w
s 
th
e 
ag
re
ed
 p
ol
ic
y 
th
at
, 
su
bj
ec
t 
to
 t
he
 c
on
di
ti
on
s 
st
at
ed
 in
 t
he
 
m
os
t 
re
ce
nt
 N
om
en
cl
at
ur
e 
R
ep
or
t 
[3
6]
, 
na
m
es
 w
ill
 b
e 
as
si
gn
ed
 t
o 
ne
w
 s
eq
ue
nc
es
 a
s 
th
ey
 a
re
 id
en
ti
ﬁ e
d.
 L
is
ts
 o
f 
su
ch
 n
ew
 n
am
es
 w
ill
 b
e 
pu
bl
is
he
d 
in
 t
he
 
fo
llo
w
in
g 
W
H
O
 N
om
en
cl
at
ur
e 
R
ep
or
t.
c  
Th
e 
ac
ce
ss
io
n 
nu
m
be
rs
 f
or
 t
he
 A
*0
1
11
N
 a
lle
le
 a
re
 A
Y8
36
15
0 
an
d 
A
Y5
74
93
4.
 T
he
 a
cc
es
si
on
 n
um
be
r 
fo
r 
th
e 
A
*0
20
60
1
 a
lle
le
 is
 A
Y8
4
7
0
0
1
.
chapter 3.indd   67 1/5/2006   10:12:16
68
β-pleated sheet followed by a short and α long α-helical region. Amino acids 177 
through 181 are involved in the formation of the short α-helical region. In addition, 
amino acids 176, 177, 179 and 180 are involved in the interaction with either 
the α1 domain and/or the α3 domain [25, 26]. Deletion of codons 175 through 
182 as observed in patient AHPEN, will most likely inﬂ uence the structure of the 
HLA-A*0111N molecule in such a way that the molecule will become unstable or 
aberrant expressed. Although we cannot exclude the possibility that an aberrant 
HLA-A*0111N protein is formed, the 11 human mAbs, detecting different epitopes, 
and the 4 polyclonal antibodies did not detect HLA-A*0111N protein expression.
Polymorphism in the enhancer B element in the HLA-A promoter region is 
responsible for the reduction of expression of the HLA-A*02010102L allele [27]. 
Since the HLA-A*0111N allele lacked this promoter polymorphism it was concluded 
that the loss of expression could not be attributed to promoter polymorphism 
(data not shown).
The occurrence of nucleotide substitutions in HLA alleles in leukaemic cells 
but not in the patient’s healthy cells was described by Sayer et al. [28]. Aberrant 
HLA expression in tumour cells might provide an escape from immunological 
surveillance. This phenomenon has been observed both in tumours from 
haematological origin and in solid tumours [13, 29-31]. However, germ line 
exon polymorphism in the HLA-Cw*0409N allele caused loss of cell membrane 
expression on patient’s cells [32]. In the present study, the HLA-A*0111N allele 
was also detected in a skin biopsy from patient AHPEN, indicating a germ line 
polymorphism. No family samples were available for segregation analysis. Previous 
reports on splicing defects, resulting in aberrantly expressed alleles, were caused 
by changes in intron sequences [10, 33, 34]. The HLA-A*0111N allele is the ﬁ rst 
identiﬁ ed null allele caused by a synonymous substitution in an exon and resulting 
in the premature splicing of exon 3.
The explanation for the loss of the HLA-A*0111N allele is the introduction 
of a new splice site causing the 24 nucleotide (8 amino acids) deletion. The RNA 
sequence of the HLA-A*0111N allele indicates the use of an alternative splice site 
introduced by the synonymous substitution at nucleotide position 597 in codon 
175. Splice site signals, a branch site and a polypyrimidine tract are sequences 
required by the splicing machinery. The generation of mRNA depends on the 
correct recognition of exon and intron boundaries in order to splice introns out and 
join exons. The 5’ splice site signal is present at the start of the intron and consists 
of the sequence 5’-GURAGU-3’ [35]. The sequence GTACCA is located at the start 
of intron 3 in the regular HLA-A*010101, showing that three mismatches are 
present with the consensus 5’ splice site sequence. Although these mismatches 
are present, the regular HLA-A1 antigen is still expressed as a cell membrane 
molecule as was observed in control sample AHRIN. In contrast, in patient sample 
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AHPEN a synonymous substitution at nucleotide position 597 changed codon 
175 from GGG to GGT, which results in a sequence consistent with the splice 
site consensus sequence. This alternative splice site is used as template by the 
spliceosome. Remarkably, the new splice site in the HLA-A*0111N allele ﬁ ts the 
consensus better leading to an alternative 5’ splice site. Nucleotides present at 
nucleotide position 596 through 601 (codons 175-177) result in the sequence 
GTAAGG at DNA level, having only one mismatch with the consensus 5’ splice 
site sequence. Although only the last eight amino acids were deleted in exon 3, 
other exons further 3’ downstream were spliced properly into mRNA in the HLA-
A*0111N allele. FACS and IEF analysis did not indicate any expression of the 
normal splice form of HLA-A*010101, suggesting a major effect of the extended 
donor splice site. 
In conclusion, the silent mutation at nucleotide position 597 introduced a 
new dominant alternative splice site, deleting 24 nucleotides, corresponding with 
8 amino acids, at RNA level. This new splice site located 24 nucleotides upstream 
results in an in-frame deletion probably causing a conformational change in the 
protein in such a way that this modiﬁ ed molecule cannot be detected by HLA class 
I speciﬁ c antibodies.
Identiﬁ cation of HLA null alleles is important for matching in SCT and the 
selection of a suitable donor. Since it was shown that patient AHPEN lacks HLA-A1 
expression, a HLA-B-C-DR-DQ identical MUD was selected, that was homozygous 
for HLA-A2. This mimicked the patient’s HLA-A expression and minimized 
transplantation-related complications. Patient AHPEN is still in complete remission 
at present.
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Abstract
Most of the 119 HLA-DPB1 alleles are deﬁ ned by polymorphism in six 
hypervariable regions (HVRs) in exon 2 of the HLA-DPB1 gene. We questioned 
how DPB1 polymorphism was represented in the entire coding region. A RNA 
sequencing based typing (SBT) approach was developed for the identiﬁ cation of 
HLA-DPB1 polymorphism from the 5’ untranslated region (UTR) through the 3’-
UTR. B-cell lymphoblastoid cell lines, encoding 16 different DPB1 alleles, were 
studied. Results show additional HLA-DPB1 polymorphism in exons 1, 3, 4 and 5 
and the 5’ and 3’-UTR. Four new HLA-DPB1 alleles were identiﬁ ed, DPB1*0502, 
DPB1*0602, DPB1*0802 and DPB1*0902, which have exon 2 sequences identical 
to other DPB1 alleles but differ in the extended region. The additional polymorphism 
represents two main polymorphic lineages in the DPB1 alleles. Among the HVRs in 
exon 2, only HVR F correlates with these two main lineages. 
Introduction
The human leukocyte antigen (HLA) class II genes HLA-DR, -DQ, and -DP are 
located centromeric in the HLA region on the short arm of chromosome 6. HLA-DP is 
composed of the α-chain, encoded by the HLA-DPA1 gene and the β-chain, encoded 
by HLA-DPB1 [1]. DPB1 allelic polymorphism is concentrated in six hypervariable 
regions (HVRs) in exon 2, “A” through “F” [2, 3] contributing in the formation of 
the ﬁ ve pockets present in the peptide-binding groove. The DP molecule is capable 
of binding peptides and presenting those to T cells [4-7]. E.g. HLA-DPB1 amino 
acids 84 through 87 in HVR F are involved in the formation of pocket 1 and are 
crucial for peptide binding and T cell allorecognition [4]. The generation of DPB1 
allelic polymorphism has mainly evolved from segmental exchange of sequence 
motifs between the six HVRs. Compared to other HLA class II genes, HLA-DPB1 
evolution is thought to have evolved relatively rapidly. Within the human DPB1 
phylogenetic tree three major branches of DPB1 alleles have been deduced based 
upon exon 2 polymorphism [8]. HLA-DPB1 has merely been investigated by the 
identiﬁ cation of polymorphism in exon 2, since exon 2 polymorphism determines 
the speciﬁ city for peptide binding in the groove. Polymorphism beyond exon 2, 
“extended DPB1 polymorphism”, has been addressed in this study. To facilitate 
DPB1 full length coding sequencing, an RNA based approach was developed.
Material and methods
EBV transformed human B-cell lymphoblastoid cell lines
Table 1 provides an overview of the HLA-DPB1 alleles studied from 
ﬁ fteen EBV transformed human B-cell lymphoblastoid cell lines (International 
Histocompatibility Working Group, IHWG; http://www.ihwg.org/) and cell line 
JRPAY from our institute. Original reference cell lines were used if possible. B-
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cell lymphoblastoid cell lines were cultured in RPMI1640 medium (Invitrogen 
Ltd., Paisley, United Kingdom), supplemented with 10% heat inactivated FCS 
(Invitrogen), 100 IE/µl penicillin (Yamanouchi, Leiderdorp, The Netherlands), 100 
µg/ml streptomycine (Fisiopharma, Milan, Italy) and 2.7% NaHCO3 (Invitrogen) in 
a 37°C, 5% CO2 incubator. 
RNA isolation and cDNA synthesis
Total RNA was isolated from approximately 5 million cells of each cell line 
with Trizol reagent according to the manufacturer’s protocol (Invitrogen). cDNA 
synthesis was performed with the Superscript RNase H- MLV-Reverse Transcriptase 
kit (Invitrogen). The quality of the cDNA was veriﬁ ed by the ampliﬁ cation of the 
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [9].
Assigned HLA-DPB1 allelea Sample name Accession number
DPB1*010101 IHW09021 AY804143
DPB1*010102 IHW09049 AY804133
DPB1*020102 IHW09032, IHW09366, IHW09376 AY804134
DPB1*0202 IHW09020 AY831404
DPB1*040101 IHW09005, IHW09014, IHW09051, IHW09095 AY804136
DPB1*0402 IHW09291, IHW09373 AY831402
DPB1*0501 JRPAY AY804138
DPB1*0502 IHW09373 AY804135
DPB1*0602 IHW09021 AY804137
DPB1*0802 IHW09366 AY804132
DPB1*0901 JRPAY AY804139
DPB1*0902 IHW09076 AY831401
DPB1*1301 IHW09095 AY831403
DPB1*1401 IHW09376 AY804140
DPB1*1501 IHW09047 AY804141
DPB1*1901 IHW09061 AY804142
Table 1: HLA-DPB1 alleles identiﬁ ed in 15 International Histocompatibility Working Group 
(IHWG) cell lines
aNew alleles are shown in bold. The names listed for these sequences have been ofﬁ cially assigned by the 
WHO Nomenclature Committee. This follows the agreed policy that, subject to the conditions stated in the 
most recent Nomenclature Report [11] names will be assigned to new sequences as they are identiﬁ ed. 
Lists of such new names will be published in the following WHO Nomenclature Report.
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RNA sequencing based typing of HLA-DPB1
Full-length HLA-DPB1 cDNA, spanning 5’-UTR through 3’-UTR giving rise 
to a 927 bp PCR product, was ampliﬁ ed using ampliﬁ cation primers DPRNARG5.1 
and DPRNARG3.1, located respectively in the 5’-UTR and the 3’-UTR. The PCR was 
performed in a volume of 50 µl, with ﬁ nal concentrations of 1.5 mM MgCl2 (Applied 
Biosystems, Foster City, CA, USA), 1x PCR buffer (Applied Biosystems), 150 µM 
of each dNTP (Invitrogen), 10 pmol of each ampliﬁ cation primer (Sigma-Genosys 
Ltd.), 0.05 units/µl of Taq Gold (Applied Biosystems) and 2 µl cDNA. The mixture 
was denatured for 10 minutes at 95°C, followed by 32 cycles of 20” at 96°C, 30” 
at 55°C and 30” at 72°C, and ending with a hold at 4°C. The 927 bp HLA-DPB1 
PCR product was puriﬁ ed with 1 unit of shrimp alkaline phosphatase (SAP) and 10 
units of Exonuclease I (both from USB Corporation, Cleveland, USA), incubated 
at 37°C for 15 min., deactivated at 80°C for 15 min. and followed by hold at 4°C. 
Sequence reactions were performed with the Big Dye Terminator Ready Reaction 
Mix v1.1 (Applied Biosystems) and subsequently electrophoresed on an ABI 377 
DNA sequencer. PCR products were sequenced in both directions with ampliﬁ cation 
and group speciﬁ c sequencing primers (GSSP). The software package SBTengine® 
(Genome Diagnostics, Utrecht, the Netherlands) was used for sequence analysis 
and subsequent allele assignment of DPB1 alleles. 
Cloning of HLA-DPB1 alleles
Cloning of HLA-DPB1 alleles was performed with the TA Cloning® Kit 
according to the manufacturer’s protocol (Invitrogen).
Results
HLA-DPB1 alleles
DPB1 allele names as assigned by the WHO Nomenclature Committee and 
GenBank accession numbers (http://www.ncbi.nlm/nih.gov/Genbank/index.html) 
are indicated in table 1. Sequences submitted were conﬁ rmatory for exons 2 
through 5 and in addition extended for exon 1, the 5’-UTR and 3’-UTR for the DPB1 
alleles *010101, *020102, *030101, *040101 and *0402. Conﬁ rmatory exon 2 
sequences were obtained for all other alleles and extended with new sequences 
including additional polymorphism present in the other exons and the 5’-UTR and 
3’-UTR.
Extended HLA-DPB1 polymorphism
Extended polymorphism in exons 1 through 5 and parts of the 5’-UTR and 
3’-UTR of the DPB1 coding sequence was determined for 16 HLA-DPB1 alleles 
through PCR and sequence analysis. Table 2 summarizes the extended HLA-DPB1 
nucleotide polymorphism identiﬁ ed in the alleles. Thirty polymorphic nucleotide 
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positions, including 21 new polymorphic nucleotide positions, were observed 
in the regions beyond exon 2. Seven out of these 30 polymorphic nucleotide 
polymorphisms encode non-synonymous substitutions. The other 23 nucleotide 
polymorphisms are either synonymous substitutions or non-coding. In exon 5 a 
“one nucleotide deletion” was observed in the DPB1*0902 and DPB1*1301 alleles. 
DPB1 alleles have the nucleotide sequence TAAACA at nucleotide position 775 
through 780. In DPB1*1301 and DPB1*0902, one adenine nucleotide is deleted: 
TAACA. This does not inﬂ uence the stop codon TAA (codon 230).
Exon 1 2 3 4
Codon -14 84-87 96 170 178 194 205 215
*030101a,b T DEAV K I L R V I
*0901 - - - - - - - -
*0902e M - - - - - - -
*1301e - - - - - - - -
*1401 - - - - - - - -
*010101 - - - - - Q - -
*010102 - - - - - Q - -
*0501 - - - - - - M -
*0502a - - - - - - M -
*1901d - - - - - - M -
*1501 - VGPM - - - - - T
*020102 - GGPM R T - - - -
*0202 - GGPM R T - - - -
*040101 - GGPM R T - - - -
*0602c - GGPM R T - - - -
*0402c - GGPM R T M - - -
*0802d - - R T - - - -
Table 3: Extended HLA-DPB1 amino acid polymorphism 
New alleles are shown in bold. Polymorphic codons in exons 1, 3 and 4 are shown. HVR F (amino acids 
84-87) with the amino acid motifs DEAV, VGPM and GGPM is shown for exon 2.
- identity with the DPB1*030101. The characters indicate amino acids: T threonine, D aspartic acid, E 
glutamic acid, A alanine, V valine, K lysine, I isoleucine, L leucine, R arginine, M methionine, Q glutamine, 
G glycine, P=proline.
a DPB1*0502 and DPB1*030101 have identical exon 2 sequences
b DPB1*030101 sequence information was obtained from the IMGT/HLA database (http://www.ebi.ac.uk/
imgt/hla/)
c DPB1*0602 and DPB1*0402 have identical exon 2 sequences
d DPB1*0802 and DPB1*1901 have identical exon 2 sequences
e DPB1*0902 and DPB1*1301 have identical exon 2 sequences
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New HLA-DPB1 alleles
Table 3 summarizes the extended amino acid polymorphism in the coding 
region for the 16 HLA-DPB1 alleles. Four new DPB1 alleles were identiﬁ ed 
with identical exon 2 sequences to other alleles, but have unique extended 
polymorphism. DPB1*0502 has an exon 2 sequence identical to DPB1*030101, 
but differs by one nucleotide in exon 4 resulting in a non-synonymous substitution. 
DPB1*0602 is identical to DPB1*0402 for its exon 2 sequence, but only differs 
in exon 3 resulting in a non-synonymous substitution. The DPB1*0802 allele, 
identical with DPB1*1901 for exon 2, differs at 21 nucleotide positions resulting in 
three non-synonymous substitutions. The DPB1*0902 allele, identical for exon 2 
with DPB1*1301, has three unique nucleotides in the 5’-UTR and exon 1, resulting 
in one non-synonymous substitution (tables 2 and 3).
HLA-DPB1 exon 2 and extended polymorphism
DPB1 alleles can be grouped by characteristic amino acids KI and RT at 
codons 96 and 170 respectively (table 3). Lineage KI includes the DPB1*010101, 
*010102, *030101, *0501, *0502, *0901, *0902, *1301, *1401, *1501 and 
*1901 alleles. Lineage RT the DPB1*020102, *0202, *040101, *0402, *0602 and 
*0802 alleles. Within both lineages limited variation is observed in exon 1, 3 and 
4 for several DPB1 alleles, present in codons -14, 178, 194, 205 and 215 (table 
3). Subsequently, extended polymorphism and assigned lineages were correlated 
with exon 2 polymorphism. Among the 6 HVRs present in exon 2 only HVR F 
correlated with the KI and RT lineages deﬁ ned by exons 3 through 6. HVR F is 
encoded by codons 84 through 87 where three different amino acid motifs are 
present: GGPM, VGPM and DEAV. All alleles with the GGPM motif have the RT 
motif in exons 3 through 6. DPB1*1501 has a VGPM motif in combination with the 
KI motif. All alleles with the DEAV motif, except the DPB1*0802 allele, have the 
KI motif in exons 3 through 6. The DPB1*0802 allele has the RT motif in exons 3 
through 6 (table 3).
Diversiﬁ cation of HLA-DPB1 alleles
Based upon HVR F, KI and RT motifs and polymorphism in exon 4, 
diversiﬁ cation of the DPB1 alleles is illustrated in ﬁ gure 1. The motifs DEAV-KI-
RVI and GGPM-RT-RVI might reﬂ ect two ancient DPB lineages. From these two 
lineages, the exceptions DPB1*1501 and DPB1*0802 could have evolved by a 
recombination, occurring between HVR F and exon 3, and in case of DPB1*1501 
an additional point mutation. 
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Discussion
HLA-DPB1 polymorphism was initially identiﬁ ed by six DP speciﬁ cities with 
the primed lymphocyte typing test (PLT) [1, 10]. With the introduction of molecular 
techniques six HVRs were identiﬁ ed in exon 2 of the DPB1 molecule [2, 3], leading 
to the highly polymorphic HLA-DPB1 gene [11]. Additional polymorphism in other 
exons of DPB1 was revealed by SBT of cDNA, using RNA as template, resulting 
in two main lineages, which correlate with HVR F in exon 2. Additional variation 
within each lineage deﬁ nes the individual alleles. The RVI motif in exon 4 is shared 
by alleles in both lineages, indicating that this might be an ancient motif in DPB1 
polymorphism. Several DPB1 alleles share the RMI motif in exon 4. Four new HLA-
DPB1 alleles were identiﬁ ed based upon differences beyond exon 2. As a result 
of the new nomenclature strategy of the nomenclature committee, allele names 
in DPB1 do not reﬂ ect a relation between the alleles, which is the case for the 
ﬁ rst two digits of the allele names of the classical HLA loci. No direct relationship 
between the alleles DPB1*0501 and DPB1*0502 exists as the allele names might 
suggest, whereas DPB1*0502 and DPB1*030101 have identical exon 2 sequence, 
and are expected to present the same peptide repertoire and that is not reﬂ ected 
in the allele names. 
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Abstract
Head and neck squamous cell carcinoma (HNSCC) is a very aggressive 
tumour from epithelial origin. Effective treatment at an early stage is possible 
but the majority of patients are diagnosed at an advanced stage of the disease 
for which the regular therapies are not effective. HLA expression is crucial for 
immunotherapeutical treatment. A variety of HLA expression patterns are 
characterized in HNSCC. Since the identiﬁ cation of HLA expression at the allelic 
level remains difﬁ cult, we determined the association of HLA alleles with HNSCC. 
Patients and controls were typed for HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-
DQB1 with sequence speciﬁ c priming (SSP), supplemented with sequencing based 
typing (SBT). MICA allelic polymorphism was included and MICA allele assignment 
was based upon the combination of high-resolution SBT of exons 2 through 4 in 
combination with repeat analysis and nucleotide polymorphism of exon 5. HLA-
B*35 (p=0.014, OR=0.31) and HLA-B*40 (p=0.013, OR=2.9) were signiﬁ cantly 
associated in respectively the metastasised patients and the oral cavity patients. 
In addition, the HLA-B*40-DRB1*13 haplotype association (p=0.016, OR=4.1) 
was identiﬁ ed in the oral cavity patient group. 
Introduction
The Human Leukocyte Antigen (HLA) system is the human equivalent of 
the Major Histocompatibility Complex (MHC) on the short arm of chromosome 6. 
Within the HLA extended region (together 7.6 Mb), approximately 250 genes are 
located including expressed genes and pseudogenes [1]. This region is comprised 
of three HLA regions: class I, class II and class III. Class I encode the classical 
HLA genes HLA-A, -B and -C and in the class II region HLA-DR, -DQ and -DP are 
located. In addition to class I and class II HLA genes, other HLA, HLA-related and 
non-HLA genes are located in these three classes, many of them involved in the 
immune system [2].
The polymorphic MHC class I chain related gene A (MICA), an HLA-related 
gene and located centromeric of HLA-B, contains 6 exons, including a tri-nucleotide 
repeat polymorphism in the transmembrane region [3-5]. Associations with either 
of the repeats have been observed for several diseases, e.g. the MICA-A9 repeat 
is signiﬁ cantly associated with in HNSCC, particularly in patients diagnosed with 
squamous cell carcinoma of the oral cavity. MICA can either be constitutively 
expressed at the cell surface membrane or induced under abnormal conditions, 
e.g. tumour transformation. Several types of carcinomas express MICA on their 
cell surface. In some tumour types soluble MICA has been detected in the sera 
of cancer patients [6-11]. Dependent on whether MICA is expressed at the cell 
surface or as a soluble molecule, upon interaction with the NKG2D receptor, 
present on NK-cells, γδ T-cells and αβ CD8+ T-cells, different immunological 
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responses might occur. Tumour cell surface expression can activate the immune 
system while soluble MICA might oppose the immune system through blocking of 
the NKG2D receptor [10, 12, 13].
Head and neck squamous cell carcinoma (HNSCC) is a solid epithelial 
tumour that occurs in general more often in males than in females. The majority of 
patients present with advanced stage of disease at time of diagnosis, deteriorating 
the prognosis for effective treatment, quality of life and survival [14]. Knowledge 
of the biological immune status of tumours is therefore important to improve and/
or develop additional (immuno)therapeutical approaches to improve the prognosis 
for these patients. 
Immunohistochemical staining with monomorphic, locus speciﬁ c and allele 
speciﬁ c monoclonal antibodies indicated that HLA expression was affected in a 
large number of HNSCC tumour specimens, indicating the complexity of the HLA 
expression patterns [15, 16]. The limited availability of allele speciﬁ c monoclonal 
antibodies hinders clear identiﬁ cation of HLA expression proﬁ les. HLA alleles, 
HLA haplotypes, alone or in combination with MICA might predict susceptibility 
to HNSCC. Therefore we performed an exploratory study to investigate whether 
HLA/MICA alleles are associated with HNSCC. 
Material and methods
Patients and controls
140 Dutch HNSCC patients, 98 male and 42 female with speciﬁ ed tumour 
location, mean age of the patient group at the time of surgery, absence or presence 
of metastases and histological grade, and 106 Dutch healthy controls were included 
in this study. The 140 HNSCC patients can be grouped according to the location 
of the tumour: oral cavity group (N=57), oropharynx group (N=28), larynx group 
(N=39) and hypopharynx group (N=16). Genomic DNA from peripheral blood was 
isolated with the salting out-method [17]. All patients and controls gave their 
informed consent for their participation in this study. This study was approved by 
the local ethical committee of the UMC Utrecht (METC protocol #96/267).
HLA typing
HNSCC patients and controls were typed for HLA-A, -B, -C, -DR and -
DQ at low resolution by sequence speciﬁ c priming (SSP) and SSP results were 
interpreted with the appropriate software according to the manufacturer’s 
protocols (Biotest, Dreieich, Germany). High-resolution sequencing based typing 
(SBT) was performed for HLA-B*40 alleles with the HLA-B High-resolution Typing 
System (Applied Biosystems, Foster City, CA, USA).
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High-resolution MICA SBT
MICA alleles were identiﬁ ed by sequencing exons 2, 3 and 4. A single PCR 
was performed, amplifying exons 2 through 5 with the Expand Long Template 
PCR system (Roche Diagnostics GmbH, Mannheim, Germany). Ampliﬁ cation was 
performed in 50 µl with ﬁ nal concentrations of 300 nM for both 5’ and 3’ ampliﬁ cation 
primers [18] (Sigma-Genosys Ltd., Haverhill, United Kingdom), 350 µM of each 
dNTP (Invitrogen Ltd., Paisley, United Kingdom), 250 ng DNA, 1.0% buffer 1, 1.75 
mM MgCl2 and 0.052 units/µl of the thermostable Taq DNA polymerase enzyme 
mix (included in the Expand Long Template PCR system). The MICA PCR was 
performed in a 9600 Perkin Elmer thermal cycler (Applied Biosystems). An initial 
denaturation step at 94°C for 2 min was followed by 28 cycles of 10 sec at 94°C, 
30 sec at 62°C and 2 min at 68°C. A ﬁ nal extension was performed for 7 min at 
68°C and hold at 4°C. Subsequently the PCR product was puriﬁ ed with 1 unit of 
SAP and 10 units of Exonuclease I (both from USB Corporation, Cleveland, USA) 
prior to sequencing.
Sequencing reactions were performed both in forward and reversed 
directions for exons 2, 3 and 4 with sequencing primers described earlier [18]. The 
Big Dye Terminator Ready Reaction Mix v1.1 kit was used for sequencing reactions 
(Applied Biosystems). MICA was sequenced on an ABI 377 DNA sequencer (Applied 
Biosystems). Assignment of MICA alleles was performed with software HETERO 
and ALLELE [19, 20].
Statistical analysis
The allele frequency distribution was evaluated in the control group and 
compared with the allele frequency distribution in the total patient group, the 
four tumour location groups, the metastasised and the non-metastasised patient 
groups performing Chi-square analysis for each HLA locus. Those alleles observed 
less than 5 times were pooled as a remaining group during the analysis. Statistical 
signiﬁ cant differences in allele frequency distribution, resulting from the Chi-square 
analysis were subsequently followed by individual HLA allele analysis for those 
alleles with the largest contribution to the overall Chi-square value. Individual 
allele analysis between patients and controls was performed using two-by-two 
tables with either Fisher’s exact test or Chi-square test, depending on the number 
of individuals, and the odds ratio (OR) with its 95% conﬁ dence interval (CI) was 
determined (GraphPad Instat Software, San Diego California USA). Since this is an 
exploratory study to identify potential HLA associations in HNSCC, no correction 
for multiple comparisons is performed. Determination of frequent HLA-B/DRB1 
haplotypes was based upon a Maximum Likelihood approach previously described 
(H. van der Zanden, personal communication) [21]. Estimation was followed by 
statistical analysis of these haplotypes between patients and controls. To evaluate 
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differences in MICA allele frequency distribution in the patients and controls Chi-
square analysis was performed.
Results
HLA allele analysis
HLA-A, -B, -C, -DRB1 and –DQB1 alleles were determined in the total patient 
group and the control group by SSP and allele frequencies are summarized in table 
1. To evaluate whether the allele frequency distribution for each HLA gene differed 
between patients and controls, a Chi-square analysis was performed. Imbalances 
in allele frequency distribution were subsequently investigated to assess which 
individual HLA allele or alleles are the causative factor for the imbalance. Chi-
square analysis indicated that the frequency distribution of the alleles for each of 
the HLA genes was not statistically signiﬁ cant different between the total patient 
group and the control group (table 2).
The total patient group was reconsidered based upon tumour location or 
presence or absence of metastases. The allele frequency distribution for each of the 
HLA genes in the subgroups was compared with the allele frequency distribution in 
the control group. No differences in allele frequency distributions were observed 
for HLA-A, HLA-C, HLA-DRB1 and HLA-DQB1 in either of the subgroups. For HLA-B 
a statistically signiﬁ cant difference in allele frequency distribution was observed 
between the control group and the patients with a metastasised tumour (p=0.045) 
and between the control group and the patients with a tumour in the oral cavity 
(p=0.009). For the other subgroups no differences were observed for HLA-B (table 
2).
To assess which HLA-B allele or alleles cause the imbalance in the allele 
frequency distribution, those HLA-B alleles with the largest contribution for the 
overall Chi-square value in the allele frequency distribution were individually 
tested. The contribution in the metastasised patient group is attributable to B*35 
and B*15, for which decreased frequencies are observed. Statistical analysis 
indicates that the number of patients having a B*35 allele is signiﬁ cantly decreased 
compared with the control group (p=0.014, OR=0.31, 95% CI: 0.12-0.80), while 
the number of patients having a B*15 allele is not signiﬁ cantly different (p=0.10, 
OR=0.47, 95% CI: 0.20-1.13) (table 3). In the oral cavity patient group B*08 
and especially B*40 contribute to the overall imbalance in the allele frequency 
distribution and both alleles are increased in the patient group. The number 
of patients having the B*08 allele is not signiﬁ cantly different compared with 
the control group (p=0.084, OR=1.94, 95% CI: 0.93-4.06), but the number of 
patients having the B*40 allele is signiﬁ cantly increased (p=0.013, OR=2.86, 
95% CI: 1.31-6.23) (table 3).
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HNSCC patients (N=110) and controls (N=93)
HLA-A patients frequency controls frequency
A*01 38 0.1727 29 0.1559
A*02 70 0.3182 61 0.3280
A*03 33 0.1500 29 0.1559
A*11 10 0.0455 13 0.0699
A*23 2 0.0091 1 0.0054
A*24 18 0.0818 23 0.1237
A*25 3 0.0136 3 0.0161
A*26 4 0.0182 2 0.0108
A*29 7 0.0318 4 0.0215
A*30 7 0.0318 1 0.0054
A*31 3 0.0136 6 0.0323
A*32 8 0.0364 8 0.0430
A*33 2 0.0091 0 0.0000
A*34 1 0.0045 0 0.0000
A*66 0 0.0000 1 0.0054
A*68 11 0.0500 5 0.0269
A*69 1 0.0045 0 0.0000
A*74 1 0.0045 0 0.0000
A*80 1 0.0045 0 0.0000
HNSCC patients (N=136) and controls (N=105)
HLA-B patients frequency controls frequency
B*07 32 0.1176 22 0.1048
B*08 34 0.1250 24 0.1143
B*13 10 0.0368 5 0.0238
B*14 10 0.0368 4 0.0190
B*15 20 0.0735 24 0.1143
B*18 8 0.0294 8 0.0381
B*27 7 0.0257 7 0.0333
B*35 22 0.0809 29 0.1381
B*37 2 0.0074 4 0.0190
B*38 5 0.0184 5 0.0238
B*39 4 0.0147 8 0.0381
B*40 31 0.1140 16 0.0762
B*41 4 0.0147 2 0.0095
B*44 33 0.1213 20 0.0952
B*45 3 0.0110 1 0.0048
B*47 2 0.0074 0 0.0000
B*48 0 0.0000 2 0.0095
B*49 2 0.0074 0 0.0000
B*50 0 0.0000 1 0.0048
B*51 21 0.0772 12 0.0571
B*52 2 0.0074 1 0.0048
B*53 4 0.0147 0 0.0000
B*55 8 0.0294 1 0.0048
B*56 0 0.0000 1 0.0048
B*57 6 0.0221 11 0.0524
B*58 2 0.0074 2 0.0095
Table 1: Allele frequencies for the HLA-A, HLA-B, HLA-C, 
HLA-DRB1 and HLA-DQB1 alleles observed in the patient 
and control groupsa
aN= the number of patients/controls typed for each HLA gene.
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HNSCC patients (N=120) and controls (N=91)
HLA-C patients frequency controls frequency
Cw*01 6 0.0250 5 0.0275
Cw*02 9 0.0375 7 0.0385
Cw*03 45 0.1875 33 0.1813
Cw*04 27 0.1125 24 0.1319
Cw*05 17 0.0708 6 0.0330
Cw*06 22 0.0917 18 0.0989
Cw*07 73 0.3042 56 0.3077
Cw*08 8 0.0333 4 0.0220
Cw*09 1 0.0042 0 0.0000
Cw*12 11 0.0458 12 0.0659
Cw*14 5 0.0208 2 0.0110
Cw*15 7 0.0292 7 0.0385
Cw*16 7 0.0292 7 0.0385
Cw*17 1 0.0042 1 0.0055
Cw*18 1 0.0042 0 0.0000
HNSCC patients (N=136) and controls (N=106)
HLA-DRB patients frequency controls frequency
DRB1*01 30 0.1103 26 0.1226
DRB1*03 37 0.1360 30 0.1415
DRB1*04 46 0.1691 26 0.1226
DRB1*07 26 0.0956 27 0.1274
DRB1*08 5 0.0184 7 0.0330
DRB1*09 2 0.0074 2 0.0094
DRB1*10 2 0.0074 2 0.0094
DRB1*11 14 0.0515 19 0.0896
DRB1*12 6 0.0221 3 0.0142
DRB1*13 56 0.2059 28 0.1321
DRB1*14 6 0.0221 11 0.0519
DRB1*15 38 0.1397 28 0.1321
DRB1*16 4 0.0147 3 0.0142
HNSCC patients (N=125) and controls (N=104)
HLA-DQB patients frequency controls frequency
DQB1*02 54 0.2160 50 0.2404
DQB1*03 69 0.2760 55 0.2644
DQB1*04 5 0.0200 6 0.0288
DQB1*05 39 0.1560 40 0.1923
DQB1*06 83 0.3320 57 0.2740
Table 1 continued
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1
all patients 0.3571 0.1279 0.9125 0.2374 0.5851
non-metastases 0.4301 0.3448 0.5489 0.6024 0.6998
metastases 0.0974 0.0451 0.7997 0.2976 0.6322
oral cavity 0.3424 0.0093 0.5028 0.2268 0.9935
larynx 0.6163 0.2486 0.9670 0.4726 0.3541
oropharynx 0.1605 0.4189 0.7050 0.6254 0.4273
hypopharynx 0.1611 0.4071 0.5581 0.1536 0.1856
Table 2: Allele frequency distribution for the HLA genes determined in the different patient 
groups. P-values obtained after Chi-square analysis for each HLA gene and patient group are 
indicated. The p-values in bold indicate that the allele frequency distribution for a particular 
HLA gene is statistically different between the control group and one of the patient groups.
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MICA allele assignment
MICA is located centromeric of HLA-B and in linkage disequilibrium with 
HLA-B. A signiﬁ cant decrease in the MICA-A9 repeat was identiﬁ ed in this patient 
group, in particular in the oral cavity patient group [11]. Therefore MICA allele 
assignment, based on SBT of exons 2 through 4 including the repeat polymorphism 
in exon 5, was compared in the control group and in the oral cavity patient 
group.
HLA haplotype analysis
In addition to individual allele analysis we investigated whether one or more 
HLA-B-DRB1 haplotypes were associated, since the B*40 allele is associated with 
the oral cavity patient group and the B*35 allele with the metastasised patient 
group. Determination of the most likely HLA-B-DRB1 haplotypes was performed 
as previously described [21]. For each individual haplotype we determined its 
association with respectively the oral cavity and the metastasised patient group. 
No signiﬁ cant association was observed for one of the B*35-DRB1 haplotypes in 
the metastasised patient group but a signiﬁ cant association was observed for the 
B*40-DRB1*13 haplotype in the oral cavity patient group (p=0.016, OR=4.09, 
95% CI: 1.30-12.91) (table 3). Frequencies of the other B*40-DRB1 haplotypes 
did not differ signiﬁ cantly between the oral cavity patients and the control group.
Metastasised patients (N=72) and controls (N=105)
+/+ +/- -/+ -/- p-value OR 95% CI
B*15 8 64 22 83 0.104 0.47 0.20-1.13
B*35 6 66 24 81 0.014 0.31 0.12-0.80
Oral cavity patients (N=53) and controls (N=105)
+/+ +/- -/+ -/- p-value OR 95% CI
B*08 18 35 22 83 0.084 1.94 0.93-4.06
B*40 18 35 16 89 0.013 2.86 1.31-6.23
Oral cavity patients (N=53) and controls (N=105)
+/+ +/- -/+ -/- p-value OR 95% CI
B*40-DRB1*13 9 44 5 100 0.016 4.09 1.30-12.91
Table 3: Individual HLA-B allele analysis and HLA-B-DRB1 haplotype analysis for 
respectively patients with a metastasised tumour and for patients with a tumour 
in the oral cavity.a 
aThe number of individuals typed for a HLA-B allele or HLA-B/DRB1 haplotype was determined 
by direct counting. +/+ = patients which have a particular allele/haplotype, +/- = patients 
which do not have a particular allele/haplotype, -/+ = controls which do have a particular 
allele/haplotype and -/- = controls which do not have a particular allele/haplotype. N= number 
of patients / controls, OR= odds ratio, CI= conﬁ dence interval.
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MICA allele assignment is complex since the nucleotide polymorphisms of 
exons 2, 3 and 4 should be combined with the repeat polymorphism in exon 5. At 
the ImmunoGeneTics database website (IMGT; http://www.ebi.ac.uk/imgt/hla/), 
exons 2, 3 and 4 nucleotide polymorphisms for 58 MICA alleles and the repeat 
length for 35 MICA alleles is well documented. For all patients and controls the 
information of the exon 5 repeat length, previously deﬁ ned [11], is combined with 
exons 2, 3 and 4 nucleotide polymorphisms.
Type 1
Allele ambiguity: the ambiguous alleles have one or more nucleotide differences 
that are located outside the ampliﬁ ed region. The alleles have the same homozygous 
sequence for exons 2, 3 and 4 and the same repeat length in exon 5.
Type 2
Repeat ambiguity: The ambiguous alleles have the same homozygous sequence 
in exons 2 through 4 but the ambiguous alleles have different repeat lengths in 
exon 5. No other nucleotide differences are located outside the ampliﬁ ed region 
in the ambiguous alleles.
Type 3
Combination of type 1 and type 2: the ambiguous alleles have the same 
homozygous sequence in exons 2 through 4 but a nucleotide difference and a 
repeat length difference in exon 5.
Type 4
Unknown MICA sequences: several MICA alleles have unknown exon 5 and / or 
exon 6 sequences. If unknown alleles display the same sequence result as known 
alleles in the ampliﬁ ed region, only completion of the unknown alleles will solve 
this type of ambiguity.
Table 4: Description of MICA ambiguities
Four different types of MICA ambiguities were deﬁ ned (table 4). 
Representative examples are shown in table 5. Sample 1 is a type 1 MICA 
ambiguity (nucleotide difference between ambiguous alleles): MICA*004,00901 or 
MICA*004,049. MICA*00901 and MICA*049 have the same nucleotide sequences 
in exons 2 through 4, the difference is located in exon 6, which could not be 
determined by the SBT approach [18]. All three MICA alleles have an A6 repeat 
in exon 5. Sample 2 is a type 2 MICA ambiguity (repeat ambiguity between the 
ambiguous alleles): MICA*00701,010 and MICA*026,010. MICA*00701 and 
MICA*026 cannot be distinguished from each other since they have the same 
nucleotide sequences in exons 2, 3 and 4. The three alleles have different repeat 
lengths in exon 5. Repeat analysis revealed an A4 and A5 repeat, leading to 
the correct MICA allele assignment, MICA*00701,010. In sample 3 a type 3 
MICA ambiguity was observed (nucleotide and repeat difference): MICA*00801, 
MICA*027 or MICA*048 or a combination of these alleles. An identical sequence 
was observed in exons 2 through 4 for the MICA*00801, MICA*027 and MICA*048 
alleles. MICA*00801 has an A5.1 repeat and MICA*027 and MICA*048 both have 
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an A5 repeat. Repeat analysis shows both the A5 and A5.1 repeat, resulting in 
the ambiguity MICA*00801,027 or MICA*00801,048. The polymorphism between 
MICA*027 and MICA*048 is located downstream the repeat in exon 5 and can be 
determined by reverse sequencing with the 3’ primer (MICA5R), used for MICA 
fragment analysis, as sequence primer [22].
MICA allele analysis in HNSCC
For 47 oral cavity patients and 48 controls a MICA typing could be obtained 
with high-resolution SBT. Types 1, 3 and type 4 ambiguities were observed in 
both groups: the ambiguous typing MICA*00201,00801 and MICA*028,035 is a 
type 4 MICA ambiguity since exon 5 and 6 are unknown for MICA*035 and part 
of exon 5 and complete exon 6 are unknown for MICA*028. A type 1 ambiguity 
was observed for the MICA*00901 and MICA*049 alleles. A type 3 ambiguity was 
observed for the MICA*027 or MICA*048 alleles.
Within the oral cavity patient group and control group 23 different MICA 
alleles were observed. The MICA*00801 allele was the most frequent MICA allele 
in the oral cavity patient group and in the control group. Other frequent alleles 
were MICA*00201, MICA*010 and the combination MICA*00901/*049 in the 
control group in the oral cavity patient group. Chi-square analysis did not indicate 
that the MICA allele frequency distribution was signiﬁ cantly different between oral 
cavity patient and controls. The observed genotype frequencies were consistent 
with earlier reports [23, 24].
HLA-B and MICA haplotype analysis
Two-locus haplotype analysis for HLA-B alleles and MICA transmembrane 
repeats was determined according to Glas et al. [25]. Haplotype associations 
were observed between the MICA-A4 repeat and B*18, B*27 and B*55, between 
the MICA-A5 repeat and B*15, between MICA-A5.1 and B*07 and B*08, between 
MICA-A6 and B*51 and between MICA-A9 and B*57 and B*35. E.g., for the B*40 
allele a trend was observed towards association with the MICA-A5.1 repeat in our 
study. However, Glas and colleagues [25] observed an association of B60 with the 
MICA-A5.1 repeat and of B61 with the MICA-A5 repeat (B60 and B61 are serological 
splits of B*40). SBT was applied to identify the alleles corresponding with B60 
and B61 antigens. We conﬁ rmed these B60-A5.1 and B61-A5 associations in the 
patients and controls. In this study several signiﬁ cant haplotype associations were 
observed for the following HLA-B and MICA allele combinations: B*14-MICA*011, 
B*15-MICA*010, B*18-MICA*018 and B*27-MICA*00701, conﬁ rming earlier 
studies indicating which HLA-B alleles are associated with which MICA allele [24, 
26].
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Discussion
HLA associations have been reported for subtypes of HNSCC in the Moroccan, 
Southern Chinese and Taiwanese population, where nasopharyngeal carcinoma is 
median to highly prevalent, [27-30]. Several HLA-A and HLA-B allele associations 
confer a decreased or an increased risk for development of NPC. For example, 
the HLA-A*02-B*46 and HLA-A*02-B*38 haplotypes observed in the Taiwanese 
population both increased the risk for developing NPC. It cannot be excluded 
that genes located close to or in linkage disequilibrium with HLA genes deﬁ ne the 
association [27, 28]. Cabrera et al. [31] observed in three types of tumours a high 
frequency of HLA-B44 allele expression loss, although no decrease in HLA-B*44 
allele frequencies was observed. The expression loss of HLA-B44 was the result of 
defective tapasin transcription in the colorectal tumours [32].
Oral cavity patients (N=47) and controls (N=48)
MICA allele patients frequency controls frequency
MICA*001 1 0.0106 0 0.0000
MICA*00201 8 0.0851 10 0.1042
MICA*00202 0 0.0000 1 0.0104
MICA*004 4 0.0426 1 0.0104
MICA*006 1 0.0106 0 0.0000
MICA*00701 1 0.0106 3 0.0313
MICA*00801 51 0.5426 40 0.4167
MICA*00901/*049 6 0.0638 9 0.0938
MICA*00902 2 0.0213 2 0.0208
MICA*010 6 0.0638 9 0.0938
MICA*011 2 0.0213 2 0.0208
MICA*01201 2 0.0213 0 0.0000
MICA*016 2 0.0213 1 0.0104
MICA*017 1 0.0106 2 0.0208
MICA*018 2 0.0213 4 0.0417
MICA*019 2 0.0213 2 0.0208
MICA*024 0 0.0000 2 0.0208
MICA*027 3 0.0319 2 0.0208
MICA*028 0 0.0000 1 0.0104
MICA*037 0 0.0000 1 0.0104
MICA*039 0 0.0000 1 0.0104
MICA*044 0 0.0000 2 0.0208
MICA*047 0 0.0000 1 0.0104
Table 6: Allele frequency of the MICA alleles in the oral cavity patient 
group and the control groupa
aN= the number of patients/controls typed for each HLA gene. The 
allele ambiguity MICA*00901/*049 and the genotype ambiguity 
MICA*00201,00801/MICA*028,035 cannot be resolved by the method 
described here. The MICA*00901/*049 alleles are combined reported. Samples 
ambiguously typed as MICA*00201,00801/MICA*028,035 are considered as 
MICA*00201,00801.
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In this study HLA polymorphism was investigated to examine whether HLA 
alleles or haplotypes are associated with HNSCC in the Dutch population. The 
patient group analysed in this study were diagnosed with squamous cell carcinoma 
of the oral cavity, larynx, oropharynx and hypopharynx. These four subtypes of 
HNSCC occur more frequently in the Dutch population than NPC. Individual HLA 
allele analysis considering the total patient group, the four tumour locations, 
metastasised and non-metastasised tumours gave in the oral cavity patient group 
a signiﬁ cant B*40 allele association and in the metastasised patient group a 
signiﬁ cant B*35 association. Haplotype analysis indicated a signiﬁ cant increase 
in the B*40-DRB1*13 haplotype in the oral cavity patients. A signiﬁ cant MICA-A9 
decrease was observed in HNSCC [11]. HLA-B*35 is in linkage disequilibrium with 
this MICA-A9 repeat [11, 25]. Preliminary data indicate that the HLA-B*35-MICA-
A9 haplotype is decreased in the metastasised HNSCC patient group, but numbers 
are low. The potential involvement of HLA in HNSCC should be conﬁ rmed in an 
independent study. A study performed by Lagaay et al. (1991) indicated a lower 
observed HLA-B*40 allele frequency in female elderly as compared with younger 
blood donors [33]. Although an opposite effect was observed in this study for the 
HLA-B*40 frequency we cannot exclude the effect of an age-related HLA effect in 
the patients.
Immunohistochemical staining of HNSCC tumour specimens with HLA class 
I locus speciﬁ c antibodies [16] and allele speciﬁ c antibodies [15] indicated that a 
variety of HLA phenotypes was present in HNSCC. Combining immunohistochemical 
staining with locus and allele speciﬁ c antibodies and HLA typing will be required to 
determine detailed HLA expression loss in tumours for future immunotherapeutic 
approaches [15]. 
We evaluated allelic polymorphism of the MICA gene in a subset of patients, 
the oral cavity patients. MICA allele frequencies did not indicate that particular 
MICA alleles were associated with the oral cavity group. Since the discovery of 
MICA in the late 90’s, several methods (e.g. SSP, sequence-speciﬁ c oligonucleotide 
probes (SSOP) and SBT) have been applied to identify MICA polymorphism [18, 
23, 26, 34]. Simultaneously with the development of these methods the number of 
MICA alleles expanded (IMGT/HLA database 2.10: 58 MICA alleles) and as a result 
the probability of observing MICA ambiguities in heterozygous samples gradually 
increased. We reﬁ ned the method for MICA allele assignment, based upon the 
SBT method developed by Katsuyama et al. [18], and included determination 
of the repeat polymorphism, present in exon 5. Exon 5 repeat info is crucial to 
identify MICA alleles. Without this repeat information allele assignment based 
only upon nucleotide polymorphism does not reﬂ ect the actual alleles present 
and approximately 90% of the samples will result in an ambiguous typing. A 
three nucleotide indel polymorphism, present in intron 1 in several MICA alleles, 
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results in a mismatch with the exon 2 forward sequencing primer MICA51. It is 
therefore important to sequence in both directions, as performed in this approach, 
to assure no alleles are missed. Microsatellite analysis can support this sequencing 
behaviour since there is a linkage between intron 1 polymorphism and exon 5 
repeat polymorphism [35].
Despite the observed signiﬁ cant HLA-B*40-DRB1*13 haplotype association 
(OR=4.09), the frequency of the B*40-DRB1*13 haplotype is low. This association 
cannot be considered as primary risk factor for the development of HNSCC. Within 
HLA haplotypes other genes at chromosome 6 could provide a stronger association. 
Knowledge concerning the HLA expression status of tumours remains necessary 
and cannot be predicted by HLA associations only.
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Abstract
Many immune related genes are located within the HLA region on chromosome 
6. The MHC class I chain-related gene A (MICA), located centromeric of HLA-B, 
is involved in the innate and adaptive immune response through activation of 
NK- and T-cells. Differences of MICA transmembrane repeat lengths have been 
associated with diseases and expression is observed on epithelial tumours. Head 
and neck squamous cell carcinoma (HNSCC) is an epithelial tumour. In the present 
study we evaluated the MICA repeat length diversity in relation to MICA expression 
in Dutch HNSCC patients. MICA short tandem repeat (STR) analysis indicated a 
signiﬁ cant decrease in the frequency for the MICA-A9 repeat in patients diagnosed 
with oral cavity squamous cell carcinoma (SCC), but not in patients with SCC 
in the hypoharynx, larynx or oropharynx. Interestingly, the majority of patients 
expressed MICA as observed with immunohistochemical staining and no soluble 
MICA (sMICA) was detected in patients’ sera by ELISA. In conclusion, the length 
of the MICA transmembrane repeats in Dutch HNSCC patients does not inﬂ uence 
the MICA expression on tumour cells.
Introduction
The HLA region on the short arm of chromosome 6 has the highest gene 
density of the entire genome. At the moment, 252 HLA, HLA-related and non-HLA 
related genes are identiﬁ ed in the class I, II and III regions and their extended 
regions. A high degree of polymorphism, linkage disequilibrium and functional 
involvement in the immune system are characteristic for these genes [1-3]. A 
cluster of genes which have gained more interest since their discovery are the 
MHC class I chain related genes or MIC genes [4]. Located dispersed in the HLA 
class I region, a total of seven genes, two functional genes (MICA and MICB), and 
ﬁ ve pseudogenes (MICC, MICD, MICE, MICF and MICG), have been identiﬁ ed [5]. 
The most thoroughly investigated MIC gene is MICA. As the name implies, the 
MICA gene is related to the HLA genes in structure, but not in function. The MICA 
molecule consists of three extracellular domains (encoded by exons 2, 3 and 4), 
a transmembrane region (exon 5) and a cytoplasmic tail (exon 6). Interaction 
with beta-2-microglobulin or peptide presentation is not required for MICA cell 
surface expression [6-8]. A STR polymorphism is present in exon 5. This repeat 
(GCT) encodes the amino acid alanine. Seven different STRs have been identiﬁ ed, 
A4, A5, A5.1, A6, A7, A9 and A10, leading to a poly-alanine structure in the 
transmembrane region of the molecule [9-11]. The A5.1 repeat is characterized by 
a single nucleotide insertion after the second GCT repeat leading to a premature 
stop codon due to a frame shift. This truncated protein has no cytoplasmic tail and 
a different transmembrane region [11]. This polymorphic GCT repeat has been 
associated with ankylosing spondylitis [12], Behçet’s disease [11, 13], ulcerative 
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colitis [14], psoriasis [15], psoriatic arthritis [16] and oral SCC [17]. The exact 
function of this repeat is unknown. Different cell types express MICA constitutively, 
but expression can be induced under abnormal conditions, e.g. viral infection, 
tumour transformation or in transplantation. In several carcinomas from epithelial 
origin as well as in rejected or injured renal and pancreatic allografts expression 
of MICA was observed [4, 7, 8, 18-23]. Soluble MICA (sMICA) expression has 
been detected in the serum of cancer patients [24, 25]. MICA on tumour cells 
can interact with the NKG2D receptor, present on NKcells, γδ T-cells and αβ CD8+ 
T-cells, activating in this way the immune system [26]. sMICA is thought to have 
opposite effects, by evading the immune surveillance through blocking of the 
NKG2D receptor and promoting tumour growth [25, 27].
Head and neck squamous cell carcinoma (HNSCC) is a solid tumour 
originating from epithelial cells. In the Netherlands, about 10 new patients per 
100,000 persons each year will develop this type of tumour. The majority of 
patients are diagnosed with a tumour in the oral cavity [28].
The present study aimed to correlate the repeat polymorphism in the 
transmembrane region with MICA expression at the tumour cell surface and in 
the serum of HNSCC patients. Repeat polymorphism was determined with STR 
analysis and MICA expression levels in tumour specimens were determined with 
immunohistochemistry and in sera with ELISA. Repeat polymorphism results and 
expression results were eventually compared.
Material and methods
Patients and controls
One-hundred-and-forty patients diagnosed with HNSCC participated in 
this study. One-hundred-and-six blood transfusions donors were used as control 
persons. All patients and controls gave their informed consent for this study. The 
local ethical committee of the UMC Utrecht gave its approval for using the patients 
and controls material (METC protocol #96/267).
General information of the 140 cases regarding location of the tumour, 
mean age of the patient group at the time of surgery, absence or presence of 
metastases and histological grade is given in table 1. Histopathological diagnosis 
and classiﬁ cation of the tumours was performed according to the criteria from the 
World Health Organization [29]. Ninety-eight patients were male (mean age 60.8 
years), and 42 were female (mean age 61.9 years). Genomic DNA from peripheral 
blood was isolated with the salting out-method [30]. The mean age of the controls 
was 34.1 years. 
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MICA repeat polymorphism in exon 5
Repeat length determination was performed as previously described [31]. 
In brief, ampliﬁ cation of the repeat was performed with ﬂ uorescent and non-
ﬂ uorescent labelled primers ﬂ anking the GCT repeat in exon 5 of the MICA gene. 
Fluorescently labelled PCR products were electrophoresed on a GeneScan gel 
and the repeat length in each individual was determined with the appropriate 
software.
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MICA immunohistochemistry
Immunohistochemistry was performed on 4 µm thick parafﬁ n sections of 
HNSCC to evaluate MICA expression. Sections were deparafﬁ nized and endogenous 
peroxidase was blocked with 1.5% H2O2 in phosphate-citrate buffer, pH 5.8. 
Antigen retrieval was performed at 100°C in citrate buffer, pH=6.0, for 20 minutes. 
Sections were subsequently incubated with the anti-MICA SR99 mouse monoclonal 
antibody for 1 hour at room temperature at a concentration of 1:100 [32]. The 
anti-MICA SR99 antibody was kindly provided by S. Caillat-Zucman, Laboratory 
of Immunology, Hôpital Necker, Paris, France. After washing with PBS, sections 
were incubated with Envision™ + System/HRP for 30 minutes (DAKO Cytomation, 
Glostrup, Denmark). Visualization was performed with the high sensitive substrate-
chromogen system DAB+ (DAKO). Sections were counterstained with Mayer's 
hematoxylin. Within each tumour section, the adjacent non-tumour tissue was 
used as internal control. Intestine tissue material was used as a positive control 
for MICA expression. Tissue used as negative control was incubated with an 
isotype-matched control Ig. All tumour slides were examined for MICA expression 
by two investigators in a random blinded manner and scored as being positive, 
negative or heterogeneous. Tumours were classiﬁ ed as positive when more than 
80% of tumour cells stained positive for MICA, as negative when less than 10% of 
tumour cells stained negative for MICA and tumour cells with more than 10% and 
less than 80% MICA expression were classiﬁ ed as heterogeneous. Heterogeneous 
MICA expression indicates that i) within one tumour section, ﬁ elds of tumour cells 
are present with MICA expression and ﬁ elds of tumour cells are present without 
MICA expression and ii) within one tumour section, tumour cells positive for 
MICA are intermingled with tumour cells negative for MICA expression. After the 
independent evaluation, differences between the two persons were re-evaluated 
in the presence of a third party.
MICA sandwich ELISA
Detection of sMICA in the serum of HNSCC patients once available was 
performed using a sandwich ELISA as previously described and kindly provided 
by S. Caillat-Zucman [32]. Serum from 52 HNSCC patients and 27 controls was 
tested in the ELISA for presence of sMICA.
Statistical analysis 
Frequencies in the patient and the control group were determined by direct 
counting. Statistical analysis was performed with two by two tables, using either 
Fisher’s exact test or Chi-square test. Corrected p-values were determined via 
multiplication with the number of alleles minus one [33].
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Results
MICA repeat polymorphism
In our patient and control group, the MICA-A4, -A5, -A5.1, -A6 and -A9 
alleles were observed. The MICA-A7 and the MICA-A10 alleles were not observed 
in either group. MICA repeat results are shown in table 2. Table 2a to 2d show the 
results for the control group compared either with the total patient group (table 2a), 
or the subgroup of oral cavity SCC patients (table 2b), the metastasised patients 
(table 2c) or the non-metastasised patients (table 2d). The MICA-A9 frequency was 
signiﬁ cantly decreased in the total patient group compared with the control group 
(corr. p-value = 0.0047; table 2a), indicating that there were less patients with a 
nine-alanine repeat in their transmembrane region compared with the controls. 
No statistical signiﬁ cant differences were observed in the frequencies for the other 
MICA repeats between the total patient group and control group. When subgroups 
according to the location of the tumour were analyzed, a signiﬁ cant decrease in 
the MICA-A9 frequency was observed in the oral cavity SCC patient group (corr. 
p-value = 0.0148; table 2b). No statistical signiﬁ cant differences in frequencies, 
including MICA-A9, were observed for any of the MICA repeats in the other three 
locations (oropharynx, larynx or hypopharynx (data not shown)). In both the 
metastasised and non-metastasised group, the frequency of the MICA-A9 repeat 
was statistically signiﬁ cant decreased compared with the control group (corr. p-
value = 0.0324 and corr. p-value = 0.0332 respectively) as is shown in table 2c 
and 2d. Signiﬁ cant differences were not observed for the other MICA repeats, 
neither in the metastasised nor in the non-metastasised group. Comparing the 
metastasised patient group with the non-metastasised group did not reveal any 
signiﬁ cant differences in frequencies (data not shown).
MICA expression
In order to determine whether HNSCC expresses MICA and whether 
the decrease in the MICA-A9 repeat was correlated with MICA expression, 
immunohistochemistry was performed on tumour sections from a total of 134 
patients. MICA expression was observed in these tumours as shown in ﬁ gure 
1. Positive, negative and heterogeneous MICA expression was scored in these 
tumours. MICA expression results for the total patient group and the four locations 
are shown in table 3. For each of these groups a distinction was made between 
metastasised and non-metastasised tumours. As shown in table 3, the majority 
of tumours were positive for MICA both in the total patient group and in the 
four location groups. Whether a metastasised tumour was or was not present 
did not result in signiﬁ cant differences in MICA expression, neither in the total 
patient group nor in the four subgroups with different tumour locations (data not 
shown).
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Although the majority of tumours (114/134, table 3) expressed MICA, for 
twenty tumours either no MICA expression or heterogeneous expression was 
observed. This will be further referred to as “aberrant expression”. Between 0% and 
6% of the tumours did not express MICA while 9% to 19% was heterogeneous for 
MICA expression. Neither the location of the tumour nor the presence or absence 
of metastases was preferred regarding the aberrant expression (table 3).
As is shown in table 4, none of the MICA repeat polymorphism was 
preferred either for the heterogeneous or negative MICA expression, the location 
of the tumour or the presence or absence of metastases. All observed repeat 
polymorphisms in this study were also present in those tumours with aberrant 
MICA expression.
Preliminary results on the 52 patients tested indicate that sMICA was 
insigniﬁ cant in HNSCC patients. Only one patient showed sMICA with a concentration 
of 3.87 ng/ml. In the control group two persons tested positive for sMICA, with a 
concentration of respectively 1.57 ng/ml and 4.09 ng/ml.
Table 2a All patients (N=139) Control group (N=106)
MICA repeat +/+a +/-b -/+c -/-d corr. p-value
A4 23 116 16 90 n.s.
A5 33 106 31 75 n.s.
A5.1 100 39 66 40 0.4346
A6 45 94 30 76 n.s.
A9 32 107 45 61 0.0047
Table 2b Oral cavity (N=56) Control group (N=106)
MICA repeat +/+ +/- -/+ -/- corr. p-value
A4 7 49 16 90 n.s.
A5 13 43 31 75 n.s.
A5.1 43 13 66 40 0.2440
A6 18 38 30 76 n.s.
A9 11 45 45 61 0.0148
Table 2c Metastases (N=73) Control group (N=106)
MICA repeat +/+ +/- -/+ -/- corr. p-value
A4 13 60 16 90 n.s.
A5 15 58 31 75 0.7642
A5.1 54 19 66 40 0.4062
A6 27 46 30 76 0.8816
A9 17 56 45 61 0.0324
Table 2d No metastases (N=66) Control group (N=106)
MICA repeat +/+ +/- -/+ -/- corr. p-value
A4 10 56 16 90 n.s.
A5 18 48 31 75 n.s.
A5.1 46 20 66 40 n.s.
A6 18 48 30 76 n.s.
A9 15 51 45 61 0.0332
Table 2: STR analysis results of the MICA repeat in the controls and in the HNSCC patients.
a+/+ = patients which have a particular MICA allele, b+/- = patients which do not have a particular MICA 
allele, c-/+ = controls which do have a particular MICA allele and d-/- = controls which do not have a 
particular MICA allele. N= number of patients / controls. n.s. = not signiﬁ cant
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Figure 1. MICA immunohistochemical staining in control intestine tissue and in HNSCC tumours. Intestine 
tissue was stained with the isotype-matched control Ig (A) and with the MICA antibody (B). No MICA 
expression in a HNSCC tumour (C), heterogeneous MICA expression (D) and positive MICA expression in 
two tumours (E and F). 
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Discussion
Since its discovery MICA has been presented as a highly interesting 
molecule of the immune system. Cell surface expression is induced under stress 
conditions and this could be beneﬁ cial for the patient. NK- and T-cells, expressing 
the receptor for MICA are theoretically able to eradicate MICA expressing tumour 
cells and thus inhibiting tumour escape from the immune response.
The longest observed MICA repeat in our study, the A9 repeat, was signiﬁ cantly 
decreased in patients with oral cavity SCC. The functional relevance of the MICA 
repeat, encoding the amino acid alanine, is not yet known. Investigating the 
MICA repeat in other tumours did reveal no association between the length of the 
MICA repeat and skin cancer [34], cervical cancer [35] and cervical intraepithelial 
neoplasia [36]. MICA cell membrane expression is induced upon stress, for example 
hypoxia, a viral infection or transformation of normal cells into tumour cells. It 
could be speculated that the length of the alanine stretch inﬂ uences the tightness 
of the incorporation of the MICA molecule into the cell membrane. Alanine is a 
hydrophobic amino acid so more alanines in the repeat might indicate a better 
incorporation into the cell membrane. The MICA-A5.1 repeat has at protein level 
a premature stop codon resulting in a shorter transmembrane region, with only 
two alanines, and no cytoplasmic tail. Speculations have been made that this 
Tumour MICA expression Location Metastases MICA repeat
T96-09835 heterogeneous hypopharynx metastases A5.1 A6
T01-05118 heterogeneous hypopharynx metastases A5 A6
T01-10186 heterogeneous hypopharynx metastases A5 A5.1
T97-00889 heterogeneous larynx metastases A5.1 A6
T01-03072 heterogeneous oral cavity metastases A5.1 A6
T01-09671 heterogeneous oral cavity metastases A9 A9
T99-13325 heterogeneous oropharynx metastases A4 A5.1
T01-07696 heterogeneous oropharynx metastases A4 A6
T96-02147 heterogeneous larynx no metastases A9 A9
T96-18932 heterogeneous larynx no metastases A4 A5
T97-01817 heterogeneous larynx no metastases A5.1 A5.1
T98-06542 heterogeneous larynx no metastases A5.1 A6
T01-01713 heterogeneous oral cavity no metastases A5.1 A5.1
T01-06254 heterogeneous oral cavity no metastases A5 A6
T01-06960 heterogeneous oral cavity no metastases A4 A5.1
T01-04138 heterogeneous oropharynx no metastases A5.1 A5.1
T01-08484 negative oral cavity metastases A5.1 A6
T00-19282 negative oral cavity no metastases A5.1 A5.1
T01-07031 negative larynx no metastases A5.1 A5.1
T99-01699 negative hypopharynx no metastases A4 A4
Table 4: MICA repeat and aberrant MICA expression in HNSCC.
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allele is secreted as a soluble form instead of a cell-membrane bound form and 
is transported differently within the cell [11, 37]. Our MICA expression results on 
the other hand suggest that MICA molecules with the A5.1 repeat are normally 
expressed as was observed in homozygous A5.1 patients. MICA STR analysis in 
Taiwanese patients with oral SCC showed a signiﬁ cant increase in the A6 frequency 
[17]. In our Dutch oral cavity SCC patient group the A9 repeat was signiﬁ cantly 
decreased. Different frequencies for MICA repeats between populations might be 
an explanation for the observed results in Taiwanese and Dutch SCC patients [11-
14, 16, 17].
MICA expression experiments were performed in this study and the majority 
of tumours expressed MICA (85%). Melanomas, lung, breast, kidney, ovary, 
prostate, colon, cervix and hepatic carcinomas express MICA as well. Although 
the percentages for MICA expression range approximately between 50% and 
80%, they are not as high as observed in HNSCC [18, 21, 23]. This result was 
associated neither with the tumour location nor with the non-metastasizing or 
metastasizing character of the tumour. Soluble MICA was not detected in HNSCC 
patients. Apparently no MICA downregulation on HNSCC tumour cells occurred 
through proteolytic shedding as was observed for other epithelial tumours 
where sMICA was measured in patients’ sera, resulting in a downregulated 
NKG2D expression on T cells [24, 25]. MICA expression was observed in normal 
epithelial cells and in tumours from epithelial origin [4, 7, 8, 18, 20-23]. So, it 
might therefore not be too surprising that MICA was also expressed in HNSCC. 
Although many tumours expressed MICA, a slight minority showed aberrant 
MICA expression, which might be inﬂ uenced by the length of the repeat present 
in the MICA transmembrane region. This appeared not to be the case in our 
study, suggesting that the length of the MICA repeat has no direct inﬂ uence on 
MICA expression on tumour cells. The underlying mechanism of this distinct 
MICA expression in HNSCC tumours may be regulated by several mechanisms. 
Methylation of the MICA gene or alternative splicing of the MICA mRNA transcript 
may result in loss or heterogeneous MICA expression. HLA expression may still 
be present on tumour cells, thereby hampering the induction of MICA expression. 
Other functional processes occurring in tumours, post-translational modiﬁ cation 
in MICA or other molecules involved in MICA expression can also not be excluded 
as cause for aberrant MICA expression. 
Concluding, although a signiﬁ cant association was found with the MICA-A9 
repeat in oral cavity SCC, no correlation was found between the length of the 
repeat and MICA expression and thus no prognostic or diagnostic value can be 
attributed to these results. The function of the repeat remains unresolved. Within 
the HLA region linkage disequilibrium exists between HLA genes. MICA is located 
closely to HLA-B and linkage disequilibrium between HLA-B and MICA has been 
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established [38-42]. HLA associations have been observed in nasopharyngeal 
carcinoma [43-46]. It is possible that HLA association analysis in HNSCC might 
reveal a stronger association with HLA alleles or a HLA haplotype rather than with 
MICA. In the latter case, a gene located in the haplotype might then be associated 
with HNSCC rather than HLA or MICA itself. 
Since HNSCC tumours expressed MICA in the present study, they may 
become a target for immunological surveillance by T and NK cells expressing the 
NKG2D receptor [26]. In order to activate NK cells, HLA class I expression should 
be downregulated. A previous study has shown that a variety of HLA phenotypes 
are present in HNSCC including loss of HLA expression [47], indicating that NK 
cells can theoretically lyse tumour cells. Circulating NK cells have been found 
in patients’ sera, but it appeared that these NK cells were functionally impaired 
[48, 49]. Apparently MICA does not induce NK reactivity to remove tumour cells. 
However, it would be interesting to investigate whether tumours, that have a 
MICA-A9 repeat and also express MICA, are lysed more efﬁ ciently by T and NK 
cells compared to tumours with one of the other MICA repeats. Arising tumours 
with a MICA-A9 repeat may thus become more susceptible for immune surveillance 
in an early tumour stage. 
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Abstract
The majority of genes in the human leukocyte antigen (HLA) region are 
directly or indirectly involved in immunological functions. They comprise HLA, 
HLA-related and non-HLA related genes. Complex HLA expression patterns are 
observed in specimens from head and neck squamous cell carcinoma, but the 
underlying basis indicate complex metabolism. To explore the possible role of 
genes in the HLA region other than the classical HLA genes, susceptibility regions 
within the HLA region for head and neck squamous cell carcinoma were deﬁ ned 
in this study. Microsatellite analysis for 49 microsatellites dispersed throughout 
the HLA region, in combination with the DNA pooling approach of respectively 
one control DNA pool and three patient DNA pools, based upon tumour location, 
offered an efﬁ cient method to deﬁ ne susceptibility regions. In the oral cavity three 
signiﬁ cant susceptibility regions could be localized, one in the class I region (330 
kb), and two in the class II region (170 kb and 210 kb). Eighteen selected genes 
from these regions were tested for their RNA expression in oral cavity tumour 
tissue and compared to expression in the surrounding healthy tissue. A signiﬁ cant 
increased MHC class I polypeptide-related sequence A RNA expression in tumour 
tissues compared to healthy surrounding tissue and a signiﬁ cant decreased 
hydroxysteroid (17-beta) dehydrogenase 8 RNA expression in tumour tissues 
compared to surrounding healthy tissue, particular in those tumours without lymph 
node metastases, were observed. A non-signiﬁ cant decreased retinoid X receptor 
β and NOTCH4 RNA expression was observed in tumour tissue. In addition to 
the classical HLA genes, other genes deﬁ ne susceptibility for oral squamous cell 
carcinoma of the head and neck.
Introduction
The Human Leukocyte Antigen (HLA) region on the short arm of chromosome 
6 is the most polymorphic region in the human genome. Approximately 250 HLA, 
HLA-related and non-HLA related genes are classiﬁ ed as expressed genes and 
represent about 60% of the total number of genes present in the HLA region. 
These genes are involved in several biological processes, with emphasis on 
immunological functions [1]. Extensive research to identify disease-susceptible 
genes in the HLA region is an ongoing process [2-6] but remains difﬁ cult due to 
the number of genes present, the complex metabolism and the direct/indirect 
effects of each gene.
Head and neck squamous cell carcinoma (HNSCC) is a very aggressive 
tumour from epithelial origin and is located in the upper-aerodigestive tract. The 
conventional therapies are good and effective for patients diagnosed at an early 
stage of the disease. In general many patients present an advanced stage of disease 
at diagnosis, resulting in decreased treatment efﬁ cacy and life expectancy [7]. For 
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the development of an effective anti-tumour immunotherapeutical treatment it is 
important to understand the biological mechanisms triggering the development 
and metastases of HNSCC.
Expression patterns of the HLA genes in HNSCC showed complex patterns 
[8, 9]. In addition associations with the HLA-B*40-DRB1*13 haplotype and the 
HLA-B*35 allele in tumour location subgroups were identiﬁ ed (J. Reinders et 
al. submitted). Expression analysis of genes involved in the antigen presenting 
machinery of class I alleles could not target speciﬁ c loss of HLA expression in 
HNSCC [8]. Although these studies indicate that HLA is associated and expression 
is affected in HNSCC, genes other than the HLA genes might additionally be 
involved, resulting in escape from tumour immunosurveillance. For example, HLA-
B*44 expression loss was observed in several types of carcinomas that was due 
to the defective transcription of tapasin [10, 11].
Screening of pooled DNA samples of respectively patient and control subjects 
with microsatellite analysis offers a good and efﬁ cient method for identiﬁ cation 
of disease-susceptibility regions [12]. Pooling of DNA samples involves combining 
equal amounts of DNA from controls and patients in respectively a control and a 
patient pool to efﬁ ciently analyse large sample numbers. In the past microsatellite 
markers, dispersed throughout the HLA region, have extensively been characterized 
[13-19]. Microsatellite allele frequencies are subsequently helpful in the deﬁ nition 
of disease-associated regions. Deﬁ ning an associated region requires the testing 
of many microsatellite markers and with the use of DNA pools this is relatively 
easy. This approach has for example been applied to localize a non-melanoma skin 
cancer susceptibility region within the major histocompatibility complex [5] and 
to detect linkage disequilibrium of polymorphic restriction fragments in insulin-
dependent mellitus [20].
We investigated whether we could identify disease-susceptibility regions 
within the HLA region with HNSCC and their location using microsatellite analysis 
and DNA pooling. Genes of interest were subsequently studied for their RNA 
expression, with the quantitative PCR (Q-PCR) approach, in oral cavity tumour 
tissue compared to surrounding healthy tissue.
Materials and methods
Samples
In the period 1996-2002 HNSCC patients (N=346), with and without lymph 
node metastases, were collected in the University Medical Center Utrecht. Patients 
were grouped according to the location of their tumour: larynx (N=101), oral 
cavity (N=159) and oropharynx (N=86). Healthy volunteers (N=106) were used 
as controls in this study. Informed consent for this study was obtained from 
all patients and controls participating. This study was approved by the ethical 
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committee of the UMC-U (METC protocol #96/267).
DNA pools
Four different DNA pools were generated, one control DNA pool, and three 
patient DNA pools based upon the tumour location. Pooled DNA was prepared as 
described [12]. An accurate DNA concentration measurement was performed with 
the PicoGreen method (Molecular Probes, Eugene, Oregon, USA). Equal amounts 
of DNA for each individual were pooled and the DNA concentration of the pooled 
DNA were adjusted to 2.4 ng/µl for the control and oral cavity and 2.0 ng/µl for 
the larynx and the oropharynx DNA pool with a solution of 10 mM Tris and 0.1 
mM EDTA.
Microsatellite analysis
The four DNA pools were tested with 49 polymorphic microsatellite markers: 
30 markers were located in the HLA class I region, 16 in the class II region and 3 
in the class III region [13-19]. For all the microsatellite markers tested the same 
PCR reagents and conditions were used. Final concentrations of the reagents in 
the PCR mixture were: 1.2 ng/µl of pooled DNA, 1x PCR buffer (1.5 mM MgCl2) 
(Applied Biosystems, Japan, Co.), 200 nM of each dNTP (Applied Biosystems), 
0.025 U/µl AmpliTaq Gold DNA polymerase (Applied Biosystems) and 1 µM of each 
of the ampliﬁ cation primers, the 5´ labelled with 6-carboxyﬂ uorescein amidite 
(6-FAM) (Proligo Japan K.K.Science Center, Kyoto, Japan), in a total volume of 20 
µl. Ampliﬁ cation was initiated by a hot-start at 95ºC for 9 min, followed by 1 min 
at 57ºC and 1 min at 72ºC and ampliﬁ cation was performed in 40 cycli of 45 sec 
96ºC, 45 sec 57ºC and 1 min 72ºC and ending with hold at 4ºC. PCR products 
were subsequently 1:20 diluted with MilliQ, vacuum dried, mixed with formamide 
and the size standard marker GS500 ROX (Applied Biosystems) and denatured 
for 3 min at 95ºC. PCR products were analysed on an ABI PRISM 3700 sequencer 
(Applied Biosystems). Allele length determination for each microsatellite marker 
was performed with GeneScan software (Applied Biosystems).
DNA pools were validated by genotyping the markers D6SC1_4_1 and 
D6SC5_3_1, both located in the class I region, in the DNA pools and the individual 
samples with the same protocol as described above. For the individual samples 
10 ng of DNA was used in the PCR mixture. Subsequently the allele frequencies 
observed in the DNA pools were compared to the allele frequencies observed in the 
individual samples. Upon validation, all 49 microsatellites were tested in the four 
DNA pools. Allele frequencies for these microsatellite markers were determined 
by calculating the relative value of each peak height for an allele relative to the 
sum of all peak heights of all alleles of a particular microsatellite marker [12]. For 
identiﬁ cation of disease-susceptibility regions the allele frequency distribution for 
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each microsatellite marker was determined between the control DNA pool and 
each of the patient DNA pools, performing a multi Chi-square analysis and in 
addition Fisher’s exact test for the individual alleles (GraphPad InStat Software, 
San Diego California USA).
Q-PCR analysis
Twenty-three HNSCC patients, out of the 159 patients used for the 
microsatellite analysis, and diagnosed with a tumour in the oral cavity were selected 
based upon availability of freshly frozen tumour tissue and tumour-adjacent 
healthy tissue. Twelve patients were diagnosed with lymph node metastases at 
time of surgery. Five 10 µm sections were cut from the freshly frozen tumour 
material and from the tumour-adjacent healthy control tissue for mRNA isolation. 
At least 60% tumour in the tumour specimens was used as criterion to exclude 
the necessity of microdissection. Human Epstein-Barr virus transformed B-cell 
line LADA (IHW9273) was used as a positive control in the Q-PCR and cultured as 
previously described [21].
For isolation of total RNA from approximately 5 million Epstein-Barr virus 
transformed B-cells Trizol reagent was used according to the manufacturer’s 
protocol (Invitrogen Ltd., Paisley, United Kingdom). mRNA from ﬁ ve 10 µm tumour 
tissue sections and control tissue sections of each HNSCC patient was isolated 
using the Genoprep™ mRNA magnetic beads according to the manufacturer’s 
protocol (GenoVision Inc., Vienna, Austria). cDNA synthesis was performed 
with the Superscript RNase H- MLV-Reverse Transcriptase kit according to the 
manufacturer’s protocol (Invitrogen). To verify the quality of the cDNA isolated 
from the B-cells, tumour and control tissue, an ampliﬁ cation reaction with the 
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase was performed 
[22].
Gene expression in the tumour and the surrounding healthy control tissue 
was determined at RNA level for 18 genes and two housekeeping genes, beta-
glucuronidase (GUSß and TATA box binding protein (TBP), with the Assay on 
Demand™ Gene expression reagents (Applied Biosystems, Foster City, CA, USA). 
The different genes named according to the HUGO Gene Nomenclature Committee 
(http://www.gene.ucl.ac.uk/nomenclature/; [23]) and their previous names, are 
shown in table 1. All samples, including tumour samples, control samples, the 
positive control LADA and negative control MilliQ, were tested in duplicate for each 
gene and Ct values differing more than 0.5. between both duplicates were re-
tested. The mean Ct value was calculated from the duplicates for each sample and 
each gene. The mean Ct values were subsequently used to determine the relative 
gene expression for each gene with the -∆Ct method: “-(Ct gene of interest - 
Ct housekeeping gene)”, both for the tumour tissue and its surrounding healthy 
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Figure 1: Results from the microsatellite analysis. Microsatellite markers tested in the class I and II 
region for the oral cavity tumours are shown in respectively ﬁ gure 1A and 1B. In ﬁ gure 1C the class I 
region is shown for the larynx. Markers are shown from the centromeric to the telomeric side of the HLA 
region. Chi-square analysis is indicated by a dashed line (---) and Fisher’s exact analysis is indicated by 
a continuous line (―).
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statistical analysis were corrected for the number of assays performed: pcorr.=1-(1-
p)n, where p=uncorrected p-value and n=number of assays performed [24].
Results
Microsatellite analysis
The control and three HNSCC patient DNA pools were generated and 
subsequently validated before microsatellite analysis of all markers was performed. 
To verify that each individual patient and control sample is represented equally 
in the DNA pool, all DNA pools and individual patient and control samples were 
analysed for the microsatellite markers D6SC1_4_1 and D6SC5_3_1. Allele 
frequencies for those markers were determined both in the pools and individual 
samples and subsequently compared. The allele frequencies for the D6SC1_4_1 
and D6SC5_3_1 markers did not differ statistically signiﬁ cant between any of the 
four DNA pools and their corresponding individual samples (data not shown). This 
indicates that each individual sample is represented equally in each of the DNA 
pools and that the DNA pools are representative for their corresponding group of 
individual samples. These results also indicate that pool frequencies are a reliable 
estimation of the allele frequencies.
Figure 2: The mean -∆Ct value for either the control samples ( ) or the tumour samples (Δ) for each gene 
tested. Genes are ordered from centromeric to telomeric in the HLA region. Standard deviation for the 
control samples and tumour samples is indicated by respectively a bar above ( ) or below (Δ).
tissue. A paired T-test was performed to evaluate the relative gene expression 
in tumour and control tissue (GraphPad Prism, USA). Obtained p-values from 
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Figure 3: Expression analysis results of the HSD17B8 (ﬁ gure 3A-C), MICA (ﬁ gure 3D), RXRβ (ﬁ gure 3E) 
and NOTCH4 (ﬁ gure 3F) genes.
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Three HNSCC patient DNA pools and the control DNA pool were analysed 
for a total of 49 microsatellites dispersed throughout the HLA region to identify a 
susceptibility region for HNSCC. Results obtained for the oral cavity patients are 
shown in ﬁ gure 1. Several class I markers show a signiﬁ cance below the p<0.05 
level: D6SMICA, D6SC1_4_3, D6SC1_3_1, D6SC1_4_4 and D6SC2_2_2, indicating 
that allele frequencies for these markers are signiﬁ cantly different between the 
control and oral cavity DNA pool. These markers span a region of approximately 
330 kb (ﬁ gure 1A). The class II markers span one region of approximately 210 
kb, including markers D6SM2_2_9, D6SM2_2_21 and D6SM2_2_22 and a second 
region of approximately 170 kb, including markers D6SM2_4_25, D6SM2_4_26 and 
D6SM2_2_32 (ﬁ gure 1B). The majority of these class II markers show signiﬁ cance 
below the p<0.05 level. Neither of the microsatellite markers in the class III 
region showed signiﬁ cance within the oral cavity patients. Chi-square analysis 
and Fisher’s exact test analysis indicated that no microsatellite markers in any of 
the three HLA regions are associated with the larynx tumour location as is shown 
for the class I region (ﬁ gure 1C). For the oropharynx DNA pool one marker in the 
class II region (D6SM2_4_26), one marker in the class II region (D6SN3_3_2) 
and one marker in the class I region (D6SC1_4_4) showed association (p<0.05) 
(data not shown). Based upon these data, susceptibility regions could be deﬁ ned 
for the oral cavity but not for one of the other tumour locations. Since the majority 
of signiﬁ cantly associated markers were identiﬁ ed in the oral cavity DNA pool, this 
tumour location was studied at the RNA expression by Q-PCR
Gene expression analysis
Eighteen genes were selected for further analysis based upon the three 
susceptibility regions (table 1). The RNA expression level for the selected genes, 
and the two housekeeping genes GUSβ and TBP, was determined in oral squamous 
cell carcinoma tissue and its surrounding healthy tissue from 23 patients, 12 
with and 11 without lymph node metastases. The correlation coefﬁ cient between 
GUSβ and TBP RNA expression was R2=0.9200 and R2=0.8287 for respectively 
the surrounding healthy tissue and tumour tissue, indicating that the expression 
variability for the housekeeping genes is higher in tumour tissue than in control 
tissue. A phenomenon that Blanquicett et al (2002) observed in liver metastases 
and to a lesser extent in colorectal carcinoma for a number of housekeeping genes. 
GUSβ RNA expression was constant in control and tumour tissue, while for TBP, 
and also the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase, 
RNA expression was variable in tumour and control tissue [25]. We therefore 
used GUSβ as the housekeeping gene for the determination of the relative gene 
expression for the selected genes.
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In ﬁ gure 2 are shown the mean -∆Ct values for the tested genes in tumour 
and healthy surrounding control tissue. The genes are ordered according to their 
location within the HLA region, from centromeric to telomeric. The relative gene 
expression for the genes in the HLA region RING1, SLC39A7, HLA-DOA, HLA-DMA, 
HLA-DMB, AGER, AGPAT1, CREBL1, CYP21A2, POU5F1, TCF19, GTF2H4, DDR1 and 
TUBB did not differ statistically between the tumour tissue and the surrounding 
healthy tissue. Based on the presence or absence of metastases, no signiﬁ cant 
differences in the relative gene expression for these genes between both groups 
were found (data not shown).
Hydroxysteroid (17-beta) dehydrogenases (HSD17B8) RNA expression was 
signiﬁ cantly decreased in tumour tissue compared with the surrounding healthy 
tissue (ﬁ gure 3A). Based upon the presence or absence of lymph node metastases, 
a statistically signiﬁ cant decrease of HSD17B8 RNA expression in tumours without 
lymph node metastases (pcorr.=0.0020) but not in tumours with lymph node 
metastases was observed (ﬁ gure 3B and 3C). MHC class I polypeptide-related 
sequence A (MICA) RNA expression was signiﬁ cantly increased in tumour tissue 
compared with the surrounding healthy tissue (ﬁ gure 3D) but the increased MICA 
RNA expression was not indicative for either the tumours with or without lymph 
node metastases. For the majority of tumours a decrease in retinoid X receptor β 
(RXRβ) RNA expression was observed in the tumour tissue (19 out 23 tumours) 
(Figure 3E). For 4 tumours (indicated by arrows in ﬁ gure 3E), an increase in RXRβ 
RNA expression was observed. A signiﬁ cant decreased NOTCH4 RNA expression 
was observed in tumour tissue. Approximately 76% of the tumours had a lower 
NOTCH4 RNA expression was compared to the control tissue (pcorr.=0.0504) (ﬁ gure 
3F).
Discussion
Pooling of DNA samples, respectively controls and subjects, in combination 
with microsatellite marker analysis provides the ability to perform large-scale 
association analysis and to identify disease-susceptibility regions. This study 
was performed to identify disease-susceptibility regions within the HLA region on 
chromosome 6 in the context of HNSCC and its different tumour locations. Results 
obtained in this study indicate that the three HNSCC tumour locations display 
different HLA susceptibility. For the oral cavity tumours three regions of interest, 
one in the HLA class I region and two in the HLA class II region, comprising 
together approximately 700 kb, were identiﬁ ed with microsatellite analysis in the 
DNA pools. For the larynx tumours no signiﬁ cant associations were observed, while 
a few microsatellite markers showed association with the oropharynx tumour.
A different susceptibility pattern is displayed for the three tumour locations 
indicating that genes within the HLA region do not equally affect the development 
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of tumours at the different sites. Most striking is the association of three different 
regions with oral cavity tumours. Smoking and consumption of alcohol are risk 
factors for development of HNSCC. The oral cavity is the ﬁ rst contact site with 
tobacco smoke and alcohol. In addition, p53 mutations are frequently observed 
in HNSCC [26]. Consumption of alcohol may lead to an increased permeability of 
the oral mucosa resulting in a relatively easy entrance of carcinogenic substances 
from tobacco smoke [27]. The induction of p53 mutations in these patients 
might subsequently follow the alcohol and tobacco related events, resulting in 
dysfunctional cell metabolism and immune responses.
Microsatellite markers are mainly located in intergenic sequences and are 
in general non-coding. It is hypothesized therefore that in disease-association 
studies the associated microsattelite markers are closely located to and in linkage 
disequilibrium with genes that are involved in HNSCC. To evaluate the signiﬁ cance 
of the associated regions in this study, 18 genes were selected and analysed for 
their RNA expression level in tumour tissue compared with its surrounding healthy 
tissue from 23 patients diagnosed with oral squamous cell carcinoma.
The HSD17B8 RNA expression was signiﬁ cantly lower in tumour tissue of 
oral cavity patients without lymph node metastases compared to its surrounding 
healthy tissue. HSD17B8 regulates estrogen and androgen levels in tissues [28]. 
Downregulated mRNA and protein expression for the mouse HSD17B8 is observed 
in kidneys of mice with polycystic kidney disease (PKD) [29, 30]. The absence 
of a nuclear protein in the PKD mice is thought to play a role in the aberrant 
mouse HSD17B8 expression [31]. In addition, downregulated expression and 
aberrant activity of the HSD11B1 gene, a type 11 hydroxysteroid dehydrogenase, 
is observed in kidneys of these PKD mice. HSD11B1 expression and activity 
is suggested to be regulated by the mouse HSD17B8 gene in PKD mice [30], 
indicating that functionality of the HSD11B1 gene is dependent on the presence 
of the HSD17B8 expression.
In human a decreased HSD11B1 mRNA expression was observed in tumour 
tissue compared with non-affected mucosa [32]. HSD11B1 gene is able to 
detoxify carcinogens derived from tobacco smoke. The authors suggested that 
tobacco smoke induced the higher expression in non-affected mucosa, while the 
decreased HSD11B1 expression was the consequence of overall cell dysfunction 
of tumour cells [32]. Based upon the results observed in this study we suggest 
that also in human a correlation between HSD17B8 and HSD11B1 might be 
present. Decreased HSD17B8 mRNA expression could subsequently inﬂ uence 
HSD11B1 through downregulation of HSD11B1 mRNA expression and activity. 
For patients this would indicate that tobacco-smoke derived carcinogens would 
not be detoxiﬁ ed as efﬁ ciently anymore and in this way might contribute to the 
development of HNSCC. Whether in human, as is suggested in mice, also a nuclear 
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protein is involved in the downregulation of HSD17B8 mRNA expression remains 
to be examined. 
MICA RNA was expressed higher in tumour tissue than in healthy tissue. A 
strong MICA expression was demonstrated in the majority of HNSCC tumours by 
immunohistochemical staining (J. Reinders et al., submitted). MICA is a stress-
inducible molecule and can be recognized by gd T-cells [33] and its protein 
expression is observed in several types of carcinomas [34]. The function of MICA 
is unknown, but interference with immunological processes is suggested [35].
A decreased RXRβ RNA expression was observed in the majority of oral cavity 
tumours. Decreased or no retinoid acid receptor α (RARα) RNA expression was 
observed in several types of carcinomas, including HNSCC [36, 37]. In prostate 
and lung carcinoma tissue RXRβ RNA expression was respectively absent and 
decreased compared to healthy tissue [38, 39]. Decreased RXRβ RNA expression 
in lung carcinoma patients is an independent predictor of worse survival [39]. The 
retinoid acid receptors (RAR) and the RXR’s, to which RXRβ belongs, are receptors 
for retinoids. Retinoids are able to control cell proliferation, differentiation and 
apoptosis. In addition they are able to suppress carcinogenesis in a number of 
epithelial tissues, including HNSCC [37, 40]. Dysfunction of retinoid receptors 
might therefore direct cells towards tumour cell transformation. Hypermethylation 
of the RARβ gene contributes to loss of RARβ RNA expression in HNSCC cell 
lines and is inversely related to the presence of p53 mutation [41]. Gene 
rearrangements involving the RAR receptor RARα have been described in acute 
promyelocytic leukaemia and result in dysfunction of the receptor [42]. Whether 
hypermethylation, point mutations and rearrangements in the RXRβ gene cause 
decreased RXRβ RNA expression in oral cavity tumours is unknown. Since e.g. 
other RAR and RXR receptors still might be expressed in HNSCC, the role of RXRβ 
in oral cavity tumours is, despite the decreased RXRβ RNA expression, difﬁ cult to 
determine because of the biological complexity of the retinoid receptors and their 
retinoids. In addition, RXRβ is able to bind the region II enhancer of HLA class I 
genes and regulates HLA class I transcription [43]. It could therefore be speculated 
that decreased RXRβ RNA expression inﬂ uences the transcription of HLA class I 
genes and thus might inﬂ uence the protein expression of HLA class I molecules on 
the cell surface. This would be in concordance with the results observed previously 
indicating complex HLA expression patterns in HNSCC [8, 9].
NOTCH4 RNA expression is in the majority of oral cavity tumours 
decreased. Among others NOTCH4 is functionally involved in developmental and 
differentiation pathways; decreases in NOTCH4 expression might prevent control 
on cell differentiation and regulation and consequently promote tumour growth. 
NOTCH4 is composed of an extracellular and an intracellular domain. A variant 
of the NOTCH4 gene, composed of only the intracellular domain, is constitutively 
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expressed in mice with breast carcinomas, contributing to the development of this 
type of cancer [44]. In human a similar, but truncated, variant has been detected 
in several human tumour cell lines and this variant induces breast carcinoma, 
although with an increased latency and decreased frequency compared to the 
mouse variant [45, 46]. 
Results obtained at RNA level cannot always be extrapolated to the protein 
level. Protein expression can be inﬂ uenced by a number of mechanisms, e.g. 
mutations [47]. In the majority of HNSCCs, p53 mutations are observed, in general 
resulting in increased mRNA expression and over-expression of the p53 protein 
[26, 48]. Gene methylation inhibits the transcription of genes and prevents thus 
protein expression, as stated earlier for the RARβ gene. Some cell lines in which 
the RARβ gene was methylated could expression be restored by addition of a 
demethylating agent to the cell lines [41]. 
This study showed that, in addition to the observed HLA allele and haplotype 
associations and the aberrant HLA expression patterns in HNSCC, other genes 
within the HLA region are involved in the carcinogenic process. Whether the 
inﬂ uence of these genes on the immune response is indirect or direct remains to 
be studied. 
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General discussion
Polymorphic HLA molecules, encoded by genes located in the human 
leukocyte antigen (HLA) system, are able to bind a miscellaneous range of 
peptides, derived from endogenous and exogenous proteins. Presentation of 
these peptides to CD4+ and CD8+ T-cells allows the immune system to recognize 
and to defend against non-self and tumour antigens and to protect self. Under 
abnormal conditions, for example in carcinogenesis, tumour cells will adjust their 
cell metabolism to avoid detection and clearance by the immune system. Altering 
HLA cell surface expression is a mechanism by which tumour cells change their 
“exterior looks”. In several types of carcinoma, including head and neck squamous 
cell carcinoma (HNSCC), aberrant HLA expression patterns have been observed 
but the mechanisms that underlie these aberrant expression patterns have not 
yet been clearly established. This thesis aimed to identify and characterize the 
HLA diversity and the functionality of the HLA diversity in the context of the 
development of HNSCC. DNA-, RNA- and protein-based studies were developed 
and applied to identify and characterize the genes involved. These studies show 
that, in addition to the observed aberrant HLA expression patterns, associations 
with HLA alleles and haplotypes, HLA-related genes and aberrant expression of 
non-HLA related genes are important in the development of HNSCC. How the 
interaction of different factors, directly or indirectly, is involved in the generation 
of aberrant HLA expression on tumour cells remains to be established. 
Head and neck squamous cell carcinoma susceptibility genes in 
the HLA region
HLA association analysis indicated that the HLA-B*40-DRB1*13 haplotype 
was associated with HNSCC (chapter 5). However, since this haplotype is not 
frequently observed, it could not be the primary susceptibility factor for HNSCC. 
Reﬁ ned analysis with microsatellite markers in the class I, II and III regions 
identiﬁ ed three associated regions with candidate susceptibility genes (chapter 
7). Subsequent expression analysis of candidate genes showed associations 
with hydroxysteroid (17-beta) dehydrogenase 8 (HSD17B8), retinoid X receptor 
β (RXRβ) and MICA, for which expression differences were observed between 
tumour tissue and healthy surrounding tissue.
The MHC chain related gene A (MICA) has gained more and more interest 
since its discovery because it is involved both in innate and adaptive immunity. 
This gene encodes for a cell surface molecule structurally related to the MHC class 
I molecules but independent from β2m or peptide for its expression [1, 2]. Genetic 
diversity within the MICA gene is characterized by nucleotide polymorphism and 
repeat polymorphism, the latter affecting the length of the transmembrane region. 
Constitutive MICA expression is observed on limited cell types but expression can 
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be induced by stress conditions. Several types of carcinomas express MICA and 
a soluble form of MICA has been observed in the sera of tumour patients [3-9]. 
Interaction with its receptor NKG2D, present on NK-cells and γδ T-cells activates 
these cell types [5, 10, 11]. HNSCC expresses MICA but this expression is not 
correlated with the length of the transmembrane region (chapter 6).
Merely the presence of MICA on HNSCC tumour cells will not be sufﬁ cient 
for eliciting a proper anti-tumour response. NK-cells become active if HLA class 
I expression is downregulated or lost since the inhibitory signal from NK to HLA 
is then not present anymore. Aberrant HLA expression is present in HNSCC, 
providing NK-cells the opportunity to recognize and kill tumour cells. In vitro 
experiments showed that the presence of stimulatory and inhibitory ligands, 
HLA class I expression, for NK-cells was inversely correlated with NK cell activity 
[12]. The presence of local and regional tumour and inﬂ ammatory inﬁ ltrates in 
HNSCC has been reported [13]. Analysis of the individual components of these 
inﬁ ltrates indicated that very few NK-cells are present when compared to other 
components, as CD4+ and CD8+ T-cells [13-15]. Moreover, presence of NK-cells 
does not inevitably warrant active NK-cells. Several studies reported the presence 
of functionally impaired NK-cells in patients’ sera [14, 16, 17]. Expression of the 
NKG2D receptor on NK-cells is also required for activation of NK-cells. Cisplatin 
chemotherapy for HNSCC in a murine model suppressed NKG2D expression on 
lymphocytes. A combination therapy of cisplatin with IL-2 gene transfer, a potent 
activation and growth factor for NK-cells, resulted in signiﬁ cant anti-tumour effects, 
since NKG2D expression was not suppressed [18]. IL-18, an interferon-gamma-
inducing factor, is produced by upper aerodigestive tract epithelia, both normal 
and malignant [19]. Optimal stimulation of IFNγ secretion and cytolysis by NK-
cells requires the production of IL-18 by the HNSCC carcinoma cells themselves 
as was shown in in vitro experiments [19]. It is apparent from these studies that, 
although MICA is expressed on HNSCC tumour cells, it cannot act alone. Teamwork 
of different molecules is required for an efﬁ cient anti-tumour response.
HLA expression
Insight into the diversity of HLA genes is important to understand the 
functionality of the observed HLA diversity in biological processes. HLA diversity 
can be determined by DNA- and protein-based studies with approaches at different 
levels of resolution. Full-length sequences (coding and non-coding diversity) 
can be identiﬁ ed at the DNA level, while at protein level diversity of the HLA 
molecule is obtained. Protein-based analysis will provide information regarding 
allele expression but cannot give detailed information about the polymorphisms 
present in the peptide-binding groove, since not all HLA diversity is accessible 
to antibodies due to conformational restrictions of the groove of the proteins. 
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In general, the diversity in the peptide-binding groove is identiﬁ ed with high-
resolution molecular-based approaches, whereas expression is identiﬁ ed with low-
resolution protein-based approaches.
HLA expression identiﬁ cation with protein-based techniques is mainly 
performed with immunohistochemical staining or ﬂ ow-cytometric (FCM) analysis. 
The use of monomorphic and locus speciﬁ c antibodies generally only detects the 
absence or presence of a particular HLA antigen, but not the absence or presence of 
individual alleles. Allele speciﬁ c antibodies enhance the resolution of detection and 
show that expression loss is highly underestimated when using only monomorphic 
and locus speciﬁ c antibodies compared to allele speciﬁ c antibodies [20, 21]. The 
hurdle that has to be taken with antibody-based determination of HLA diversity is 
the generation of HLA allele speciﬁ c antibodies. For a limited number of HLA-A and 
HLA-B alleles antibodies are available for which the reactivity of speciﬁ c epitope(s) 
on the HLA molecule have been identiﬁ ed [22]. Moreover, these epitopes are 
often present in more than one HLA-A or -B antigen. This requires HLA typing 
for the identiﬁ cation of the HLA antigens present. For HLA-C almost no allele 
speciﬁ c antibodies are available for expression analysis. Thus, protein analysis 
gives limited information regarding the HLA sequence diversity but to a great 
extent information regarding the expression status. DNA analysis gives complete 
details about the HLA sequence diversity, but is limited with information regarding 
the expression status of the alleles. 
Insight into the functionality of HLA diversity on different biological processes 
requires the understanding of the effect of a speciﬁ c polymorphism in the HLA 
molecule. Substitutions, insertions and deletions are polymorphic changes that 
occur within HLA genes. The subsequent effects of these polymorphic changes on 
the genomic sequence, and thus the composition of the HLA molecule, inﬂ uence 
the peptide binding, T-cell and NK-cell interaction, HLA transcription and splicing, 
or expression.
Loss of HLA expression on tumour cells provides tumours an escape from 
immune surveillance by T- and NK-cells. In solid and haematological tumours 
aberrant HLA expression patterns have been observed. For an optimal application 
of T-cell based immunotherapy an accurate determination of the HLA expression 
status is required but, although the generation of allele speciﬁ c antibodies has 
resulted in a higher resolution level for protein analysis, relatively few allele 
speciﬁ c antibodies are available. To provide a detailed identiﬁ cation of HLA 
sequence diversity and information regarding the expression status of HLA alleles, 
either the generation of more allele speciﬁ c antibodies for all class I alleles or 
the development of an RNA sequencing based typing (SBT) approach is required 
(chapter 2). Performing RNA SBT i) will identify the HLA alleles present; ii) may 
elucidate the cause of expression loss and iii) may show whether a particular 
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polymorphism results in expression loss due to the generation of an alternative 
spliced product or an HLA null allele. E.g. the HLA-A*0111N allele is an alternatively 
spliced null allele for which no protein expression was observed. The consequence 
of the polymorphism causing this null allele could not be identiﬁ ed at DNA level 
whereas RNA analysis was conclusive (chapter 3).
Aberrant HLA expression
Cell metabolism is deregulated in and by tumour cells, providing them 
the opportunity to escape immune surveillance. Aberrant expression is the loss 
or reduced expression of HLA molecules at the cell surface. It can be classiﬁ ed 
according to the type of aberrant HLA expression: i) total HLA expression 
loss; ii) HLA haplotype loss; iii) HLA locus loss; iv) HLA allelic loss and v) HLA 
compound loss [23, 24]. Aberrant HLA expression has been observed in both 
solid and haematological tumours: leukaemia [20, 25], bladder tumours [26], 
gastric tumours [27], colorectal tumours [26, 28-30], cervical tumours [31], 
breast tumours [30], melanoma [26, 32, 33], B-cell lymphoma of the testis and 
the central nervous system [34], esophageal squamous cell carcinoma [35] and 
head and neck squamous cell (HNSCC) tumours [21, 26, 30, 36-40]. In addition 
to the aberrant expression patterns of HLA class I molecules in tumours, altered 
expression for beta2-microglobulin (β2m) and genes involved in the class I antigen 
processing and presenting pathway was detected [21, 28, 29, 37-39, 41-43].
Aberrant HLA class I expression can be initiated by several mechanisms 
operating at the (epi)genetic, transcriptional and post-transcriptional level and 
either affect the HLA genes themselves, the genes involved in the assembly of the 
HLA complex or the genes involved in the expression regulation of HLA molecules. 
Genetic alterations, (mutations, insertions and deletions) in HLA-A and HLA-B 
alleles were reported in cervical tumours that caused allelic expression loss [31, 
44] while in B-cell lymphomas mutations in class II genes were reported [45]. 
Locus and allele speciﬁ c loss of HLA-A and HLA-B has been described for HNSCC 
[21, 37-39]. Analysis of the HLA-A and HLA-B transcripts in tumour tissue with 
the RNA SBT protocol (chapter 2) will reveal whether genetic alterations within 
the HLA-A and -B genes themselves are present and can explain HLA expression 
loss on tumour cells. Preliminary results indicate that the ﬁ rst two studied HNSCC 
tumours with aberrant HLA-A expression do not have genetic alterations in their 
HLA-A alleles. Other mechanisms than genetic alterations are thus responsible 
for expression loss in these tumours. Genetic alterations in the β2m gene have 
been detected in colorectal tumours [29], B-cell lymphomas [46] cervical tumours 
[31] and melanomas [26]. However, others reported no alterations in the β2m 
gene in colorectal tumours, bladder tumours and HNSCC [26, 39, 47]. Loss of 
heterozygosity (LOH) of the HLA region or of the β2m gene on chromosome 15 
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are also phenomena that are observed in tumours resulting in loss of a gene or 
haplotype and thus the loss of HLA or β2m expression [26, 30, 31, 36, 43, 46]. 
Altered expression levels of genes involved in the assembly of the HLA complex, as 
TAP1, TAP2, PSMB’s and tapasin result in aberrant HLA cell surface expression [29, 
42, 43]. Expression of these genes can be restored by IFNγ treatment, suggesting 
that dysfunction rather than structural alterations are causing expression loss 
of the genes involved in assembly of the HLA complex [42]. Locus speciﬁ c 
transcriptional regulation of the HLA genes can also result in loss of cell surface 
expression [48, 49].
The main epigenetic event is DNA methylation of promoters with CpG rich 
regions, in which the cytosine residues are methylated. Multiple cellular functions 
as cell growth and differentiation, cell cycle control, DNA repair, angiogenesis and 
invasion are affected [50]. DNA methylation silences transcriptional activity, thus 
controlling gene expression. It is thought that methylation interferes either directly 
or indirectly with gene transcription. Direct interferences can be accomplished 
through the modiﬁ ed cytosine, that hinders the binding of transcription factors 
necessary for gene transcription or altering the secondary DNA structure, especially 
the conformation of the major binding groove. Indirect inhibition of transcriptional 
activity can either be achieved via proteins that preferentially bind methylated 
promoters, and thus in this way prevent binding of transcription factors, or 
induction of chromosome remodelling through histone deacetylation [35, 51]. 
Tumour-suppressor genes, genes involved in tumour invasion, tumour metastasis, 
DNA repair, angiogenesis inhibitors and tumour antigens have been described as 
being highly methylated in tumours, thus promoting tumour growth, invasiveness 
and metastasis [51]. Investigation of CpG distribution in the HLA class I genes 
indicates that these genes have a CG content, exceeding 60%. The majority of 
CpG dinucleotides are located between the 5’-untranslated region and exon 3 in 
all three class I genes [35]. In primary oral squamous cell carcinoma tumours 
and cell lines, tumour-suppressor and cancer-related genes were found to be 
transcriptionally silenced through methylation [52-56]. In cell lines demethylating 
agents could restore transcription and expression [54]. With respect to the HLA 
genes, methylation of HLA genes has been detected in oesophageal squamous cell 
carcinoma [35] and melanoma [57, 58] but has not yet been studied in HSNCC. 
Although the class I genes display a high number of potential methylation sites, 
HLA gene methylation in tumours will only partially contribute to HLA expression 
loss. 
Many different mechanisms involved in HNSCC demonstrate either 
a primary or a secondary HLA effect on HLA cell surface expression. Primary 
effects are established by e.g. mutations in and LOH of HLA, whereas secondary 
effects are accomplished by gene methylation or deﬁ ciencies in genes involved in 
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antigen processing and presentation. DNA-, RNA- and protein-based approaches 
are now available for detection of primary HLA effects. To obtain full insight into 
the heterogeneous mechanisms in HNSCC, detection of the secondary effects is 
required for the implementation of immunotherapy. Tapasin is one of the molecules 
involved in secondary processes responsible for HLA expression loss [42, 43], as 
are β2m [29, 37, 39, 47, 59], TAP1, TAP2 [21, 39, 42, 60], and PSMB’s [21, 29, 
42]. 
Alternative splicing
In the process of RNA splicing, exons are joined and introns are spliced out, 
to generate mature RNA transcripts. Correct generation is a complex process in 
which 5’ and 3’ splice sites, a branch site, a polypyrimidine tract and exonic and 
intronic regulatory elements are required [61]. Sequences present at these sites 
are in general evolutionary conserved in eukaryotes [62] (A. Houben, submitted 
for publication). Alternative splicing is a phenomenon that occurs in normal tissue 
and in tumours. Transcription factors, cell signalling molecules, transmembrane 
proteins and secreted extracellular proteins are affected by aberrant and 
alternative splicing of RNA transcripts in many types of tumours [63]. Alternative 
splicing leads to truncation and/or expression loss of the protein subsequently 
resulting in an alteration or absence of the chemical and biological activity of the 
protein. The CD44 molecule, a transmembrane protein normally involved in cell 
proliferation, differentiation, adhesion and migration, is a well-known example 
of an alternative spliced molecule. More than twenty CD44 isoforms have been 
detected and, depending on the isoform present, they play a role in tumour cell 
invasion and metastasis [63-65]. However, characterization of one of the CD44 
splice variants in HNSCC indicates that this variant does not play a role in the 
pathogenesis of HNSCC [66]. 
Alternatively spliced HLA transcripts, along with their normally spliced 
transcripts, have been described [67-69]. In tumours, generation of alternatively 
spliced products is an additional mechanism to explain escape from the immune 
system [67]. Five different mechanisms initiate alternative splicing: i) exon 
skipping/inclusion; ii) alternative 5’ splice site; iii) alternative 3’ splice site; iv) 
mutually exclusive exons and v) intron retention. The length of 5’ and 3’ ends 
of mRNA can also be affected using alternative promoters and/or alternative 
polyadenylation sites [61]. Alternatively spliced transcripts for HLA-A*23 and 
A*24 alleles were detected lacking two or more exons in their transcript (chapter 
2). Alternatively spliced HLA-A24 transcripts lacking exon 5, the transmembrane 
region, were detected as secreted forms in a leukaemic T-cell line [69]. The 
combination of different splice sites and different polyadenylation signals in the 
3’ untranslated region (UTR) resulted in allele-dependent length polymorphism in 
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DQA1 genes and divide the DQA1 alleles into three groups [70].
Theoretical analysis of potential alternative 5’ and 3’ splice sites in the 
classical HLA class I genes revealed numerous alternative splice sites throughout 
the entire classical class I genes, both in exons and introns. This indicates that, 
in addition to the regular splices sites, alternatively spliced HLA products can be 
formed (A. Houben et al, submitted for publication).
Several non-expressed HLA alleles and a soluble allele identiﬁ ed to date 
are due to alternative splicing: HLA-A*0104N [71], HLA-A*0111N [72], HLA-
A*24020102L [73, 74], HLA-A*29010102N [75], HLA-B*15010102N [76], HLA-
B*44020102S [77] and HLA-DRB4*01030102N [78]. In the majority of these 
alleles, the cause of the alternative splicing is a variation at either the 5’ or 3’ 
splice site. Alternative splicing also occurs in alleles with normal expression, as 
is shown for the HLA-A*1101, HLA-A*1102 and HLA-A*1103 alleles [79]. In the 
HLA-A*0111N [72] and the HLA-AA*11 alleles [79] a variation resulted in a new 
alternative splice site that matched the splice site consensus better than the 
regular splice site [72, 79]. Although alternative spliced products were formed 
in these null, soluble and normal alleles, normally spliced transcripts were still 
detectable for several alleles. However, elevated expression for the alternatively 
spliced transcripts was observed when compared to the normally spliced transcripts 
[68, 70, 73, 79]. 
The majority of splice variants is transcribed into RNA; whether they 
are translated into a truncated protein product is not completely known yet. If 
alternatively spliced products are translated into a truncated protein, subsequent 
identiﬁ cation can be difﬁ cult. The presence of normal and alternative spliced 
products will hinder their independent identiﬁ cation [68, 79]. Speciﬁ c antibodies 
for the normal and alternative spliced products have to be used to discriminate 
between both products. Detection may also be hampered if alternative splicing 
results in exon skipping and the epitope, against which the antibody is directed, 
has been lost due to the alternative splicing. It might also be possible that a 
very low level of steady state RNA and/or a low translation efﬁ ciency are present 
that hamper the detection of the truncated protein product [67]. Structural 
and conformational changes in a truncated protein, due to exon skipping, exon 
inclusion or intron retention, might also hamper detection. 
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Future perspectives
The pathogenesis of head and neck squamous cell carcinoma (HNSCC) 
is a complex and heterogeneous interplay of multiple genes. HNSCC tumours 
display heterogeneous expression of HLA molecules on their cell surfaces, among 
others. An inventory of genomics, transcripteomics and proteomics is required to 
understand the biology and signiﬁ cance of these genes participating in HNSCC and 
may ultimately result in development of therapeutic interventions. This complex 
and heterogeneous interplay involves primary and secondary mechanisms and 
affects general and immune speciﬁ c tumour cell metabolism. In this thesis the 
immune speciﬁ c metabolism was investigated. Aberrant HLA expression patterns, 
HLA, HLA-related and non-HLA related genes were found to be associated with 
HNSCC that either have a direct or an indirect effect on the immune response. 
Genes with a general effect on HNSCC tumour cell metabolism have been identiﬁ ed 
with micro-array technology [80-84]. An expression proﬁ le for predicting the 
development of lymph node metastases in HNSCC identiﬁ ed 102 genes potentially 
involved [82]. Thus, patients who are at risk for developing metastases may in the 
future receive a different treatment than patients who are not at risk. However, 
this micro-array based expression proﬁ ling of tumours cannot be used to develop 
and offer these patients immunotherapy. The heterogeneous expression patterns 
observed in HNSCC tumours are enormous, hindering the development and 
application of speciﬁ c (immuno)therapy for all patients, as an adjuvant for current 
therapies. In addition, these expression proﬁ les do not guarantee cell surface 
expression of the genes involved neither they indicate whether these genes are 
directly or indirectly involved in the pathogenesis of HNSCC. Expression analysis 
involving genes located in the HLA region on chromosome 6 revealed associations 
of HSD17B8, RXRβ and MICA with HNSCC (chapter 7).
Investigation of HLA expression of the tumour cells is required if 
immunotherapeutical intervention is considered for individual patients. Aberrant 
HLA expression on tumour cells will be disadvantageous for the patient; anti-
tumour responses will not or only partially occur, depending on the signiﬁ cance 
of the aberrant expression. Antibodies will reveal presence or absence of HLA 
expression on the tumour cells and the cause of HLA expression loss can be 
identiﬁ ed with RNA SBT, revealing whether polymorphism in the HLA gene/
transcript attributes to the aberrant HLA expression. The combination of HLA 
genomics, HLA transcripteomics and HLA proteomics will hopefully provide the 
information required to understand the role of HLA diversity and the functionality 
of HLA diversity in HNSCC and to successfully implement immunotherapy. 
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Summary
The human equivalent of the major histocompatibility complex (MHC), the 
human leukocyte antigen (HLA) system, is the most polymorphic region of the 
human genome and includes three regions, HLA class I, II and III, in which many 
HLA, HLA-related and non-HLA related genes are located. The HLA genes in the 
class I and II regions are characterized as either classical or non-classical HLA 
genes. HLA-A, HLA-B and HLA-C, the classical class I genes, and HLA-DR, HLA-
DQ and HLA-DP, the classical class II genes, can bind self and foreign peptides in 
their peptide-binding groove, evoking immune responses. The bound peptides are 
subsequently presented to CD8+ and CD4+ T-cells by respectively the class I and 
class II molecules. For most of the HLA genes numerous allelic variants have been 
identiﬁ ed, resulting in numerous HLA molecules that differ by one or more amino 
acids. Identiﬁ cation of HLA alleles is important in clinical settings as transplantation 
and predicting susceptibility to diseases. Identiﬁ cation is performed at various 
levels, low-, intermediate- and high-resolution, and with various techniques, DNA-
, RNA- or protein-based approaches. In transplantation settings immune responses 
can occur when patient and donor differ in their HLA antigens. Donor and recipient 
should be HLA matched as accurately as possible, since mismatching may result 
in transplantation related complications such as graft failure and graft-versus-
host disease in stem cell transplantation. Although HLA associations have been 
found with diseases, autoimmune diseases and cancer, it is less obvious what 
the role of HLA is. In head and neck squamous cell carcinoma (HNSCC) aberrant 
expression for HLA molecules is observed on primary tumour cells and lymph node 
metastases, suggesting an aberrant immune response. Whether the HLA genes 
themselves or other genes within the HLA region are responsible for this aberrant 
expression and the development of HNSCC is poorly understood.
The aim of this thesis was to investigate if and how the HLA region on the 
short arm of chromosome 6 is associated with HNSCC. DNA-, RNA- and protein-
based approaches were developed and applied to elucidate the inﬂ uence of gene 
polymorphism and expression in the pathogenesis of HNSCC. The ﬁ rst part of the 
thesis focused on the identiﬁ cation of polymorphism and the correlation between 
polymorphism and expression. The second part of the thesis focused on the 
association of HLA, HLA-related and non-HLA related genes in the HLA region with 
the pathogenesis of HNSCC.
Determination of HLA protein cell surface expression is complicated due 
to the extreme HLA polymorphism and the limited availability of allele speciﬁ c 
mAbs. Identiﬁ cation of polymorphism at the DNA level is not per se conclusive 
regarding the expression status of the allele. E.g. in the case of null alleles and 
alternative spliced variants, polymorphism inﬂ uences the expression status of an 
allele. Therefore an RNA sequencing based typing (SBT) protocol was developed 
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for the classical HLA genes HLA-A, HLA-B and HLA-C to investigate the inﬂ uence 
of polymorphism on the RNA transcripts of HLA alleles. HLA expressed and non-
expressed alleles, selected from reference cell lines, covering all major allelic 
groups of the three class I genes, were tested. The HLA-A, HLA-B and HLA-C (null) 
alleles identiﬁ ed with the RNA SBT protocol conﬁ rmed the HLA typing obtained 
with DNA SBT. The amount of mRNA present of the (null) alleles differed. 
The mechanism resulting in the identiﬁ cation of a new HLA-A null allele 
was determined with DNA, RNA and protein studies. Patient AHPEN was typed as 
HLA-A homozygous at the protein level, but DNA analysis revealed a heterozygous 
HLA-A typing. In the null allele, a synonymous substitution in exon 3 was observed 
that could not explain expression loss. Application of the RNA SBT protocol was 
crucial for revealing the consequence of the synonymous substitution on RNA 
transcription. An in-frame deletion of 8 amino acids was identiﬁ ed in the RNA 
transcript. The mechanism responsible for this deletion is the introduction of a new 
alternative splice site in exon 3, matching the splice site consensus better than the 
regular splice site. The functional consequence of this new HLA polymorphism is 
that alternative splicing of the allele resulted in loss of cell surface expression.
Few antibodies are available which recognize β1 epitopes of the HLA-DPB1 
molecule encoded by exon 2. HLA-DPB1 alleles have mainly been deﬁ ned based 
upon exon 2, since polymorphism in this region contributes to the characteristics 
of the peptide-binding groove of the HLA-DP molecule. An RNA SBT protocol was 
developed to investigate the polymorphism in the coding regions, including the 
untranslated regions. Sixteen different HLA-DPB1 alleles were evaluated for their 
extended polymorphism. Results show limited polymorphism in the extended 
regions compared to exon 2. A one-nucleotide deletion was observed in exon 5 of 
HLA-DPB1*1301 and HLA-DPB1*0902 and four new DPB1 alleles were discovered 
(HLA-DPB1*0502, HLA-DPB1*0602, HLA-DPB1*0802 and HLA-DPB1*0902) 
with unique polymorphism in exons beyond exon 2. Based upon the extended 
polymorphism, DPB1 alleles are grouped into lineages. Whether this extended 
polymorphism and/or allele groups represent functional diversiﬁ cation remains to 
be established. 
In the second part of the thesis, HLA analysis was performed in 159 HNSCC 
patients, with or without lymph node metastases, and 106 controls. HLA alleles 
were determined for the HLA loci HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 
in patients and controls. No individual HLA allele associations for one of the HLA 
loci were observed in the total patient group compared to the control group. HLA 
allele and haplotype associations were observed based upon the location of the 
tumours (hypopharynx, larynx, oral cavity and oropharynx) and the presence or 
absence of lymph node metastases: i) a signiﬁ cant decrease in the HLA-B*35 
allele frequency in the patient group with lymph node metastases compared to the 
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control group and ii) a signiﬁ cant increase in the HLA-B*40 allele frequency in the 
oral cavity patient group compared to the control group. Subsequent haplotype 
analysis indicated that, although at low frequency, a signiﬁ cant higher number 
of patients diagnosed with an oral cavity tumour carried the HLA-B*40-DRB1*13 
haplotype than controls. Since the MICA gene is in linkage disequilibrium with 
HLA-B and thought to be involved in the innate and adaptive immune system, 
MICA allelic polymorphism was evaluated in the oral cavity patients. A reﬁ ned 
method for MICA allele assignment was implemented in this study, combining the 
nucleotide polymorphisms in exons 2 through 4 and the repeat polymorphism 
present in exon 5. No differences in MICA allelic polymorphism were identiﬁ ed 
between the oral cavity patients and the control group.
Since no MICA allelic association was observed in HSNCC, we evaluated the 
MICA repeat length polymorphism, present in the MICA transmembrane region, 
in the same group of HNSCC patients and in the control group. We hypothesized 
that the length of the MICA repeat could be correlated with MICA expression. This 
repeat polymorphism is present in the transmembrane region and could affect 
anchorage in the membrane. The MICA repeat polymorphism is associated with 
several diseases. MICA repeat analysis indicated a signiﬁ cant decrease in the 
MICA-A9 frequency in the total patient group compared to the controls. Based 
on the tumour locations only patients diagnosed with a tumour in the oral cavity 
showed a signiﬁ cant decrease in the MICA-A9 repeat frequency compared to the 
control group and the other tumour locations. MICA protein expression analysis 
indicated that the majority of tumours expressed MICA protein; no difference in 
MICA expression was observed between the tumour locations and whether or not 
lymph node metastases were present in the patient. Also no soluble MICA was 
detected in patients’ sera. Since the majority of tumours expressed MICA, no 
correlation exists between MICA expression and MICA repeat length. 
To evaluate the role of other genes in the HLA region, conferring 
susceptibility to HNSCC development, 49 polymorphic microsatellite markers 
dispersed throughout the HLA region were analysed to deﬁ ne possible disease-
associated regions. To efﬁ ciently test these microsatellite markers in a large 
number of samples, four different DNA pools were generated: one control DNA 
pool and three patient DNA pools, each with approximately 100 individuals. These 
different DNA pools were based upon tumour location: oral cavity, oropharynx 
and larynx. Microsatellite analysis revealed three signiﬁ cantly associated regions 
with the oral cavity DNA pool, one within the class I region and two in the class 
II region. The oropharynx tumours showed association with a few microsatellites 
whereas no association was observed in the larynx tumours. From the associated 
regions with the oral cavity tumours, 18 genes were selected and tested for their 
mRNA expression in oral cavity tumour tissue compared to its surrounding healthy 
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tissue. A signiﬁ cant decreased mRNA expression in tumour tissue was observed 
for the HSD17B8 gene, a hydroxysteroid dehydrogenase, especially in those 
tumours without lymph node metastases. A not signiﬁ cant but decreased mRNA 
expression was observed for the receptors retinoid X receptor β (RXRβ), a retinoid 
receptor, and NOTCH4, involved in developmental and differentiation pathways. 
A signiﬁ cant increased MICA mRNA expression was observed in tumour tissue 
compared to healthy tissue, but no difference was observed between the oral 
cavity tumours with and without lymph node metastases. This study has shown 
that other genes in the HLA region are associated with HNSCC pathogenesis. 
MICA has a direct functional involvement in the immune response while HSD17B8 
and RXRβ are indirectly involved in the pathogenesis of HNSCC through other 
metabolic pathways.
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De humane variant van het Major Histocompatibiliteits Complex (MHC) is 
het Humane Leukocyten Antigen (HLA) systeem gelegen op de korte arm van 
chromosoom 6. Het HLA systeem is het meest polymorfe gebied van het humane 
genoom en bevat drie regio’s: de klasse I, II en III regio. In deze drie regio’s 
liggen HLA, HLA-gerelateerde en niet-HLA gerelateerde genen die via directe of 
indirecte mechanismen betrokken zijn bij het initiëren van een immuun respons. De 
polymorfe HLA moleculen, die gecodeerd worden door de HLA genen in de klasse I 
en II regio’s, presenteren lichaamsvreemde peptiden aan T-cellen. De presentatie 
van deze peptiden door de klasse I moleculen aan CD8+ T-cellen en door klasse II 
moleculen aan CD4+ T-cellen kan leiden tot respectievelijk een directe cellulaire 
immuun respons of een indirecte cellulaire of een humorale immuun respons. Het 
polymorﬁ sme in de HLA genen heeft geleid tot de identiﬁ catie van grote aantallen 
allel varianten die op eiwit niveau één of meerdere aminozuren van elkaar 
verschillen. HLA polymorﬁ sme in de HLA antigenen en allelen kan met behulp 
van DNA, RNA en eiwit technieken getypeerd worden met lage, intermediaire en 
hoge resolutie. De identiﬁ catie van HLA allelen van de verschillende klasse I en 
II HLA genen is onder andere belangrijk voor stamcel- en orgaantransplantatie, 
omdat in HLA gematchte transplantaties de minste transplantatie gerelateerde 
complicaties, zoals afstoting van het transplantaat en graft-versus-host ziekte, 
voorkomen. 
De rol van HLA bij auto-immuunziekten en kanker is minder goed 
gedeﬁ nieerd dan bij transplantaties, alhoewel verschillende associaties met HLA 
allelen en haplotypen zijn beschreven. In tumoren is aberrante HLA expressie 
karakteristiek voor primaire tumoren en metastasen van hoofd-hals plaveiselcel 
carcinomen, waarbij aangenomen wordt dat deze aberrante expressie de immuun 
respons direct beïnvloedt. Het is niet duidelijk of de aberrante HLA expressie 
wordt veroorzaakt door de HLA genen zelf of door genen gelegen in de HLA regio 
op chromosoom 6 die in linkage disequilibrium zijn met de HLA genen.
De studies beschreven in dit proefschrift werden uitgevoerd met als doel om 
te onderzoeken of en op welke manier de genen in de HLA regio, gelegen op de 
korte arm van chromosoom 6, geassocieerd zijn met de pathogenese van hoofd-
hals kanker. De invloed van polymorﬁ sme op de RNA en eiwit expressie in relatie 
tot de pathogenese van hoofd-hals kanker is bestudeerd. De focus van het eerste 
gedeelte van het proefschrift ligt op de identiﬁ catie van polymorﬁ sme van HLA 
genen en de correlatie tussen polymorﬁ sme en expressie. Het tweede gedeelte 
van het proefschrift focust op de associatie van HLA, HLA-gerelateerde genen en 
andere genen op chromosoom 6 in de pathogenese van hoofd-hals kanker.
De hoge mate van HLA polymorﬁ sme en de toegankelijkheid van het 
polymorﬁ sme naast de beperkte beschikbaarheid van allel speciﬁ eke HLA 
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antilichamen limiteert de identiﬁ catie van celmembraan expressie van individuele 
HLA allelen. Identiﬁ catie van het polymorﬁ sme op DNA niveau geeft niet altijd 
uitsluitsel over de HLA expressiestatus van een allel, bijvoorbeeld in het geval 
van HLA nul allelen en alternative spliced HLA varianten waar polymorﬁ sme RNA 
en/of eiwit expressie beïnvloedt. Om te onderzoeken in welke mate polymorﬁ sme 
RNA transcripten van HLA allelen beïnvloedt, is een RNA sequencing based typing 
(SBT) protocol ontwikkeld voor de klassieke HLA klasse I genen HLA-A, HLA-B en 
HLA-C. HLA allelen en HLA nul allelen zijn getest. De (nul) allelen geïdentiﬁ ceerd 
met het RNA SBT protocol bevestigden allel typeringen verkregen met DNA analyse 
en bevestigen de aanwezigheid van RNA. De hoeveelheid RNA aanwezig voor de 
(nul) allelen verschilde. Voor enkele HLA allelen kon de aanwezigheid van RNA 
transcripten alleen aangetoond worden met allel speciﬁ ek sequencen.
Een heterozygote HLA-A typering werd gevonden met DNA analyse in 
patiënt AHPEN maar serologische technieken met antilichamen identiﬁ ceerden 
de aanwezigheid van één HLA-A antigen. DNA, RNA en eiwit technieken werden 
toegepast voor de identiﬁ catie van dit nieuw HLA-A nul allel. Alhoewel een 
synonieme substitutie werd gevonden in exon 3 van het nul allel met DNA analyse, 
verklaarde dit niet het verlies van expressie van dit HLA-A nul allel. Toepassing 
van het RNA SBT protocol in deze patiënt bleek cruciaal voor de bepaling van de 
invloed van de synonieme substitutie op RNA transcriptie. Een in-frame deletie 
van 8 aminozuren was aanwezig in het RNA transcript van het HLA-A nul allel met 
als gevolg van een nieuwe alternative splice site in exon 3. De sequentie aanwezig 
in de nieuwe alternative splice site correspondeert beter met de sequentie van 
de consensus splice site dan de reguliere splice site met de consensus. De 
functionele consequentie van dit nieuwe HLA polymorﬁ sme is de introductie van 
een nieuwe splice site, die via alternative splicing resulteert in verlies van HLA 
celmembraanexpressie. 
Het merendeel van de HLA-DPB1 allelen wordt gedeﬁ nieerd op basis van 
het polymorﬁ sme aanwezig in exon 2, dat codeert voor een gedeelte van de 
β1 keten van het HLA-DPB1 gen en participeert in de vorming van de peptide 
bindingsgroeve. De hoge mate van polymorﬁ sme in de HLA-DPB1 allelen en de 
beperkte beschikbaarheid van HLA-DPB1 antilichamen bemoeilijkt de herkenning 
van de epitopen gelegen in de β1 keten van het HLA-DPB1 molecuul. Om het 
polymorﬁ sme in de coderende regio’s en de onvertaalde gebieden te onderzoeken 
is een RNA SBT protocol ontwikkeld. Zestien verschillende HLA-DPB1 allelen zijn 
geëvalueerd voor hun polymorﬁ sme buiten exon 2. Vergeleken met exon 2 is 
minder polymorﬁ sme aanwezig in de coderende en onvertaalde gebieden buiten 
exon 2. In exon 5 is een deletie van één nucleotide aanwezig in HLA-DPB1*1301 
en HLA-DPB1*0902. Uniek polymorﬁ sme gelegen buiten exon 2 leidde tot de 
identiﬁ catie van vier nieuwe HLA-DPB1 allelen (HLA-DPB1*0502, HLA-DPB1*0602, 
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HLA-DPB1*0802 en HLA-DPB1*0902). De HLA-DPB1 allelen kunnen op basis 
van het polymorﬁ sme buiten exon 2 worden verdeeld in twee hoofdgroepen. 
De functionele betekenis van dit extended polymorﬁ sme en de verdeling in allel 
groepen moet nog verder bestudeerd worden.
In het tweede gedeelte van het proefschrift is de invloed van HLA-A, HLA-B, 
HLA-C, HLA-DRB1 en HLA-DQB1 genen in 159 patiënten met hoofd-hals kanker, 
met en zonder lymfeklier metastasen, en in 106 controle personen bepaald. 
Hoewel individuele HLA allel associaties niet werden gevonden in de totale 
patiënten groep vergeleken met de controle groep, werden allel en haplotype 
associaties gevonden wanneer de totale patiënten groep opgedeeld wordt in 
groepen gebaseerd op de locatie van de tumor (hypofarynx, larynx, orofarynx en 
mondholte). Een signiﬁ cante verlaging in de HLA-B*35 allelfrequentie is aanwezig 
in patiënten met lymfeklier metastasen en een signiﬁ cante verhoging in de HLA-
B*40 allelfrequentie is aanwezig in de patiënten groep met een mondholte tumor. 
Haplotype analyse gaf aan dat het HLA-B*40-DRB1*13 haplotype signiﬁ cant vaker 
voorkomt in patiënten met een mondholte tumor vergeleken met controle personen. 
Het MICA gen, centromeer gelegen van HLA-B en in linkage disequilibrium met 
HLA-B, is betrokken bij de aangeboren en verworven immuun respons. Het MICA 
allel polymorﬁ sme werd onderzocht in de patiënten met een mondholte tumor. 
Een methode voor de volledige identiﬁ catie van de MICA allelen werd toegepast, 
gebaseerd op de combinatie van nucleotide polymorﬁ sme in exonen 2, 3 en 
4 en het repeat polymorﬁ sme in exon 5. Er werden geen verschillen in MICA 
allelfrequentie gevonden tussen patiënten en controles.
Aangezien geen MICA allel associatie gevonden werd, is in dezelfde groep 
patiënten en controles gekeken naar de lengte van de MICA repeat, aanwezig 
in het transmembraan gebied van het MICA. Onderzocht werd of de lengte van 
de MICA repeat correleerde met de MICA expressie op tumor cellen. Daar de 
MICA repeat aanwezig is in het transmembraan gebied, kan dat de verankering 
van het molecuul in de membraan beïnvloeden. Een signiﬁ cante verlaging in de 
allelfrequentie voor de MICA-A9 repeat werd waargenomen in de patiënten met 
een mondholte tumor. De meerderheid van de hoofd-hals tumoren brengt MICA tot 
expressie, maar er werden geen onderlinge verschillen gevonden in tumor locatie 
of de aan- of afwezigheid van lymfeklier metastasen. Ook werd geen soluble MICA 
in het serum van patiënten gevonden. Uit deze studie blijkt dat er geen correlatie 
is tussen de lengte van de MICA repeat in het transmembraan gebied van het 
MICA molecuul en de expressie van dit molecuul op de membraan.
Om te onderzoeken of andere genen dan de HLA en HLA gerelateerde 
genen, gelegen in de HLA regio, betrokken zijn in de pathogenese van hoofd-
hals kanker, zijn 49 microsatelliet markers geanalyseerd in hoofd-hals patiënten, 
om gebieden te deﬁ niëren die geassocieerd zijn met hoofd-hals kanker. Deze 
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microsatelliet markers zijn gelegen in de klasse I, II en III regio van de HLA regio. 
Om deze markers zo efﬁ ciënt mogelijk te testen op zoveel mogelijk patiënten is 
gebruik gemaakt van 4 verschillende DNA pools: één controle DNA pool en drie 
patiënten DNA pools, gebaseerd op de locatie van de tumor: larynx, orofarynx 
en mondholte; elk met ongeveer 100 individuele samples. Microsatelliet analyse 
identiﬁ ceerde drie geassocieerde gebieden in de patiënten met een mondholte 
tumor, één gebied gelegen in de klasse I regio en twee gebieden in de klasse II 
regio. Associaties van een aantal individuele markers werd gezien in patiënten 
met een orofarynx tumor en geen associaties werden gevonden in de patiënten 
met een larynx tumor. Achttien genen werden geselecteerd uit de genen aanwezig 
in de geassocieerde gebieden en geanalyseerd voor hun RNA expressie in tumor 
weefsel van mondholte tumoren en vergeleken met de RNA expressie in het 
omringende gezonde weefsel. Een signiﬁ cant verlaging van de RNA expressie van 
het hydroxysteroid (17-beta) dehydrogenase 8 (HSD17B8) in tumor weefsel was 
aanwezig ten opzichte van het gezonde omringende weefsel, met name in tumoren 
met een lymfeklier metastase. De genen retinoid X receptor β (RXRβ) en NOTCH4 
lieten een verlaagde, maar niet-signiﬁ cante, RNA expressie zien in tumor weefsel. 
Voor MICA is een signiﬁ cante verhoging in RNA expressie aanwezig in tumor weefsel, 
maar er werd geen verschil gevonden tussen tumoren met en zonder lymfklier 
metastasen. Dit proefschrift laat zien dat, naast associaties met HLA allelen en 
haplotypen, ook andere genen gelegen binnen de HLA regio geassocieerd zijn met 
de pathogenese van hoofd-hals kanker. Naar alle waarschijnlijkheid is MICA direct 
betrokken bij de immuun respons terwijl HSD17B8 en RXRβ indirect betrokken 
zijn bij de pathogenese van hoofd-hals kanker. Het mechanisme waarop deze 
factoren de HLA expressie en het immuun systeem beïnvloeden behoeft verder 
onderzoek.
hoofdstuk 10.indd   159 1/5/2006   12:30:23
160
hoofdstuk 10.indd   160 1/5/2006   12:30:23
161
Chapter 10
Publicatielijst
Reinders J, Rozemuller EH, Ongkosuwito JV, Jager MJ, Tilanus MGJ and 
 Suttorp-Schulten MS. MICA association with presumed ocular histoplasmosis syndrome 
(POHS). Mol Vis. 2003: 9: 420-4.
De Graaff PM, Heidema J, Poelen MC, Van Dijk ME, Lukens MV, Van Gestel SP, 
Reinders J, Rozemuller EH, Tilanus MGJ, Hoogerhout P, Van Els CA, Van der Most RG, 
Kimpen JL and Van Bleek GM. HLA-DP4 presents an immunodominant peptide from the 
RSV G protein to CD4 T cells. Virology 2004: 326: 220-30.
Van Steenbergen W, De Goede E, Emonds MP, Reinders J, Tilanus MGJ and Fevery J. 
Primary sclerosing cholangitis in two brothers: report of a family with special emphasis 
on molecular HLA and MICA genotyping. Eur J Gastroenterol Hepatol. 2005: 17: 767-
71.
Reinders J, Rozemuller EH, Otten H, Houben AJS, Dormoy A, Mulder A, Van den Tweel 
JG, Petersen EJ and Tilanus MGJ. Identiﬁ cation of HLA-A*0111N: A synonymous 
substitution, introducing an alternative splice site in exon 3, silenced the expression of 
an HLA-A allele. Hum Immunol. 2005, 66: 912-920
Reinders J, Rozemuller EH, Van Gent R, Arts-Hilkes YHA, Van den Tweel JG and 
Tilanus MGJ. Extended HLA-DPB1 polymorphism: an RNA approach for HLA-DPB1 
typing. Immunogenetics, 2005: 57: 790-794
Reinders J, Rozemuller EH, Otten HG, Van der Veken LTJN, Slootweg PJ and 
Tilanus MGJ. HLA and MICA associations in head and neck squamous cell carcinoma. 
Submitted for publication
Reinders J, Rozemuller EH, Van der Ven KJW, Caillat-Zucman S, Slootweg PJ, 
De Weger RA and Tilanus MGJ. MHC class I chain-related gene A diversity in head and 
neck squamous cell carcinoma. Submitted for publication
Reinders J, Rozemuller EH, Van der Weide P, Oka A, Slootweg PJ, Inoko H and 
Tilanus MGJ. Identiﬁ cation of susceptibility genes in the HLA region in Dutch head and 
neck squamous cell carcinoma patients: application of microsatellite analysis and DNA 
pools. Submitted for publication
Reinders J, Houben A, Van Mill A, Rozemuller EH, Van den Tweel JG and Tilanus MGJ. 
RNA based high-resolution HLA sequencing based typing. Submitted for publication
 
hoofdstuk 10.indd   161 1/5/2006   12:30:23
162
Dankwoord
Als je begint lijkt je promotie nog zover weg. Niets is minder waar, voor je 
het weet verdedig je je proefschrift in het Academiegebouw. Deze periode is voorbij 
gevlogen, vooral omdat ik het naar mijn zin had, en dat was mede te danken aan jullie, 
collega’s, vrienden en familie. Dus bij deze, voor eenieder 
Dank jullie wel allemaal!!
Mijn promotoren, professor Van den Tweel en professor Slootweg. Dank u wel 
dat ik de kans heb gekregen om bij u beiden te promoveren.
Mijn co-promotoren, Marcel en Erik. Marcel, als er een Nederlands woord 
bestaat (of misschien nog uitgevonden moet worden) voor iemand die zo enthousiast 
en bevlogen is over HLA als jij, dat enthousiasme over kan brengen en ook nog het 
onderste uit de kan weet te halen bij mensen, dan hoor ik dat graag (iets in de trant 
van HLA-……? En dan eventueel met of zonder tussenstreepje voor het volgende 
Groot Dictee der Nederlandse Taal?). Dank je wel dat je mij de kans hebt gegeven 
om te promoveren, ik heb in de afgelopen jaren heel veel geleerd. Erik, HLA, HLA-
gerelateerde en niet-HLA gerelateerde zaken, het kwam allemaal aan bod tijdens de 
vele uurtjes achter de computer (en de pogingen daartoe), tijdens congressen en onze 
wandelingen van en naar congresgebouwen. Jouw droge humor en commentaar zal ik 
niet snel vergeten.
Alle collega’s en ex-collega’s van de MIP wil ik bedanken voor de gezellige pauzes, 
lunches, borrels, etentjes, dagjes uit en alle hulp op het lab. Kevin, dank je wel voor 
het IH-werk en de mooie plaatjes in hoofdstuk 6. Yvonne, dank je wel voor de gezellige 
uurtjes op het VMT-lab met de DPB-tjes. De NS-wandelaars(ters), Dick, Helga, Marina, 
Petra H. en Sabrina, zullen we weer eens een keer gaan wandelen? Dick, volgens mij 
ken jij de wandelpaden in Zuid-Limburg beter dan ik de wandelpaden ken! Heb je 
trouwens al een nieuw “slachtoffer” gevonden om “op de kast te jagen”?
Beste Linda, Rogier en Anna, mijn studenten. Ik heb het leuk en leerzaam 
gevonden om jullie te begeleiden en ik wil jullie bedanken voor het werk dat jullie voor 
mij gedaan hebben (en de artikelen die daaruit zijn voortgekomen!). Rogier en Anna, 
heel veel succes met jullie eigen promotie.
Geert, mede-Limburger in het Utrechtse. Het promoveren heb ik afgelopen jaar 
van jou kunnen afkijken, nu ben ik zelf aan de beurt. Dank voor alle (lay-out) tips. Mijn 
mede-AIO’s Annette, Jennifer, Peggy, Arjan, Eelke en Pieter. Ik wens jullie allemaal veel 
succes bij jullie eigen promotie, het is wel even doorpezen maar het is heerlijk als het 
proefschrift dan eindelijk bij de commissie ligt. Peggy, voor jou zijn de laatste loodjes 
in zicht. Jennifer, heb je zin in een zakje boerenkool? Ik wens je nog een ﬁ jne tijd in 
Londen. Mijn kamergenote Annette, “kopje kofﬁ e”? Het afgelopen jaar zijn we allebei 
heel druk geweest met ons proefschrift. Het gaat jou ook gewoon lukken, dat weet 
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ik zeker! Dank je wel voor de afgelopen jaren, voor de gezelligheid en de praatjes op 
onze kamer.
Mijn paranimfen, Marja en Petra. Naar eigen zeggen staat Marja niet vaak met 
haar mond vol tanden, maar op het moment dat ik haar vroeg om één van mijn 
paranimfen te zijn, gebeurde dat wel. Marja, ik ben erg blij dat je mijn paranimf wilde 
zijn. En dank voor het beantwoorden van al mijn vragen in het lab (en dat zijn er veel 
geweest). Petra, zonder het er met elkaar over gehad te hebben wisten we allebei al 
hoe de voorkant van mijn proefschrift eruit zou gaan zien, het uitzicht waarmee we 
elke morgen in Japan wakker werden. Hoeveel foto’s hebben we wel niet genomen van 
Fuji-san? Aligatoo gozaimas voor het werk dat je gedaan hebt!
En dan was er nog de muziek…… een geweldige uitlaatklep na een week 
werken. Ik had het grote geluk dat, toen ik net begon als AIO in Utrecht, er een 
plaats vrij was voor een klarinettiste bij het Verenigd Utrechts Symfonie Orkest. Beste 
mede-muzikanten en dirigent, dank jullie wel voor de leuke en intensieve repetities, 
repetitieweekenden, concerten, kamermuziekmiddagen en bestuursvergaderingen. 
Corine, we begonnen tegelijkertijd als AIO in Utrecht en bij het VUSO. Tijdens NS-
wandelingen kwam het promoveren altijd wel ter sprake, het lukte ons ook om telkens 
op de hei te verdwalen. Ik vraag me af of daar een verband tussenzit. Misschien iets 
om wetenschappelijk te onderzoeken?
Beste Hanneke, Ingrid, Isabelle, Jacky en René (gang 37 in de wandelgangen), 
tijd om weer eens een afspraak te maken om ouderwets gezellig te koken en bij te 
kletsen. Pasta met een sausje? Wie kookt en wie wast af? Betste Jolanda, tsezame 
jónge vier noa sjoeël en sjtoedere. Dank vuur t “gescrabbel” en alle anger sjpeller, ‘t 
tsezame kaoche, en ’t bezukke va oessjtellónge. Wat weëd de nieëkste oessjtellóng?
Betste famillieë, e Kirchröadsj meëdsje dat mit d’r vasteloavend “promoveert”, 
tsouwval of nit? Dank vuur de intresse en iech wunsj üch vöal sjpas op karnevalsdeesdieg 
(Alaaf!!).
Lieve Mirjam, als grote zus ben ik maar wat trots op mijn “kleine” sjwester. Voor 
jou & Theo, een groot dank je wel voor alles en een dikke kus voor jullie beiden.
Leef pap en mam, danke vuur al wat uur vuur miech jedoa hat. Vuur ’t sjpatsere 
durch ós Limburg, de hulp bij ’t voettrekke va de ing noa de anger sjtad, de zamsdiege 
en zóndiege heem woare ummer ing kling vakans. Ee lekker mülsje vuur üch allebei.
Judith,
Januari 2006.
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Curriculum Vitae
Judith Reinders werd geboren op 21 augustus 1976 te Kerkrade. In 1994 behaalde 
zij aldaar haar atheneum diploma aan het College Sancta Maria. Aansluitend 
begon zij met haar studie Biologie aan de Faculteit der Natuurwetenschappen, 
Wiskunde en Informatica van de Radboud Universiteit Nijmegen, die zij in 2000 
afsloot met haar doctoraal diploma. Gedurende de opleiding Biologie werden drie 
wetenschappelijke stages gevolgd. De eerste stage werd voltooid op de Afdeling 
Cellulaire Dierfysiologie, Radboud Universiteit Nijmegen, onder begeleiding van 
Dr. R. Ubink en Professor Dr. E.W. Roubos. De tweede stage werd uitgevoerd op de 
Afdeling Tumorimmunologie, Universitair Medisch Centrum St. Radboud Nijmegen, 
onder begeleiding van Dr. M.W. Schreurs, Professor Dr. G.J. Adema en Professor 
Dr. C.G. Figdor. De laatste wetenschappelijke stage werd uitgevoerd op de Afdeling 
Oncologie, Radiologie en Klinische Immunologie van het Academisch Universiteits 
Ziekenhuis in Uppsala, Zweden, onder begeleiding van Dr. A. Björkland en Prof. 
Dr. T. Tötterman. Gedurende de periode 2001-2005 werd een promotieonderzoek 
verricht op de Afdeling Pathologie van het Universitair Medisch Centrum Utrecht 
onder begeleiding van de promotores Prof. Dr. J.G. Van den Tweel en Prof. Dr. 
P.J. Slootweg en de co-promotores Dr. M.G.J. Tilanus en Dr. Ir. E.H. Rozemuller. 
Gedurende haar promotie bracht zij een werkbezoek aan de Afdeling Genetische 
Informatie, Tokai University School of Medicine, Isehara, Japan. Resultaten 
verkregen gedurende dit promotieonderzoek, en beschreven in dit proefschrift, 
zijn gepresenteerd als poster of orale presentatie op verschillende binnenlandse 
en buitenlandse congressen. In april 2005 werd tijdens het Bootcongres, 
georganiseerd door de Nederlands Transplantatie Vereniging, een prijs toegekend 
aan de promovenda voor beste orale presentatie in haar sessie. 
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